<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Luteal phase support for assisted reproduction cycles - van der Linden, M - 2015 | Cochrane Library</title> <meta content="Luteal phase support for assisted reproduction cycles - van der Linden, M - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009154.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Luteal phase support for assisted reproduction cycles - van der Linden, M - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009154.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009154.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Luteal phase support for assisted reproduction cycles" name="citation_title"/> <meta content="Michelle van der Linden" name="citation_author"/> <meta content="Radboud University Medical Center" name="citation_author_institution"/> <meta content="Michelle.vanderLinden@radboudumc.nl" name="citation_author_email"/> <meta content="Karen Buckingham" name="citation_author"/> <meta content="Repromed" name="citation_author_institution"/> <meta content="Cindy Farquhar" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Jan AM Kremer" name="citation_author"/> <meta content="Radboud University Nijmegen Medical Center" name="citation_author_institution"/> <meta content="Mostafa Metwally" name="citation_author"/> <meta content="Sheffield Teaching Hospitals" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009154.pub3" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/07/07" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009154.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009154.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009154.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Reproductive Techniques, Assisted; Chorionic Gonadotropin [adverse effects, *therapeutic use]; Drug Therapy, Combination; Estrogens [*therapeutic use]; Gonadotropin‐Releasing Hormone [*agonists]; Live Birth [epidemiology]; Luteal Phase [*drug effects, physiology]; Ovarian Hyperstimulation Syndrome [chemically induced]; Pregnancy Maintenance [drug effects]; Progesterone [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009154.pub3&amp;doi=10.1002/14651858.CD009154.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="cdmLYOAV";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009154\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009154\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009154.pub3",title:"Luteal phase support for assisted reproduction cycles",firstPublishedDate:"Jul 7, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009154.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009154.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009154.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009154.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009154.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009154.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009154.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009154.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009154.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009154.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11668 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009154.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-sec-0224"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-sec-0213"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/appendices#CD009154-sec-0229"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/table_n/CD009154StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/table_n/CD009154StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Luteal phase support for assisted reproduction cycles</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information#CD009154-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Michelle van der Linden</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information#CD009154-cr-0003">Karen Buckingham</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information#CD009154-cr-0004">Cindy Farquhar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information#CD009154-cr-0005">Jan AM Kremer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information#CD009154-cr-0006">Mostafa Metwally</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information/en#CD009154-sec-0245">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 07 July 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009154.pub3">https://doi.org/10.1002/14651858.CD009154.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009154-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009154-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009154-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009154-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009154-abs-0001" lang="en"> <section id="CD009154-sec-0001"> <h3 class="title" id="CD009154-sec-0001">Background</h3> <p>Progesterone prepares the endometrium for pregnancy by stimulating proliferation in response to human chorionic gonadotropin (hCG) produced by the corpus luteum in the luteal phase of the menstrual cycle. In assisted reproduction techniques (ART), progesterone and/or hCG levels are low, so the luteal phase is supported with progesterone, hCG or gonadotropin‐releasing hormone (GnRH) agonists to improve implantation and pregnancy rates. </p> </section> <section id="CD009154-sec-0002"> <h3 class="title" id="CD009154-sec-0002">Objectives</h3> <p>To determine the relative effectiveness and safety of methods of luteal phase support provided to subfertile women undergoing assisted reproduction. </p> </section> <section id="CD009154-sec-0003"> <h3 class="title" id="CD009154-sec-0003">Search methods</h3> <p>We searched databases including the Cochrane Menstrual Disorders and Subfertility Group (MDSG) Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO and trial registers up to November 2014. Further searches were undertaken in August 2015. </p> </section> <section id="CD009154-sec-0004"> <h3 class="title" id="CD009154-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of luteal phase support using progesterone, hCG or GnRH agonist supplementation in ART cycles. </p> </section> <section id="CD009154-sec-0005"> <h3 class="title" id="CD009154-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. Our primary outcome was live birth or ongoing pregnancy. The overall quality of the evidence was assessed using GRADE methods. </p> </section> <section id="CD009154-sec-0006"> <h3 class="title" id="CD009154-sec-0006">Main results</h3> <p>Ninety‐four RCTs (26,198 women) were included. Most studies had unclear or high risk of bias in most domains. The main limitations in the evidence were poor reporting of study methods and imprecision due to small sample sizes. </p> <p><i>1. hCG vs placebo/no treatment (five RCTs, 746 women)</i> </p> <p>Findings suggested benefit for the hCG group in live birth or ongoing pregnancy rates when data were analysed with a fixed‐effect model (OR 1.76, 95% CI 1.08 to 2.86, three RCTs, 527 women, I<sup>2</sup> = 24%, very low‐quality evidence) but there was no clear evidence of a difference using a random‐effects model (OR 1.67, 95% CI 0.90 to 3.12). hCG may increase ovarian hyperstimulation syndrome (OHSS) rates (OR 4.28, 95% CI 1.91 to 9.6, one RCT, 387 women, low‐quality evidence). </p> <p><i>2. Progesterone vs placebo/no treatment (eight RCTs, 875 women)</i> </p> <p>Findings suggested benefit for the progesterone group in live birth or ongoing pregnancy rates when data were analysed with a fixed‐effect model (OR 1.77, 95% CI 1.09 to 2.86, five RCTs, 642 women, I<sup>2</sup> = 35%, very low‐quality evidence) but there was no clear evidence of a difference using a random‐effects model (OR 1.77, 95% CI 0.96 to 3.26). OHSS was not reported. </p> <p><i>3. Progesterone vs hCG regimens (16 RCTs, 2162 women)</i> </p> <p>hCG regimens included hCG alone and hCG with progesterone. There was no evidence of a difference between progesterone and hCG regimens in live birth or ongoing pregnancy rates (OR 0.95, 95% CI 0.65 to 1.38, five RCTs, 833 women, I<sup>2</sup> = 0%, low‐quality evidence). Progesterone was associated with lower OHSS rates than hCG regimens (OR 0.46, 95% CI 0.30 to 0.71, 5 RCTs, 1293 women , I<sup>2</sup>=48%). </p> <p><i>4. Progesterone vs progesterone with oestrogen (16 RCTs, 2577 women)</i> </p> <p>There was no evidence of a difference between the groups in rates of live birth or ongoing pregnancy (OR 1.12, 95% CI 0.91 to 1.38, nine RCTs, 1651 women, I<sup>2</sup> = 0%, low‐quality evidence) or OHSS (OR 0.56, 95% CI 0.2 to 1.63, two RCTs, 461 women, I<sup>2</sup> = 0%, low‐quality evidence). </p> <p><i>5. Progesterone vs progesterone + GnRH agonist (seven RCTs, 1708 women)</i> </p> <p>Live birth or ongoing pregnancy rates were lower in the progesterone‐only group than the progesterone plus GnRH agonist group (OR 0.62, 95% CI 0.48 to 0.81, nine RCTs, 2861 women, I<sup>2</sup> = 55%, random effects, low‐quality evidence). Statistical heterogeneity was high but the direction of effect was consistent across studies. OHSS was reported in one study only; there was no evidence of a difference between the groups (OR 1.00, 95% CI 0.33 to 3.01, one RCT, 300 women, very low quality evidence). </p> <p><i>6. Progesterone regimens (45 RCTs, 13,814 women)</i> </p> <p>There were nine different comparisons between progesterone regimens. Findings for live birth or ongoing pregnancy were as follows: intramuscular (IM) versus oral: OR 0.71, 95% CI 0.14 to 3.66 (one RCT, 40 women, very low‐quality evidence); IM versus vaginal/rectal: OR 1.37, 95% CI 0.94 to 1.99 (seven RCTs, 2309 women, I<sup>2</sup> = 71%, random effects, very low‐quality evidence); vaginal/rectal versus oral: OR 1.19, 95% CI 0.83 to 1.69 (four RCTs, 857 women, I<sup>2</sup> = 32%, low‐quality evidence); low‐dose versus high‐dose vaginal: OR 0.97, 95% CI 0.84 to 1.11 (five RCTs, 3720 women, I<sup>2</sup> = 0%, moderate‐quality evidence); short versus long protocol: OR 1.04, 95% CI 0.79 to 1.36 (five RCTs, 1205 women, I<sup>2</sup> = 0%, low‐quality evidence); micronised versus synthetic: OR 0.9, 95% CI 0.53 to 1.55 (two RCTs, 470 women, I<sup>2</sup> = 0%, low‐quality evidence); vaginal ring versus gel: OR 1.09, 95% CI 0.88 to 1.36 (one RCT, 1271 women, low‐quality evidence); subcutaneous versus vaginal gel: OR 0.92, 95% CI 0.74 to 1.14 (two RCTs, 1465 women, I<sup>2</sup> = 0%, low‐quality evidence); vaginal versus rectal: OR 1.28, 95% CI 0.64 to 2.54 (one RCT, 147 women, very low‐quality evidence). OHSS rates were reported for only two comparisons: IM versus oral, and low versus high‐dose vaginal; there was no evidence of a difference between the groups. </p> <p><i>7. Progesterone and oestrogen regimens (two RCTs, 1195 women)</i> </p> <p>The included studies compared two different oestrogen protocols. There was no evidence of a difference in live birth or ongoing pregnancy rates between a short or long protocol (OR 1.08, 95% CI 0.81 to 1.43, one RCT, 910 women, low‐quality evidence) or between a low or high dose of oestrogen (OR 0.65, 95% CI 0.37 to 1.13, one RCT, 285 women, very low‐quality evidence). Neither study reported OHSS. </p> </section> <section id="CD009154-sec-0007"> <h3 class="title" id="CD009154-sec-0007">Authors' conclusions</h3> <p>hCG or progesterone given during the luteal phase may be associated with higher rates of live birth or ongoing pregnancy than placebo or no treatment, but the evidence is not conclusive. The addition of GnRHa to progesterone appears to improve outcomes. hCG may increase the risk of OHSS compared to placebo. Moreover hCG, with or without progesterone, is associated with higher rates of OHSS than progesterone alone. Neither the addition of oestrogen nor the route of progesterone administration appears to be associated with an improvement in outcomes. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009154-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009154-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009154-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009154-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009154-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009154-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009154-abs-0003" lang="en"> <h3>Luteal phase support for assisted reproduction</h3> <p><b><i>Review question</i> </b> </p> <p>Many different interventions, dosages and administration routes of luteal phase support have been investigated. We made seven different comparisons to prepare a complete overview of this topic. </p> <p><b><i>Background</i> </b> </p> <p>After ovulation, the luteal phase of the menstrual cycle starts, and continues until the next menstruation. Remnants of the ovulated egg in the ovary are known as 'corpus luteum', or yellow body. The yellow body produces hormones, including progesterone. Progesterone stimulates proliferation of the lining of the uterus to prepare for implantation. </p> <p>During assisted reproduction, the woman's pituitary gland is desensitised with medications so that the ovaries can be stimulated in a controlled manner. This results in more mature eggs, which can be harvested and fertilised outside the woman's body. Hyperstimulation of the ovaries causes a luteal phase defect, as the corpus luteum is unable to produce sufficient progesterone. </p> <p>As a low progesterone level may lower the chance of implantation, the luteal phase needs to be supported. This may involve oral, vaginal or intramuscular progesterone, human chorionic gonadotropin (hCG) (which stimulates progesterone production) or gonadotropin‐releasing hormone (GnRH) agonists. GnRH agonists stimulate the production of GnRH, a hormone responsible for follicle‐stimulating hormone (FSH), and luteinising hormone (LH), which triggers ovulation and develops the yellow body. GnRH agonists are thought to restore LH levels and support the luteal phase naturally. </p> <p><b><i>Study characteristics</i> </b> </p> <p>We found 94 randomised controlled trials comparing different luteal phase support regimens in a total of 26,198 women. Our primary outcome was live birth or ongoing pregnancy. Other outcomes were clinical pregnancy, ovarian hyperstimulation syndrome (OHSS), miscarriage and multiple pregnancy. The evidence is current to August 2015. </p> <p><b><i>Key results</i> </b> </p> <p>hCG or progesterone given during the luteal phase may be associated with higher rates of live birth or ongoing pregnancy than placebo or no treatment, but the evidence is not conclusive. The addition of GnRHa to progesterone appears to improve outcomes. hCG may increase the risk of OHSS compared to placebo. Moreover hCG, with or without progesterone, is associated with higher rates of OHSS than progesterone alone. Neither the addition of oestrogen nor the route of progesterone administration appears to be associated with an improvement in outcomes. </p> <p><b><i>Quality of the evidence</i> </b> </p> <p>Evidence for most comparisons was of low or very low quality. The main limitations in the evidence were poor reporting of study methods and imprecision due to small sample sizes. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009154-sec-0224" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009154-sec-0224"></div> <h3 class="title" id="CD009154-sec-0225">Implications for practice</h3> <section id="CD009154-sec-0225"> <p>hCG or progesterone given during the luteal phase may be associated with higher rates of live birth or ongoing pregnancy than placebo or no treatment, but the evidence is not conclusive. The addition of GnRHa to progesterone appears to improve outcomes. hCG may increase the risk of OHSS compared to placebo. Moreover hCG, with or without progesterone, is associated with higher rates of OHSS than progesterone alone. Neither the addition of oestrogen nor the route of progesterone administration appears to be associated with an improvement in outcomes. </p> </section> <h3 class="title" id="CD009154-sec-0226">Implications for research</h3> <section id="CD009154-sec-0226"> <p>Of the 94 included studies, only 10 used blinding. The method of blinding used and specification of who was blinded were poorly reported. If high‐quality evidence is to be gained, studies should be properly blinded and should use a double‐dummy design. </p> <p>Only 31 studies reported live birth as an outcome. We believe this outcome is more valuable than short‐term outcomes such as clinical pregnancy rate. Therefore researchers should use live birth as the main outcome of their study. </p> <p>Early studies were placebo controlled. As research has shown that luteal phase support has a positive effect on pregnancy outcomes, it is unethical to not use luteal phase support. Therefore we support the trend in more recent studies to compare different kinds of support, doses or routes of administration. GnRH agonist is relatively new as a method of providing luteal phase support, but it shows promising results. Therefore, high‐quality randomised double‐blind controlled trials should be conducted to compare GnRH agonist support versus progesterone. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009154-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009154-sec-0015"></div> <div class="table" id="CD009154-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">hCG compared with placebo/no treatment for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>hCG compared with placebo/no treatment for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> <b>Intervention:</b> hCG<br/> <b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo/No treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> hCG</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000<br/> (128 to 281) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.76<br/> (1.08 to 2.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<br/> (141 to 256) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.3<br/> (0.9 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>746<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Very low<sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000<br/> (76 to 292) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 4.28<br/> (1.91 to 9.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most domains of most studies. </p> <p><sup>b</sup>Serious imprecision with low event rate. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Findings compatible with meaningful benefit for hCG group, or with no effect. </p> <p><sup>e</sup>Serious imprecision; single study with low event rate. </p> <p><sup>f</sup>Findings not statistically significant when random‐effects model was used (OR 1.67, 95% CI 0.90 to 3.12), or when analysis was restricted to studies reporting live birth. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009154-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progesterone compared with placebo/no treatment for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with placebo/no treatment for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> <b>Intervention:</b> progesterone<br/> <b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo/no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/> (42 to 103) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.77<br/> (1.09 to 2.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>642<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174 per 1000<br/> (126 to 234) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.89<br/> (1.3 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>841<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported in any included studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most domains of most studies. </p> <p><sup>b</sup>Serious imprecision with low event rate. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup> Findings not statistically significant when random‐effects model was used (OR 1.77, 95% CI 0.96 to 3.26), or when analysis was restricted to studies reporting live birth. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009154-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Progesterone compared with hCG regimens for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with hCG regimens for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> <b>Intervention:</b> progesterone<br/> <b>Comparison:</b> hCG (alone or with progesterone) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> hCG (alone or with progesterone)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000<br/> (138 to 254) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.95<br/> (0.65 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>833<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/> (263 to 340) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.08<br/> (0.9 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2355<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>118 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 1000</p> <p>(39 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.46</p> <p>(0.30 to 0.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1293</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> Low<sup>a,c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most domains of most studies. </p> <p><sup>b</sup>Serious imprecision with low event rate. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Findings compatible with meaningful benefit for either group, or with no effect </p> <p>e Some inconsistency: I<sup>2</sup>=48% overall, I<sup>2</sup>=60% in progesterone vs hCG subgroup </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009154-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Progesterone compared with progesterone + oestrogen for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with progesterone + oestrogen for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> <b>Intervention:</b> progesterone<br/> <b>Comparison:</b> progesterone + oestrogen (route of oestrogen: oral, transdermal, vaginal or oral + transdermal) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone + oestrogen</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000<br/> (345 to 444) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.12<br/> (0.91 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1651<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a, b, c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>397 per 1000<br/> (355 to 443) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.86<br/> (0.72 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2169<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a, d, f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/> (11 to 82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.58<br/> (0.2 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b, c, e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most domains of most studies. </p> <p><sup>b</sup>Serious imprecision with low event rate. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Serious inconsistency with substantial statistical heterogeneity (I<sup>2</sup> = 56%). Limiting analysis to the 9 studies using oral oestrogen yielded OR of 1.01 (95% CI 0.80 to 1.27) and reduced heterogeneity (I<sup>2</sup> = 16%). </p> <p><sup>e</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias both 'high risk' and 'low risk' </p> <p><sup>f</sup>Two studies with an outlying result. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009154-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Progesterone compared with progesterone + GnRH agonist for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with progesterone + GnRH agonist for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women who had undergone IVF/ICSI<br/> <b>Setting:</b> clinic<br/> <b>Intervention:</b> progesterone luteal support<br/> <b>Comparison:</b> progesterone + GnRH agonist </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone + GnRH agonist</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone luteal support</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000<br/> (209 to 309) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.62<br/> (0.48 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2861<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>405 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000<br/> (258 to 367) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.66<br/> (0.51 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2435<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000<br/> (17 to 137) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> <p>(0.33 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>e,f,</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Evidence of significant heterogeneity I<sup>2</sup> = 69% </p> <p><sup>b</sup> Only three of the studies reported on live birth as an outcome </p> <p><sup>c</sup> Evidence of heterogeneity I<sup>2</sup>=47% </p> <p><sup>d</sup> Some studies used multiple doses and some used single doses. We have used subgroup analysis to explore this further </p> <p><sup>e</sup> Lack of detail to make a judgement of risk of bias </p> <p><sup>f</sup> Evidence based on a single trial </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009154-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Progesterone regimens for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone regimens for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> Comparisons of progesterone regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>IM vs oral</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>151 per 1000<br/> (34 to 478) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.71<br/> (0.14 to 3.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>IM vs vaginal/rectal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000<br/> (272 to 353) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.24<br/> (1.03 to 1.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2309<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Vaginal/rectal vs oral</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 per 1000<br/> (176 to 303) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.19<br/> (0.83 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>857<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Low dose vaginal vs high dose vaginal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000<br/> (266 to 324) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.97<br/> (0.84 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3720<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Short protocol vs long protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>664 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>672 per 1000<br/> (609 to 728) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.04<br/> (0.79 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1205<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Low<sup>a,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Micronised vs synthetic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000<br/> (130 to 305) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.9<br/> (0.53 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Vaginal ring vs vaginal gel</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>441 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>462 per 1000<br/> (409 to 517) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.09<br/> (0.88 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1271<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c,f,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Subcutaneous vs vaginal gel</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>358 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>339 per 1000<br/> (292 to 388) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.92<br/> (0.74 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1465<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c,g,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth or ongoing pregnancy</p> <p>Vaginal vs rectal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>306 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>360 per 1000</p> <p>(220 to 528)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.28</p> <p>(0.64 to 2.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS</p> <p>IM vs oral</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> <p>(3 to 475)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> <p>(0.06 to 17.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS</p> <p>Low dose vaginal vs high dose vaginal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>55 per 1000</p> <p>(35 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.91 (0.57 to 1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1251</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> Low<sup>b,c,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>OHSS rates not reported for other comparisons.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most study domains. </p> <p><sup>b</sup>Very serious imprecision with low event rate; findings compatible with meaningful benefit in either arm or with no effect. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Very serious inconsistency with varying directions of effect (I<sup>2</sup> = 71%). Findings not statistically significant when random‐effects model was used, or when analysis was restricted to studies reporting live births. </p> <p><sup>e</sup>Serious imprecision with low event rate; findings compatible with meaningful benefit in the oral arm or with no effect. </p> <p><sup>f</sup>Serious imprecision; findings compatible with meaningful benefit in the gel arm or with no effect. </p> <p><sup>g</sup>Serious risk of bias due to inadequate reporting of study methods in 1 or more studies. </p> <p><sup>h</sup>Serious imprecision; findings compatible with meaningful benefit in the subcutaneous arm or with no effect. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009154-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Progesterone + oestrogen regimens for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone + oestrogen regimens for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction <br/> Comparisons of progesterone and oestrogen regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth/ongoing pregnancy ‐ short vs long protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000<br/> (251 to 372) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.08</p> <p>(0.81 to 1.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>910</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth/ongoing pregnancy ‐ low vs high dose protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>342 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000<br/> (161 to 370) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.65</p> <p>(0.37 to 1.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS ‐ short vs long protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in any studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS ‐ low vs high dose protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported in any studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the risk in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most study domains. </p> <p><sup>b</sup>Serious imprecision; findings compatible with meaningful benefit in either arm or with no effect. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Very serious imprecision with low event rate; findings compatible with meaningful benefit in either arm or with no effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009154-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009154-sec-0016"></div> <section id="CD009154-sec-0017"> <h3 class="title" id="CD009154-sec-0017">Description of the condition</h3> <p>Assisted reproductive technology (ART), such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI), is used increasingly to assist couples to have a family. In cases of fertility treatment during which one or more embryos were transferred, less than one‐third of cases resulted in a live birth (<a href="./references#CD009154-bbs2-0252" title="Centers for Disease Control and Prevention ASfRM, Society for Assisted Reproductive Technology 2007. Assisted Reproductive Technology Success Rates: National Summary and Fertility Clinic Reports. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention,2009. ">CDC 2009</a>; <a href="./references#CD009154-bbs2-0255" title="deMouzonJ , GoossensV , BhattacharyaS , CastillaJA , FerrarettiAP , KorsakV , et al. Assisted reproductive technology in Europe, 2006: results generated from European registers by ESHRE. Human Reproduction2010;25(8):1851‐62. ">de Mouzon 2010</a>; <a href="./references#CD009154-bbs2-0261" title="MacaldowieA , WangYA , ChughtaiAA , ChambersGM . Assisted reproductive technology in Australia and New Zealand 2012. Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales.2014. ">Macaldowie 2014</a>). These figures suggest that implantation failure is an important limiting factor in the outcomes of ART. </p> <p>The endometrium, which lines the uterus, prepares for implantation of the embryo. This process starts in the proliferative phase (from menstruation to ovulation) and extends throughout the luteal phase (from ovulation until menstruation). The luteal phase begins on the day of the luteinising hormone (LH) surge, which causes ovulation. The luteal phase ends at the onset of the next menstruation and usually lasts 12 to 16 days. During the luteal phase, the corpus luteum undergoes morphological and biochemical changes known as 'luteinisation'. Under the influence of LH, specific cells called granulosa cells produce progesterone. This in turn induces the secretory transformation of the endometrium, preparing it for implantation by thickening and increasing vascularisation to facilitate implantation (<a href="./references#CD009154-bbs2-0257" title="FarquharC , RobertsH . Introduction to Obstetrics and Gynaecology. Third Edition. Auckland: Department of Obstetrics &amp; Gynaecology, The University of Auckland, 2010. ">Farquhar 2010</a>). Implantation occurs six days after fertilisation in natural cycles. </p> <p>After implantation, trophoblastic tissue of the placenta secretes human chorionic gonadotropin (hCG), which acts on the ovary. hCG maintains and stimulates the corpus luteum, the remnant of the follicle, to produce oestradiol and progesterone (<a href="./references#CD009154-bbs2-0266" title="PabuccuR , AkarME . Luteal phase support in assisted reproductive technology. Current Opinion in Obstetrics and Gynecology2005;17(3):277‐81. ">Pabuccu 2005</a>). This is important in maintaining the pregnancy until the placenta takes over steroid hormone production at approximately seven weeks. </p> <p>From the early phase of assisted reproduction, it has been clear that the luteal phase in ART is not sufficient, although the underlying mechanism is unclear (<a href="./references#CD009154-bbs2-0256" title="EdwardsRG , SteptoePC , PurdyJM . Establishing full‐term human pregnancies using cleaving embryos grown in vitro. British Journal of Obstetrics and Gynaecology1980;87(9):737‐56. ">Edwards 1980</a>). Several theories have been proposed to explain the deficient luteal phase in ART. In ART cycles, the corpus luteum is formed from the remnants of aspirated follicles under the influence of LH and produces progesterone and oestradiol (<a href="./references#CD009154-bbs2-0263" title="MessinisIE , MessiniCI , DafopoulosK . Luteal‐phase endocrinology. Reproductive Biomedicine Online2009;19(4):4314. ">Messinis 2009</a>). It was first thought that oocyte retrieval caused a luteal phase defect and, in particular, steroid secretion, but this theory was rejected when Kerin (<a href="./references#CD009154-bbs2-0260" title="KerinJF , BroomTJ , RalphMM , EdmondsDK , WarnesGM , JeffreyR , et al. Human luteal phase function following oocyte aspiration from the immediately preovular graafian follicle of spontaneous ovular cycles. British Journal of Obstetrics and Gynaecology1981;88(10):1021‐8. ">Kerin 1981</a>) demonstrated that aspiration of a single follicle did not lead to impaired steroid function. Another theory was that gonadotropin‐releasing hormone (GnRH) agonist co‐treatment caused prolonged pituitary recovery, which resulted in lack of LH; thus the corpus luteum did not develop fully (<a href="./references#CD009154-bbs2-0269" title="SmitzJ , ErardP , CamusM , DevroeyP , TournayeH , WisantoA , et al. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH‐agonists and HMG in a desensitization or flare‐up protocol. Human Reproduction1992;7(9):1225‐9. ">Smitz 1992a</a>). Lack of LH was thought to be caused by a short‐loop negative feedback mechanism after hCG administration for oocyte maturation. This theory was also rejected, as long‐loop negative feedback by ovarian oestrogens has a greater effect on LH levels (<a href="./references#CD009154-bbs2-0264" title="MiyakeA , AonoT , KinugasaT , TanizawaO , KurachiK . Suppression of serum levels of luteinizing hormone by short‐ and long‐loop negative feedback in ovariectomized women. Journal of Endocrinology1979;80(3):353‐6. ">Miyake 1979</a>), and hCG does not lower LH secretion in non‐stimulated, normal ovulating women (<a href="./references#CD009154-bbs2-0270" title="TavaniotouA , DevroeyP . Effect of human chorionic gonadotropin on luteal luteinizing hormone concentrations in natural cycles. Fertility and Sterility2003;80(3):654‐5. ">Tavaniotou 2003</a>). Currently it is thought that LH levels are lowered by high steroid levels (<a href="./references#CD009154-bbs2-0258" title="FatemiHM . The luteal phase after 3 decades of IVF: what do we know?. Reproductive Biomedicine Online2009;19(4):4331. ">Fatemi 2009</a>). Steroid levels are high because of the multiple corpora lutea, which produce more steroids than are produced in a natural cycle. This causes negative feedback on the pituitary gland and lowers LH levels. In this way, the luteal phase is shortened (known as premature luteolysis), and chances of pregnancy are reduced. In summary, premature luteolysis results from high concentrations of steroids caused by higher numbers of corpora lutea (secondary to controlled ovarian stimulation) during the early luteal phase, which in turn inhibit LH release directly by negative feedback. </p> <p>In 2005, GnRH was introduced as a new means of providing luteal phase support. GnRH blocks the LH surge, and it was assumed that GnRH agonists might maintain their stimulatory effect throughout the luteal phase and restore LH levels ‐ a process that would support the luteal phase (Pirard 2006a). In 2004, Tesarik reported on the use of GnRH agonists six days after ICSI amongst oocyte donors. This study showed that single‐dose agonist administration increased the implantation rate without affecting miscarriage and abortion rates, resulting in an improved birth rate. However the multiple pregnancy rate was also increased (<a href="./references#CD009154-bbs2-0271" title="TesarikJ , HazoutA , MendozaC . Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation. Human Reproduction2004;19(5):1176‐80. ">Tesarik 2004</a>). </p> <p>Adequate luteal phase support is therefore essential during IVF and ICSI for improving implantation and pregnancy rates. This can be achieved by substituting deficient LH with GnRH agonists or hCG, which has a longer half‐life, or directly by using progesterone with or without oestrogen. The ideal method of luteal phase supplementation remains a matter of debate and is the focus of this review. </p> </section> <section id="CD009154-sec-0018"> <h3 class="title" id="CD009154-sec-0018">Description of the intervention</h3> <p>The following agents can be used during the luteal phase.</p> <p> <ol id="CD009154-list-0001"> <li> <p>Progesterone (including micronised progesterone or synthetic progestogens such as dydrogesterone, which have higher bioavailability (<a href="./references#CD009154-bbs2-0268" title="SchindlerAE . Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas2009;65(1):S3‐11. ">Schindler 2009</a>)), administered by the following routes. </p> <ol id="CD009154-list-0002"> <li> <p>Intramuscular (IM).</p> </li> <li> <p>Oral.</p> </li> <li> <p>Vaginal ‐ an oral progesterone supplement administered by the vaginal route can lead to higher serum progesterone concentrations (<a href="./references#CD009154-bbs2-0254" title="ChoavaratanaR , ManochD . Efficacy of oral micronized progesterone when applied via vaginal route. Journal of the Medical Association of Thailand2004;87(5):455‐8. ">Choavaratana 2004</a>). Progesterone can also be administered vaginally by a gel or cream, which can generate high concentrations by bypassing the first‐pass effect through the liver (<a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>). </p> </li> <li> <p>Rectal.</p> </li> </ol> </li> <li> <p>Human chorionic gonadotropin (hCG) is similar to LH in its mode of action and physiological effects. Molecular structure is also similar. However hCG differs from LH in that elevated sialic acid residues are responsible for the longer serum half‐life and potency (<a href="./references#CD009154-bbs2-0251" title="BalaschJ . The role of FSH and LH in ovulation induction: current concepts and the contribution of recombinant gonadotropins. In: GardnerDK , WeissmanA , Howles and ShohamV editor(s). Textbook of Assisted Reproductive Techniques. Laboratory and Clinical Perspectives. 2nd Edition. London and New York: Taylor &amp; Francis, 2004:541‐65. ">Balasch 2004</a>). Two types of hCG have been used: human derived and recombinant (<a href="./references#CD009154-bbs2-0265" title="MochtarMH , Van derVeenF , ZiechM , vanWelyM , MustersA . Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews2007, Issue 2. [DOI: 10.1002/14651858.CD005070] ">Mochtar 2007</a>). hCG is administered by the following routes. </p> <ol id="CD009154-list-0003"> <li> <p>Intramuscular (IM).</p> </li> <li> <p>Subcutaneous (SC). It has been suggested that the bioavailability of hCG is lower after SC injections than after IM injections, but this remains unclear (<a href="./references#CD009154-bbs2-0253" title="ChanCC , NgEH , ChanMM , TangOS , LauEY , YeungWS , et al. Bioavailability of hCG after intramuscular or subcutaneous injection in obese and non‐obese women. Human Reproduction2003;18(11):2294‐7. ">Chan 2003;</a><a href="./references#CD009154-bbs2-0262" title="MannaertsBM , GeurtsTB , OdinkJ . A randomized three‐way cross‐over study in healthy pituitary‐suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Human Reproduction1998;13(6):1461‐4. ">Mannaerts 1998</a>; <a href="./references#CD009154-bbs2-0267" title="SaalW , GlowaniaHJ , HengstW , HappJ . Pharmacodynamics and pharmacokinetics after subcutaneous and intramuscular injection of human chorionic gonadotropin. Fertility and Sterility1991;56(2):225‐9. ">Saal 1991</a>; <a href="./references#CD009154-bbs2-0272" title="WiklandM , BorgJ , ForsbergAS , JakobssonAH , SvalanderP , WaldenstromU . Human chorionic‐gonadotropin self‐administered by the subcutaneous route to induce oocyte maturation in an in‐vitro fertilization and embryo‐transfer program. Human Reproduction1995;10(7):1667‐70. ">Wikland 1995</a>). </p> </li> </ol> </li> <li> <p>Oestrogen: oral, transdermal or vaginal administration in combination with progesterone.</p> </li> <li> <p>GnRH agonists.</p> <ol id="CD009154-list-0004"> <li> <p>Intranasal.</p> </li> <li> <p>Intramuscular (IM).</p> </li> <li> <p>Subcutaneous (SC).</p> </li> </ol> </li> </ol> </p> </section> <section id="CD009154-sec-0019"> <h3 class="title" id="CD009154-sec-0019">How the intervention might work</h3> <p>In ART, levels of progesterone in the luteal phase are insufficient (see above); therefore the levels of progesterone need to be increased. The progesterone level can be increased directly by giving progesterone, or progesterone and oestrogen in combination, or indirectly by giving hCG, which in turn stimulates progesterone secretion. Addition of a GnRH agonist is thought to restore LH levels during the luteal phase. </p> </section> <section id="CD009154-sec-0020"> <h3 class="title" id="CD009154-sec-0020">Why it is important to do this review</h3> <p>Less than one‐third of all cases involving an embryo result in a live birth. Luteal phase support has a positive effect on the outcome of ART compared with no treatment (<a href="./references#CD009154-bbs2-0274" title="van derLindenM , BuckinghamK , FarquharC , KremerJA , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009154.pub2] ">van der Linden 2011</a>). Many randomised trials have compared different methods of administration and different preparations to identify the best method of providing luteal phase support. This updated Cochrane review examines all currently available evidence on hCG, progesterone, oestrogen and GnRH analogues as agents for luteal phase support in ART. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009154-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009154-sec-0021"></div> <p>To determine the relative effectiveness and safety of methods of luteal phase support provided to subfertile women undergoing assisted reproduction. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009154-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009154-sec-0022"></div> <section id="CD009154-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009154-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) comparing any of the agents used for luteal phase support during the luteal phase of an ART cycle. We included cross‐over trials in the review for completeness but used only first phase data in the analysis. We did not include quasi‐RCTs. We excluded studies investigating luteal phase support involving intrauterine insemination (IUI). </p> </section> <section id="CD009154-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included all subfertile women undergoing treatment with ART, including IVF or ICSI. We did not take the cause of subfertility into account. We excluded studies including women who had cycles of gamete intrafallopian transfer (GIFT) or zygote intrafallopian transfer (ZIFT), unless these treatments took place in less than 20% of cycles, as pregnancy outcomes with GIFT and ZIFT are less than with IVF. This 20% threshold was arbitrary. </p> </section> <section id="CD009154-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included trials if they investigated or included:</p> <p> <ol id="CD009154-list-0005"> <li> <p>any type, dose or route of progesterone, provided at least five doses were given during the luteal phase, to ensure the inclusion of true luteal phase support studies; </p> </li> <li> <p>any type, dose or route of hCG, provided at least two doses were given during the luteal phase, to ensure the inclusion of true luteal phase support studies; </p> </li> <li> <p>progesterone combined with oestrogen;</p> </li> <li> <p>progesterone combined with hCG; or</p> </li> <li> <p>GnRH agonist during the luteal phase.</p> </li> </ol> </p> <p>We considered all ovarian stimulation protocols.</p> <p>We excluded trials if they investigated or included:</p> <p> <ol id="CD009154-list-0006"> <li> <p>luteal phase support after frozen embryo transfer;</p> </li> <li> <p>luteal phase support after embryo transfer from donated oocytes;</p> </li> <li> <p>luteal phase support after embryo transfer from frozen oocytes or frozen ovarian tissue;</p> </li> <li> <p>luteal phase support after in vitro maturation (IVM) cycles; or</p> </li> <li> <p>luteal phase support after intrauterine insemination (IUI) cycles.</p> </li> </ol> </p> </section> <section id="CD009154-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD009154-sec-0028"> <h5 class="title">Primary outcomes</h5> <p>1. Live birth rate (LBR) or ongoing pregnancy per woman ('live birth' defined as the delivery of one or more living infants; 'ongoing pregnancy' defined as a pregnancy beyond 12 weeks' gestation). </p> </section> <section id="CD009154-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p>2. Clinical pregnancy rate (CPR) per woman (defined as the presence of a gestational sac, with or without a foetal heartbeat, on ultrasonography). </p> <p>3. Miscarriage rate (MR) per woman.</p> <p>4. Ovarian hyperstimulation syndrome (OHSS) per woman.</p> <p>5. Multiple pregnancy rate per woman (counted as one).</p> </section> </section> </section> <section id="CD009154-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>This review used information provided in the Cochrane Menstrual Disorder and Subfertility Group (MDSG) module regarding search strategies (<a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/MENSTR/frame.html" target="_blank">www.mrw.interscience.wiley.com/cochrane/clabout/articles/MENSTR/frame.html</a>). We sought all published and unpublished RCTs that described progesterone or hCG, or both, for luteal support in women undergoing ART. We used indexed and free‐text terms. We designed search strategies in consultation with the MDSG Trials Search Co‐ordinator. All searches were run from inception until 05.08.15 </p> <section id="CD009154-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases.</p> <p> <ol id="CD009154-list-0007"> <li> <p>MDSG Specialised Register (see <a href="./appendices#CD009154-sec-0230">Appendix 1</a>). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (see <a href="./appendices#CD009154-sec-0231">Appendix 2</a>). </p> </li> <li> <p>MEDLINE (see <a href="./appendices#CD009154-sec-0232">Appendix 3</a>). </p> </li> <li> <p>EMBASE (see <a href="./appendices#CD009154-sec-0233">Appendix 4</a>). </p> </li> <li> <p>PsycINFO (see <a href="./appendices#CD009154-sec-0234">Appendix 5</a>). </p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (see <a href="./appendices#CD009154-sec-0235">Appendix 6</a>). </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE) (see <a href="./appendices#CD009154-sec-0236">Appendix 7</a>). </p> </li> </ol> </p> <p>The MDSG Specialised Register has been prepared through handsearching.</p> <p>We combined the MEDLINE search with the Cochrane highly sensitive search strategy for identifying randomised trials, which appears in the <i>Cochrane Handbook for Systematic Reviews of Interventions,</i> Version 5.1.0, Chapter 6, 6.4.11 (<a href="./references#CD009154-bbs2-0259" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We combined the EMBASE search with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="http://www.sign.ac.uk/mehodology/filters.html#random" target="_blank">www.sign.ac.uk/mehodology/filters.html#random</a>). </p> <p>We imposed no language restrictions on the searches.</p> </section> <section id="CD009154-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We searched the following.</p> <p> <ol id="CD009154-list-0008"> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/ct2/home" target="_blank">http://clinicaltrials.gov/ct2/home</a>) for ongoing and registered trials (<a href="./appendices#CD009154-sec-0237">Appendix 8</a>) </p> </li> <li> <p>The World Health Organization International Trials Registry Platform (<a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">www.who.int/trialsearch/Default.aspx</a>) for ongoing and registered trials (<a href="./appendices#CD009154-sec-0237">Appendix 8</a>) </p> </li> <li> <p>Conference abstracts on the Web of Science (http://wokinfo.com) (see <a href="./appendices#CD009154-sec-0238">Appendix 9</a>). </p> </li> <li> <p>OpenSigle for grey literature from Europe (<a href="http://opensigle.inist.fr" target="_blank">http://opensigle.inist.fr</a>), using the search string "((chorionic gonadotropin) OR (progesterone)) AND (luteal phase)". </p> </li> <li> <p>Latin American Caribbean Health Sciences Literature (LILACS) (<a href="http://regional.bvsalud.org/php/index.php?lang=en" target="_blank">http://regional.bvsalud.org/php/index.php?lang=en</a>), using the keywords "luteal phase support". </p> </li> </ol> </p> </section> </section> <section id="CD009154-sec-0033"> <h3 class="title" id="CD009154-sec-0033">Data collection and analysis</h3> <section id="CD009154-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MvdL, MM) independently screened titles and abstracts to exclude studies that were clearly irrelevant. We retrieved the full texts of potentially eligible studies for further independent scrutiny by two review authors (MvdL, MM) and checked compliance with the inclusion criteria by using the study eligibility form (see <a href="./appendices#CD009154-sec-0239">Appendix 10</a>). We provided reasons for exclusion in the 'Characteristics of excluded trials' table. When it was unclear whether a study was eligible, we contacted the original study authors. We resolved disagreements through consultation with a third review author (CF). </p> </section> <section id="CD009154-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>We extracted data using a data extraction form (see <a href="./appendices#CD009154-sec-0240">Appendix 11</a>) that was designed and pilot‐tested by the review authors. In the case of multiple publications, we referenced studies by their main trial report and linked the references. We contacted the original study authors if further information was required. Three review authors (MvdL, MM, KB) independently extracted data and resolved disagreements through consultation with the other review authors. </p> </section> <section id="CD009154-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias with regard to sequence generation, allocation, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data, selective reporting and other potential sources of bias. We summarised conclusions in a 'Risk of bias' table (see <a href="./appendices#CD009154-sec-0241">Appendix 12</a>). Review authors judged all six domains as at 'low risk', 'high risk' or 'unclear risk' of bias and described in the table the methods used. When information was missing, we contacted study authors. </p> <p> <ol id="CD009154-list-0009"> <li> <p>Random sequence generation (selection bias).</p> <ol id="CD009154-list-0010"> <li> <p>Proper methods included use of a computer random number generator, coin tossing, dice throwing and shuffling of cards or envelopes. </p> </li> <li> <p>Allocation by judgement of clinician, preference of participant, lab tests, date of birth, record number and inadequate sequence generation such as day of the week was not sufficient. </p> </li> </ol> </li> <li> <p>Allocation concealment (selection bias).</p> <ol id="CD009154-list-0011"> <li> <p>Proper methods required sequentially numbered drug containers of identical appearance, numbered opaque sealed envelopes or secure third party randomisation such as by telephone or computer allocation. </p> </li> <li> <p>Prior knowledge of the allocation because of an open random allocation schedule or alternation, rotation, etc, was not sufficient. </p> </li> </ol> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> <ol id="CD009154-list-0012"> <li> <p>Review authors assigned low risk of bias when blinding of clinicians and participants (when possible) was ensured, or when incomplete blinding had no effect on the outcome measurement. </p> </li> <li> <p>When no blinding was provided and this had an influence on the outcome measurement, review authors identified the study as having risk of bias. </p> </li> </ol> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> <ol id="CD009154-list-0013"> <li> <p>Review authors assigned low risk of bias when blinding of researchers (when possible) was ensured, or when incomplete blinding had no effect on the outcome measurement. </p> </li> <li> <p>When no blinding was provided and this had an influence on the outcome measurement, review authors identified the study as having risk of bias. </p> </li> </ol> </li> <li> <p>Incomplete outcome data (attrition bias).</p> <ol id="CD009154-list-0014"> <li> <p>Review authors assigned low risk of bias when missing outcome data were unlikely to be related to true outcomes, or when all outcome data were complete. </p> </li> <li> <p>High risk of bias indicated that missing outcome data were likely to be related to true outcomes, or that the proportion of missing outcome results compared with observed event risk was sufficient to induce clinically relevant bias in observed effect size. </p> </li> </ol> </li> <li> <p>Selective reporting (reporting bias).</p> <ol id="CD009154-list-0015"> <li> <p>Review authors assigned low risk of bias when all prespecified outcomes that were of interest or described in the protocol were reported. </p> </li> <li> <p>High risk of bias indicated that not all prespecified outcomes were mentioned, reported outcomes were not prespecified or a key outcome that would be expected was not reported. </p> </li> </ol> </li> <li> <p>Free of other bias.</p> <ol id="CD009154-list-0016"> <li> <p>Risk of other bias (e.g. embryo transfer policies different in different arms of the study) showed extreme baseline imbalance. </p> </li> </ol> </li> </ol> </p> <p>When risk of bias tables had been completed, we generated a risk of bias summary figure (<a href="./references#CD009154-bbs2-0259" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD009154-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We retrieved only dichotomous data for this review; thus we calculated Peto odds ratios (ORs) with 95% confidence intervals (CIs). </p> </section> <section id="CD009154-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The primary analysis was per woman randomly assigned. We counted multiple live births as one live birth and included cross‐over data from the first phase of the study. When information were missing, we contacted the study authors. </p> </section> <section id="CD009154-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>To obtain complete data, as much as possible, we contacted the original study authors. In case data could not be obtained, we undertook imputation for the primary outcome and assumed that no live birth occurred when this was not reported. When data for secondary outcomes were missing, we analysed only available data. </p> </section> <section id="CD009154-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by examining a forest plot and the I<sup>2</sup> statistic according to guidelines set forth in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009154-bbs2-0259" title="HigginsJPT , GreenS , editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane‐handbook.org. ">Higgins 2011</a>). If we detected substantial heterogeneity, that is, I<sup>2</sup> ≥ 50%, we performed a sensitivity analysis to explore possible explanations. </p> </section> <section id="CD009154-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias by examining a funnel plot if more than 10 studies were included. An asymmetrical funnel plot indicates possible publication bias, although the asymmetry may have other causes. We assessed within‐study reporting bias if study protocols were available, and if we noted differences between outcomes in the protocol and in the subsequent publication. </p> </section> <section id="CD009154-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We combined the data from primary studies by using a fixed‐effect model in the following comparisons. </p> <p> <ol id="CD009154-list-0017"> <li> <p>hCG versus placebo or no treatment.</p> </li> <li> <p>Progesterone versus placebo or no treatment.</p> </li> <li> <p>Progesterone versus hCG regimens.</p> <ol id="CD009154-list-0018"> <li> <p>Progesterone versus hCG.</p> </li> <li> <p>Progesterone versus progesterone and hCG.</p> </li> </ol> </li> <li> <p>Progesterone versus progesterone and oestrogen.</p> <ol id="CD009154-list-0019"> <li> <p>Oral oestrogen.</p> </li> <li> <p>Transdermal oestrogen.</p> </li> <li> <p>Vaginal oestrogen.</p> </li> <li> <p>Oral and transdermal oestrogen.</p> </li> </ol> </li> <li> <p>Progesterone versus progesterone and GnRH agonist.</p> <ol id="CD009154-list-0020"> <li> <p>Single dose.</p> </li> <li> <p>Multiple dose.</p> </li> </ol> </li> <li> <p>Progesterone regimens.</p> <ol id="CD009154-list-0021"> <li> <p>IM progesterone versus oral progesterone.</p> </li> <li> <p>IM progesterone versus vaginal or rectal progesterone.</p> </li> <li> <p>Vaginal or rectal progesterone versus oral progesterone.</p> </li> <li> <p>Low‐dose vaginal progesterone (≤ 100 mg) versus high‐dose vaginal progesterone (&gt; 100 mg). </p> </li> <li> <p>Short protocol versus long protocol.</p> </li> <li> <p>Micronised progesterone versus synthetic progesterone.</p> </li> <li> <p>Vaginal ring versus vaginal gel.</p> </li> <li> <p>Subcutaneous versus vaginal gel.</p> </li> <li> <p>Vaginal progesterone versus rectal progesterone.</p> </li> </ol> </li> <li> <p>Progesterone + oestrogen regimens.</p> <ol id="CD009154-list-0022"> <li> <p>Short protocol versus long protocol.</p> </li> <li> <p>Low‐dose oestrogen (≤ 2 mg) versus high‐dose oestrogen (&gt; 2 mg).</p> </li> </ol> </li> </ol> </p> <p>When studies contributed to more than one comparison in a pooled analysis, we split as equally as possible comparisons data from the group that appeared in both comparisons. When data were split in this way, we provided details in a footnote in the forest plot. </p> </section> <section id="CD009154-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We analysed data in the following subgroups as well.</p> <p> <ol id="CD009154-list-0023"> <li> <p>Ovarian stimulation protocols including:</p> <ol id="CD009154-list-0024"> <li> <p>clomiphene citrate alone without GnRH agonists;</p> </li> <li> <p>human gonadotropins with clomiphene citrate without GnRH agonists;</p> </li> <li> <p>human gonadotropins with or without GnRH agonists; and</p> </li> <li> <p>human gonadotropins with or without GnRH antagonists.</p> </li> </ol> </li> <li> <p>Participants with previously failed cycles.</p> <ol id="CD009154-list-0025"> <li> <p>≤ 2 failed ART cycles.</p> </li> <li> <p>&gt; 2 failed ART cycles.</p> </li> </ol> </li> <li> <p>Duration of progesterone.</p> <ol id="CD009154-list-0026"> <li> <p>Stop at day of positive pregnancy test.</p> </li> <li> <p>Given up to 12 weeks for women who conceive.</p> </li> </ol> </li> <li> <p>Number of embryos transferred.</p> <ol id="CD009154-list-0027"> <li> <p>Single embryo transfer.</p> </li> <li> <p>&gt; one embryo transferred.</p> </li> </ol> </li> </ol> </p> </section> <section id="CD009154-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis for the primary outcome to determine differences in results caused by: </p> <p> <ol id="CD009154-list-0028"> <li> <p>eligibility restricted to studies without high risk of bias;</p> </li> <li> <p>alternative imputation strategies that had been adopted;</p> </li> <li> <p>use of risk ratio rather than odds ratio as the effect estimate; or</p> </li> <li> <p>use of a random‐effects rather than a fixed‐effect analysis.</p> </li> </ol> </p> <section id="CD009154-sec-0045"> <h5 class="title">Overall quality of the body of evidence: 'Summary of findings' table</h5> <p>We prepared 'Summary of findings' tables using GRADEPRO software. These tables evaluate the overall quality of the body of evidence for the primary review outcomes, using GRADE (Grades of Recommendation, Assessment, Development and Evaluation) criteria (study limitations (i.e. risk of bias), consistency of effect, imprecision, indirectness and publication bias). We have justified, documented and incorporated into reporting of results for each outcome judgements about evidence quality (high, moderate or low). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009154-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009154-sec-0046"></div> <section id="CD009154-sec-0047"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009154-sec-0251" title="">Characteristics of included studies</a> and <a href="./references#CD009154-sec-0252" title="">Characteristics of excluded studies</a>. </p> <section id="CD009154-sec-0048"> <h4 class="title">Results of the search</h4> <p>We conducted our searches on 05 August 2015 (using the strings reported in the appendices (<a href="./appendices#CD009154-sec-0231">Appendix 2</a>; <a href="./appendices#CD009154-sec-0232">Appendix 3</a>; <a href="./appendices#CD009154-sec-0233">Appendix 4</a>; <a href="./appendices#CD009154-sec-0234">Appendix 5</a>; <a href="./appendices#CD009154-sec-0230">Appendix 1</a>; <a href="./appendices#CD009154-sec-0235">Appendix 6</a>; <a href="./appendices#CD009154-sec-0236">Appendix 7</a>; <a href="./appendices#CD009154-sec-0237">Appendix 8</a>; <a href="./appendices#CD009154-sec-0238">Appendix 9</a>), and in Open System for Information on Grey Literature in Europe (OpenSigle) and Latin American Caribbean Health Sciences Literature (LILACS). We identified 2441 studies and found six studies by using other methods such as handsearching. </p> <p>On the website <a href="http://clinicaltrials.gov/ct2/home" target="_blank">ClinicalTrials.gov</a> in November 2014, we found 10 ongoing studies after using the keywords "luteal phase support". One study did not provide sufficient contact details. Five study authors did not reply (NCT01178931, NCT00828191, NCT00656201, NCT00708539, NCT01850030). One study author replied, and this study turned out to be already published (NCT00827983 as <a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>). Three studies were already published (NCT01147770 as <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>, NCT01367912 as <a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a> and NCT01177904 as <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>). The World Health Organization <a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">International Trials Registry Platform</a> (ICTRP), when searched with the keywords "luteal phase support", brought up eight new studies. Three studies did not provide sufficient contact details. Three studies were already published (ISRCTN88722916 as <a href="./references#CD009154-bbs2-0003" title="AboulgharMA , AminYM , Al‐InanyHG , AboulgharMM , MouradLM , SerourGI , et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Human Reproduction2008;23(4):857‐62. ">Aboulghar 2008</a>, ICTR2013050713265N1 as <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>, and ICTR138807192568N1 as <a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>). One study author did reply but had no data ready (EUCTR2013‐001105‐81‐HU). One study author did not reply (NCT01237535). From both these sites there were 11 ongoing studies. </p> <p>Further database searches on 4 August 2015 identified two new studies eligible for inclusion and we have incorporated their data in the abstract, results and discussion sections of the review. Two studies requiring additional information before we could assess eligibility await classification for inclusion or exclusion at the next update of this review. </p> <p>A further search of the ICTRP and clinicaltrials.gov (<a href="./appendices#CD009154-sec-0237">Appendix 8</a>) sites on 4 August 2015 found another 17 ongoing studies. After de‐duplication a total of 22 ongoing studies remained. For full details of all ongoing studies see <a href="./references#CD009154-sec-0254" title="">Characteristics of ongoing studies</a>. </p> <p>After duplicates were removed, 578 studies were left for screening. We excluded 352 clearly irrelevant studies. We obtained and fully reviewed the full‐text articles for the other 226 studies. We excluded all quasi‐randomised trials, together with articles that did not meet our inclusion criteria. We excluded another 31 articles from the review and included in the meta‐analysis a total of 94 studies (see <a href="#CD009154-fig-0001">Figure 1</a> for a study flow diagram). Three trials are awaiting assessment (<a href="./references#CD009154-bbs2-0226" title="PirardC , LoumayeE , LaurentP , WynsC . Contribution to More Patient‐Friendly ART Treatment: Efficacy of Continuous Low‐Dose GnRH Agonist as the Only Luteal Support‐Results of a Prospective, Randomized, Comparative Study. International Journal of Endocrinology2015;Apr 05:727569. ">Pirard 2015</a>; <a href="./references#CD009154-bbs2-0227" title="TomicV , TomicJ , KlaicDZ , KasumM , KunaK . Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. European journal of obstetrics, gynecology, and reproductive biology2015;186:49‐53. [PUBMED: 25622239] ">Tomic 2015</a>; <a href="./references#CD009154-bbs2-0228" title="ZafardoustS , et al. Effect of administration of single dose GnRH agonist in luteal phase on outcome of ICSI‐ET cycles in women with previous history of IVF/ICSI failure: A randomized controlled trial.. Journal of Reproduction and Infertility2015;16(2):116‐120. ">Zafardoust 2015</a>) . </p> <div class="figure" id="CD009154-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009154-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009154-sec-0049"> <h4 class="title">Included studies</h4> <section id="CD009154-sec-0050"> <h5 class="title">Study design</h5> <p>We included 94 studies, all of which were randomised controlled trials. We found no cross‐over trials for inclusion. In total, included studies consisted of 25,471 women with a mean age of 32.4 years. Inclusion and exclusion criteria varied among studies. Some studies included women with polycystic ovarian syndrome (PCOS), but this was an exclusion criterion in other studies. A few studies included women undergoing their first cycle, but most studies included women who had already undergone ART. Overall a mean of 2.43 embryos per woman were transferred, most with a maximum of three or four embryos. </p> <p>For 24 studies, only the abstract was published (<a href="./references#CD009154-bbs2-0007" title="AlbertJ , PfeiferS . Luteal phase hormone levels after in vitro fertilization and embryo transfer (IVF‐ET): a prospective randomized trial of human chorionic gonadotropin (hCG) vs. intramuscular (im) progesterone (P) for luteal phase support following stimulation with gonadotropin‐releasing hormone agonist (GnRH‐a) and human menopausal gonadotropins (hMG) [abstract]. Fertility and Sterility. 1991:S18 (Abs # O‐041). ">Albert 1991</a>; <a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>; <a href="./references#CD009154-bbs2-0015" title="BeltsosA , SanchezM , DoodyK , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin®) compared to intramuscular progesterone in oil for luteal support in PCOS patients. Fertility and Sterility2011;96(Suppl):S130 (Abs # P‐71). ">Beltsos 2011</a>; <a href="./references#CD009154-bbs2-0017" title="BriganteCMM , Mignini RenziniM , Dal CantoM , CoticchioG , ComiR , FadiniR . Efficacy of luteal phase support with GnRH agonists: a preliminary comparative study. Fertility and Sterility2013;100(Suppl):S299 (Abs # P‐521). ">Brigante 2013</a>; <a href="./references#CD009154-bbs2-0018" title="CaligaraC , CarranzaF , RamosJ , RodriguezI , GonzalezA , Fernandez‐SanchezM . Luteal phase support in IVF patients at low risk for OHSS: progesterone vs. progesterone plus HCG. A prospective randomized study. Fertility and Sterility2007;88:S163 (Abs#P‐166). ">Caligara 2007</a>; <a href="./references#CD009154-bbs2-0021" title="ColakogluM , ToyH , IcenMS , VuralM , MahmoudAS , YaziciF . The impact of estrogen supplementation on IVF outcome in patients with polycystic ovary syndrome. Human Reproduction2011;26(Suppl 1):i296 (Abs # P‐450). ">Colakoglu 2011</a>; <a href="./references#CD009154-bbs2-0026" title="DunstoneT , ZosmerA , HussainS , TozerA , PaneyN , WilsonC , et al. A comparison between Cyclogest pessaries and Crinone gel as luteal support in IVF‐ET cycles [abstract]. British Fertility Society Annual Meeting Abstract Book. 1999:62 (Abs # FC21). ">Dunstone 1999</a>; <a href="./references#CD009154-bbs2-0029" title="ErdemM , KutlusoyF , ErdemA , GulerI , MesutO , BiberogluK . Luteal phase support with estrogen in addition to progesterone in patients with poor response to gonadotropins undergoing IVF. Fertility and Sterility2013;100(Suppl 1):S300‐1 (Abs # P‐526). ">Erdem 2013</a>; <a href="./references#CD009154-bbs2-0035" title="GeberS , MaiaL , LauarI , ValleMP , SampaioAC . Does recombinant LH combined to progesterone for luteal phase interfere in the outcome of assisted reproduction technique cycles? [abstract]. Fertility and Sterility2007;88 Suppl 1:25 (Abs #66). ">Geber 2007</a>; <a href="./references#CD009154-bbs2-0037" title="GeusaS , CausioF , MarinaccioM , StanzianoA , SarcinaE . Luteal phase support with progesterone in IVF/ET cycles: a prospective, randomized study comparing vaginal and intramuscular administration [abstract]. Human Reproduction2001;16 Suppl 1:145 (Abs # P‐111). ">Geusa 2001</a>; <a href="./references#CD009154-bbs2-0047" title="Kably AmbeA , Ruiz AnguasJ , Walters ArballoF , García BenitezCQ , Karchmer KrivitskyS . Results' analysis of estradiol and progesterone supplementation in luteal phase vs progesterone alone in an assisted reproduction program. Ginecologia y Obstetricia de Mexico2005;73:173‐82. ">Kably Ambe 2005</a>; <a href="./references#CD009154-bbs2-0057" title="LohSKE , LeongNKY . Luteal phase support in IVF‐cycles ‐ is intramuscular progesterone the therapy of choice? [abstract]. Fertility Society of Australia XV Annual Meeting Abstract Book (Abs #O24). 1996. ">Loh 1996</a>; <a href="./references#CD009154-bbs2-0060" title="MacrolinG , BuvatJ , GuittardC , HerbautJC , LouvetAL , DehaeneJL . [Fécondation in vitro après agoniste de la LHRH: comparison randomisée de soutiens lutéaux par progestérone vaginale seule ou associee a la gonadotrophine chorionique]. Contraception Fertilité Sexualité1993;21(5):434. ">Macrolin 1993</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0065" title="NallapetaS , SharmaV . Intra‐muscular progesterone as a luteal phase support increases live birth rate as compared to vaginal route. Fertility and Sterility2013;100(Supp):S8 (Abs #O‐25). NallapetaS , SharmaV . Relationship of different progesterone preparations on ovarian volumes in women undergoing IVF/ICSI treatment. Fertility and Sterility2013;100(Suppl):S60 (Abs # O‐196). ">Nallapeta 2013</a>; <a href="./references#CD009154-bbs2-0071" title="PorcuE . Intramuscular versus vaginal progesterone in assisted reproduction [abstract]. Fertility and Sterility. 2003; Vol. 80:S131 (Abs # P‐32). ">Porcu 2003</a>; <a href="./references#CD009154-bbs2-0075" title="Rodriguez‐PezinoJ , Saucedo‐de la LlataE , Batiza‐ResendizV , Galache‐VegaP , Santos‐HaliscakR , Hernandez‐AyupS , et al. Vaginal progesterone in assisted reproduction. Human Reproduction. Berlin, Germany, 2004; Vol. 19 Suppl 1:i51. ">Rodriguez‐Pezino 2004</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>; <a href="./references#CD009154-bbs2-0077" title="Saucedo‐de la LlataE , GalacheVP , HernandezAS , SantosHR , ArenasML , PatrizioP . Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility2000;74 Suppl 1:S150 (Abs # P‐175). ">Saucedo 2000</a>; <a href="./references#CD009154-bbs2-0078" title="Saucedo‐de la LlataE , BatizaV , ArenasL , SantosR , GalacheP , Hernandez‐AyupS , et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration [abstract]. Fertility and Sterility2003;18 Suppl 1:130 (Abs # P‐382). ">Saucedo 2003</a>; <a href="./references#CD009154-bbs2-0080" title="SerourAG . Luteal phase support in fresh IVF/ICSI cycles. International Journal of Gynecology and Obstetrics2012;119:S533 (Abs# M007). ">Serour 2012</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>; <a href="./references#CD009154-bbs2-0083" title="SumitaS , SofatSSr . Intramuscular versus intra vaginal progesterone as luteal phase and early pregnancy support in patients undergoing IVF‐ET [abstract]. Fertility and Sterility2003;80 Suppl 3:134‐5 (Abs # P‐44). ">Sumita 2003</a>; <a href="./references#CD009154-bbs2-0088" title="UgurM , YenicesuO , OzcanS , KelesG , GokmenO . A prospective randomized study comparing hCG, vaginal micronized progesterone and a combination regimen for luteal phase support in an in‐vitro fertilization programme [abstract]. Fertility and Sterility2001;76 Suppl 1:118 (Abs # P‐19). ">Ugur 2001</a>); the other studies were full‐text journal publications. Only 13 were multi‐centre studies (<a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0015" title="BeltsosA , SanchezM , DoodyK , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin®) compared to intramuscular progesterone in oil for luteal support in PCOS patients. Fertility and Sterility2011;96(Suppl):S130 (Abs # P‐71). ">Beltsos 2011</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>; <a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>). </p> <p>Thirteen of our included studies were carried out in the United States of America (<a href="./references#CD009154-bbs2-0007" title="AlbertJ , PfeiferS . Luteal phase hormone levels after in vitro fertilization and embryo transfer (IVF‐ET): a prospective randomized trial of human chorionic gonadotropin (hCG) vs. intramuscular (im) progesterone (P) for luteal phase support following stimulation with gonadotropin‐releasing hormone agonist (GnRH‐a) and human menopausal gonadotropins (hMG) [abstract]. Fertility and Sterility. 1991:S18 (Abs # O‐041). ">Albert 1991</a>; <a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0015" title="BeltsosA , SanchezM , DoodyK , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin®) compared to intramuscular progesterone in oil for luteal support in PCOS patients. Fertility and Sterility2011;96(Suppl):S130 (Abs # P‐71). ">Beltsos 2011</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>; <a href="./references#CD009154-bbs2-0054" title="LicciardiF , KwiatkowskiA , NoyesN , BerkeleyAS , KreyLL , GrifoJA . Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertility and Sterility1999;71:614‐8. ">Licciardi 1999</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>; <a href="./references#CD009154-bbs2-0090" title="WilliamsSC , OehningerS , GibbonsWE , VanCleaveWC , MuasherSJ . Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertility and Sterility2001;76:1140‐3. ">Williams 2001</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>). Ten studies were reported from Turkey (<a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0021" title="ColakogluM , ToyH , IcenMS , VuralM , MahmoudAS , YaziciF . The impact of estrogen supplementation on IVF outcome in patients with polycystic ovary syndrome. Human Reproduction2011;26(Suppl 1):i296 (Abs # P‐450). ">Colakoglu 2011</a>; <a href="./references#CD009154-bbs2-0029" title="ErdemM , KutlusoyF , ErdemA , GulerI , MesutO , BiberogluK . Luteal phase support with estrogen in addition to progesterone in patients with poor response to gonadotropins undergoing IVF. Fertility and Sterility2013;100(Suppl 1):S300‐1 (Abs # P‐526). ">Erdem 2013</a>; <a href="./references#CD009154-bbs2-0039" title="GorkemliH , AkD , AkyurekC , AktanM , DumanS . Comparison of pregnancy outcomes of progesterone or progesterone plus estradiol for luteal phase support in ICSI‐ET cycles. Gynecologic and Obstetric Investigation2004;58(3):140‐4. ">Gorkemli 2004</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>; <a href="./references#CD009154-bbs2-0088" title="UgurM , YenicesuO , OzcanS , KelesG , GokmenO . A prospective randomized study comparing hCG, vaginal micronized progesterone and a combination regimen for luteal phase support in an in‐vitro fertilization programme [abstract]. Fertility and Sterility2001;76 Suppl 1:118 (Abs # P‐19). ">Ugur 2001</a>; <a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>) and eight from Italy (<a href="./references#CD009154-bbs2-0001" title="AbateA , BrigandiA , AbateFG , MantiF , UnferV , PerinoM . Luteal phase support with 17alpha‐hydroxyprogesterone versus unsupported cycles in in vitro fertilization: a comparative randomized study. Gynaecologic and Obstetric Investigation1999;48(2):78‐80. AbateA , BrigandiA , CostabileL , AbateFG , BalzanoE , PerinoM . 17‐alpha‐Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics &amp; Gynecology1997;24(4):190‐2. ">Abate 1999</a>; <a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0017" title="BriganteCMM , Mignini RenziniM , Dal CantoM , CoticchioG , ComiR , FadiniR . Efficacy of luteal phase support with GnRH agonists: a preliminary comparative study. Fertility and Sterility2013;100(Suppl):S299 (Abs # P‐521). ">Brigante 2013</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0037" title="GeusaS , CausioF , MarinaccioM , StanzianoA , SarcinaE . Luteal phase support with progesterone in IVF/ET cycles: a prospective, randomized study comparing vaginal and intramuscular administration [abstract]. Human Reproduction2001;16 Suppl 1:145 (Abs # P‐111). ">Geusa 2001</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0071" title="PorcuE . Intramuscular versus vaginal progesterone in assisted reproduction [abstract]. Fertility and Sterility. 2003; Vol. 80:S131 (Abs # P‐32). ">Porcu 2003</a>). Twenty‐seven studies were conducted in other European countries: Austria (<a href="./references#CD009154-bbs2-0031" title="FeichtingerM , HejekJ , KemterP , FeichtingerW . Effect of luteal phase support comparing early (day 1) and late (day 4) initiation with pregnancy rates. Journal of Reproductive Medicine and Endocrinology2011;8(4):288‐90. ">Feichtinger 2011</a>), Belgium (<a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>), Denmark (<a href="./references#CD009154-bbs2-0041" title="HumaidanP , BungumL , BungumM , AndersenCY . Rescue of corpus luteum function with peri‐ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online2006;13(2):173‐8. ">Humaidan 2006</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>), Finland (<a href="./references#CD009154-bbs2-0089" title="VimpeliT , TinkanenH , HuhtalaH , RonnbergL , KujansuuE . Salivary and serum progesterone concentrations during two luteal support regimens used in in vitro fertilization treatment. Fertility and Sterility2001;76:847‐8. ">Vimpeli 2001</a>), France (<a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0060" title="MacrolinG , BuvatJ , GuittardC , HerbautJC , LouvetAL , DehaeneJL . [Fécondation in vitro après agoniste de la LHRH: comparison randomisée de soutiens lutéaux par progestérone vaginale seule ou associee a la gonadotrophine chorionique]. Contraception Fertilité Sexualité1993;21(5):434. ">Macrolin 1993</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>), Germany (<a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>), Greece (<a href="./references#CD009154-bbs2-0025" title="DrakakisP , LoutradisD , VomvolakiE , StefanidisK , KiapekouE , AnagnostouE , et al. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection‐embryo transfer. Gynecological Endocrinology2007;23(11):645‐52. ">Drakakis 2007</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>), the Netherlands (<a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a>), Spain (<a href="./references#CD009154-bbs2-0018" title="CaligaraC , CarranzaF , RamosJ , RodriguezI , GonzalezA , Fernandez‐SanchezM . Luteal phase support in IVF patients at low risk for OHSS: progesterone vs. progesterone plus HCG. A prospective randomized study. Fertility and Sterility2007;88:S163 (Abs#P‐166). ">Caligara 2007</a>; <a href="./references#CD009154-bbs2-0047" title="Kably AmbeA , Ruiz AnguasJ , Walters ArballoF , García BenitezCQ , Karchmer KrivitskyS . Results' analysis of estradiol and progesterone supplementation in luteal phase vs progesterone alone in an assisted reproduction program. Ginecologia y Obstetricia de Mexico2005;73:173‐82. ">Kably Ambe 2005</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0061" title="MartinezF , CoroleuB , PareraN , AlvarezM , TraverJM , BoadaM , et al. Human chorionic gonadotropin and intravaginal natural progesterone are equally effective for luteal phase support in IVF. Gynaecological Endocrinology2000;14:316‐20. ">Martinez 2000</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>) and the UK (<a href="./references#CD009154-bbs2-0026" title="DunstoneT , ZosmerA , HussainS , TozerA , PaneyN , WilsonC , et al. A comparison between Cyclogest pessaries and Crinone gel as luteal support in IVF‐ET cycles [abstract]. British Fertility Society Annual Meeting Abstract Book. 1999:62 (Abs # FC21). ">Dunstone 1999</a>; <a href="./references#CD009154-bbs2-0065" title="NallapetaS , SharmaV . Intra‐muscular progesterone as a luteal phase support increases live birth rate as compared to vaginal route. Fertility and Sterility2013;100(Supp):S8 (Abs #O‐25). NallapetaS , SharmaV . Relationship of different progesterone preparations on ovarian volumes in women undergoing IVF/ICSI treatment. Fertility and Sterility2013;100(Suppl):S60 (Abs # O‐196). ">Nallapeta 2013</a>; <a href="./references#CD009154-bbs2-0084" title="TayPYS , LentonEA . The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia2005;60(2):151‐7. ">Tay 2005</a>). Thirteen were carried out in Asia: China (<a href="./references#CD009154-bbs2-0052" title="LamPM , CheungMC , CheungLP , LokHI , HainesCJ . Effects of early luteal‐phase vaginal progesterone supplementation on the outcome of in vitro fertilization and embryo transfer. Gynecological Endocrinology2008;24(12):674‐80. ">Lam 2008</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0066" title="NgEHY , MiaoB , CheungW , HoPC . A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. European Journal of Obstetrics Gynecology and Reproductive Biology2003;111:50‐4. ">Ng 2003</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0091" title="WongYF , LoongEPL , MaoKR , TamPPL , PanesarNS , NealeE , et al. Salivary oestradiol and progesterone after in vitro fertilization and embryo transfer using different luteal support regimens. Reproduction Fertility and Development1990;2:351‐8. ">Wong 1990</a>), India (<a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0043" title="InamdarDB , MajumdarA . Evaluation of the impact of gonadotropin‐releasing hormone agonist as an adjuvant in luteal‐phase support on IVF outcome. Journal of Human Reproductive Sciences2012;5(3):279‐84. ">Inamdar 2012</a>; <a href="./references#CD009154-bbs2-0069" title="PatkiA , PawarVC . Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecological Endocrinology2007;23 Suppl 1:68‐72. ">Patki 2007</a>; <a href="./references#CD009154-bbs2-0083" title="SumitaS , SofatSSr . Intramuscular versus intra vaginal progesterone as luteal phase and early pregnancy support in patients undergoing IVF‐ET [abstract]. Fertility and Sterility2003;80 Suppl 3:134‐5 (Abs # P‐44). ">Sumita 2003</a>), Japan (<a href="./references#CD009154-bbs2-0033" title="FujimotoA , OsugaY , FujiwaraT , YanoT , TsutsumiO , MomoedaM , et al. Human chorionic gonadotropin combined with progesterone for luteal support improves pregnancy rate in patients with low late‐midluteal estradiol levels in IVF cycles. Journal of Assisted Reproduction and Genetics2002;19(12):550‐4. FujimotoA , OsugaY , OoiN , FujiwaraT , YanoT , TaketaniY . Addition of hCG to progesterone as a luteal support improves pregnancy rates for patients with low mid‐luteal oestradiol levels in IVF and ICSI [abstract]. Human Reproduction. 2001; Vol. 16, issue Suppl 1:143 (Abs #P‐143). ">Fujimoto 2002</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>) and Singapore (<a href="./references#CD009154-bbs2-0057" title="LohSKE , LeongNKY . Luteal phase support in IVF‐cycles ‐ is intramuscular progesterone the therapy of choice? [abstract]. Fertility Society of Australia XV Annual Meeting Abstract Book (Abs #O24). 1996. ">Loh 1996</a>). We also found studies from Australia (<a href="./references#CD009154-bbs2-0087" title="TorodeHW , PorterRN , VaughanJI , SaundersDM . Luteal phase support after in vitro fertilisation: a trial and rationale for selective use. Clinical Reproduction and Fertility1987;5:255‐61. ">Torode 1987</a>), Brasil (<a href="./references#CD009154-bbs2-0035" title="GeberS , MaiaL , LauarI , ValleMP , SampaioAC . Does recombinant LH combined to progesterone for luteal phase interfere in the outcome of assisted reproduction technique cycles? [abstract]. Fertility and Sterility2007;88 Suppl 1:25 (Abs #66). ">Geber 2007</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>), Canada (<a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>), Egypt (<a href="./references#CD009154-bbs2-0003" title="AboulgharMA , AminYM , Al‐InanyHG , AboulgharMM , MouradLM , SerourGI , et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Human Reproduction2008;23(4):857‐62. ">Aboulghar 2008</a>; <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a>; <a href="./references#CD009154-bbs2-0080" title="SerourAG . Luteal phase support in fresh IVF/ICSI cycles. International Journal of Gynecology and Obstetrics2012;119:S533 (Abs# M007). ">Serour 2012</a>; <a href="./references#CD009154-bbs2-0004" title="Aboulghar , MohamedA , Marie , Heba , Amin , YahiaM , Aboulghar , MonaM , Nasr , Ahmed , Serour , GamalI , Mansour , RagaaT . GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.. Reproductive Biomedicine Online2015;30:52‐56. ">Aboulghar 2015</a>), Israel (<a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0038" title="GolanA , HermanA , SofferY , BukovskyI , CaspiE , Ron‐ElR . Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin‐releasing hormone agonist/menotrophin in‐vitro fertilization cycles. Human Reproduction1993;8:1372‐5. ">Golan 1993</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>), Iran (<a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>; <a href="./references#CD009154-bbs2-0064" title="MoiniA , Zadeh ModarressS , AmirchaghmaghiE , MirghavamN , KhafriS , Reza AkhoondM , Salman YazdiR . The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles ‐ a randomized controlled study. Archives of Medical Science2011;7:112‐6. ">Moini 2011</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>), Jordan (<a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>) and Mexico (<a href="./references#CD009154-bbs2-0075" title="Rodriguez‐PezinoJ , Saucedo‐de la LlataE , Batiza‐ResendizV , Galache‐VegaP , Santos‐HaliscakR , Hernandez‐AyupS , et al. Vaginal progesterone in assisted reproduction. Human Reproduction. Berlin, Germany, 2004; Vol. 19 Suppl 1:i51. ">Rodriguez‐Pezino 2004</a>; <a href="./references#CD009154-bbs2-0077" title="Saucedo‐de la LlataE , GalacheVP , HernandezAS , SantosHR , ArenasML , PatrizioP . Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility2000;74 Suppl 1:S150 (Abs # P‐175). ">Saucedo 2000</a>; <a href="./references#CD009154-bbs2-0078" title="Saucedo‐de la LlataE , BatizaV , ArenasL , SantosR , GalacheP , Hernandez‐AyupS , et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration [abstract]. Fertility and Sterility2003;18 Suppl 1:130 (Abs # P‐382). ">Saucedo 2003</a>), and we found three multi‐centre, multi‐national studies: one from Chile, Colombia and Brazil (<a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>), one from Denmark and Sweden (<a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>) and one from Hungary, Germany, Italy, Switzerland and the UK (<a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>). </p> </section> <section id="CD009154-sec-0051"> <h5 class="title">Participants</h5> <p>Participants were women undergoing ART for a large variety of indications, including (low‐grade) endometriosis, polycystic ovarian syndrome or an unknown or unspecified cause of infertility. </p> </section> <section id="CD009154-sec-0052"> <h5 class="title">Interventions</h5> <p>Thirteen studies investigated down‐regulation using GnRH antagonists (<a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>; <a href="./references#CD009154-bbs2-0035" title="GeberS , MaiaL , LauarI , ValleMP , SampaioAC . Does recombinant LH combined to progesterone for luteal phase interfere in the outcome of assisted reproduction technique cycles? [abstract]. Fertility and Sterility2007;88 Suppl 1:25 (Abs #66). ">Geber 2007</a>; <a href="./references#CD009154-bbs2-0041" title="HumaidanP , BungumL , BungumM , AndersenCY . Rescue of corpus luteum function with peri‐ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online2006;13(2):173‐8. ">Humaidan 2006</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0075" title="Rodriguez‐PezinoJ , Saucedo‐de la LlataE , Batiza‐ResendizV , Galache‐VegaP , Santos‐HaliscakR , Hernandez‐AyupS , et al. Vaginal progesterone in assisted reproduction. Human Reproduction. Berlin, Germany, 2004; Vol. 19 Suppl 1:i51. ">Rodriguez‐Pezino 2004</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>), and six studies did not use down‐regulation with GnRH analogues (<a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>; <a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>; <a href="./references#CD009154-bbs2-0087" title="TorodeHW , PorterRN , VaughanJI , SaundersDM . Luteal phase support after in vitro fertilisation: a trial and rationale for selective use. Clinical Reproduction and Fertility1987;5:255‐61. ">Torode 1987</a>; <a href="./references#CD009154-bbs2-0091" title="WongYF , LoongEPL , MaoKR , TamPPL , PanesarNS , NealeE , et al. Salivary oestradiol and progesterone after in vitro fertilization and embryo transfer using different luteal support regimens. Reproduction Fertility and Development1990;2:351‐8. ">Wong 1990</a>); clomiphene citrate, human menopausal gonadotropin (hMG) or both were used in most of those studies. Fifty‐three studies investigated GnRH agonists, and two studies investigated both GnRH agonists and antagonists (<a href="./references#CD009154-bbs2-0047" title="Kably AmbeA , Ruiz AnguasJ , Walters ArballoF , García BenitezCQ , Karchmer KrivitskyS . Results' analysis of estradiol and progesterone supplementation in luteal phase vs progesterone alone in an assisted reproduction program. Ginecologia y Obstetricia de Mexico2005;73:173‐82. ">Kably Ambe 2005</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>). The other studies did not define the down‐regulation protocol used. </p> </section> <section id="CD009154-sec-0053"> <h5 class="title">Outcomes</h5> <p>Live birth was reported in only 28 studies (<a href="./references#CD009154-bbs2-0001" title="AbateA , BrigandiA , AbateFG , MantiF , UnferV , PerinoM . Luteal phase support with 17alpha‐hydroxyprogesterone versus unsupported cycles in in vitro fertilization: a comparative randomized study. Gynaecologic and Obstetric Investigation1999;48(2):78‐80. AbateA , BrigandiA , CostabileL , AbateFG , BalzanoE , PerinoM . 17‐alpha‐Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics &amp; Gynecology1997;24(4):190‐2. ">Abate 1999</a>; <a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>; <a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0038" title="GolanA , HermanA , SofferY , BukovskyI , CaspiE , Ron‐ElR . Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin‐releasing hormone agonist/menotrophin in‐vitro fertilization cycles. Human Reproduction1993;8:1372‐5. ">Golan 1993</a>; <a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>; <a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>; <a href="./references#CD009154-bbs2-0084" title="TayPYS , LentonEA . The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia2005;60(2):151‐7. ">Tay 2005</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>; <a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>). </p> <p>Fifty‐five studies reported ongoing pregnancy (<a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>; <a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>; <a href="./references#CD009154-bbs2-0004" title="Aboulghar , MohamedA , Marie , Heba , Amin , YahiaM , Aboulghar , MonaM , Nasr , Ahmed , Serour , GamalI , Mansour , RagaaT . GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.. Reproductive Biomedicine Online2015;30:52‐56. ">Aboulghar 2015</a><a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0015" title="BeltsosA , SanchezM , DoodyK , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin®) compared to intramuscular progesterone in oil for luteal support in PCOS patients. Fertility and Sterility2011;96(Suppl):S130 (Abs # P‐71). ">Beltsos 2011</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0017" title="BriganteCMM , Mignini RenziniM , Dal CantoM , CoticchioG , ComiR , FadiniR . Efficacy of luteal phase support with GnRH agonists: a preliminary comparative study. Fertility and Sterility2013;100(Suppl):S299 (Abs # P‐521). ">Brigante 2013</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>; <a href="./references#CD009154-bbs2-0031" title="FeichtingerM , HejekJ , KemterP , FeichtingerW . Effect of luteal phase support comparing early (day 1) and late (day 4) initiation with pregnancy rates. Journal of Reproductive Medicine and Endocrinology2011;8(4):288‐90. ">Feichtinger 2011</a>; <a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0038" title="GolanA , HermanA , SofferY , BukovskyI , CaspiE , Ron‐ElR . Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin‐releasing hormone agonist/menotrophin in‐vitro fertilization cycles. Human Reproduction1993;8:1372‐5. ">Golan 1993</a>; <a href="./references#CD009154-bbs2-0039" title="GorkemliH , AkD , AkyurekC , AktanM , DumanS . Comparison of pregnancy outcomes of progesterone or progesterone plus estradiol for luteal phase support in ICSI‐ET cycles. Gynecologic and Obstetric Investigation2004;58(3):140‐4. ">Gorkemli 2004</a>; <a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>; <a href="./references#CD009154-bbs2-0043" title="InamdarDB , MajumdarA . Evaluation of the impact of gonadotropin‐releasing hormone agonist as an adjuvant in luteal‐phase support on IVF outcome. Journal of Human Reproductive Sciences2012;5(3):279‐84. ">Inamdar 2012</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0060" title="MacrolinG , BuvatJ , GuittardC , HerbautJC , LouvetAL , DehaeneJL . [Fécondation in vitro après agoniste de la LHRH: comparison randomisée de soutiens lutéaux par progestérone vaginale seule ou associee a la gonadotrophine chorionique]. Contraception Fertilité Sexualité1993;21(5):434. ">Macrolin 1993</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>; <a href="./references#CD009154-bbs2-0084" title="TayPYS , LentonEA . The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia2005;60(2):151‐7. ">Tay 2005</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>; <a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>; <a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a><a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>). </p> <p>All studies reported (clinical) pregnancy, except for seven studies, which used miscarriage rate (<a href="./references#CD009154-bbs2-0065" title="NallapetaS , SharmaV . Intra‐muscular progesterone as a luteal phase support increases live birth rate as compared to vaginal route. Fertility and Sterility2013;100(Supp):S8 (Abs #O‐25). NallapetaS , SharmaV . Relationship of different progesterone preparations on ovarian volumes in women undergoing IVF/ICSI treatment. Fertility and Sterility2013;100(Suppl):S60 (Abs # O‐196). ">Nallapeta 2013</a>) or ongoing pregnancy as the main outcome (<a href="./references#CD009154-bbs2-0015" title="BeltsosA , SanchezM , DoodyK , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin®) compared to intramuscular progesterone in oil for luteal support in PCOS patients. Fertility and Sterility2011;96(Suppl):S130 (Abs # P‐71). ">Beltsos 2011</a>; <a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>; <a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>; <a href="./references#CD009154-bbs2-0031" title="FeichtingerM , HejekJ , KemterP , FeichtingerW . Effect of luteal phase support comparing early (day 1) and late (day 4) initiation with pregnancy rates. Journal of Reproductive Medicine and Endocrinology2011;8(4):288‐90. ">Feichtinger 2011</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0084" title="TayPYS , LentonEA . The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia2005;60(2):151‐7. ">Tay 2005</a>). </p> <p>Miscarriage is reported in 45 studies (<a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>; <a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0025" title="DrakakisP , LoutradisD , VomvolakiE , StefanidisK , KiapekouE , AnagnostouE , et al. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection‐embryo transfer. Gynecological Endocrinology2007;23(11):645‐52. ">Drakakis 2007</a>; <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>; <a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0038" title="GolanA , HermanA , SofferY , BukovskyI , CaspiE , Ron‐ElR . Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin‐releasing hormone agonist/menotrophin in‐vitro fertilization cycles. Human Reproduction1993;8:1372‐5. ">Golan 1993</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0047" title="Kably AmbeA , Ruiz AnguasJ , Walters ArballoF , García BenitezCQ , Karchmer KrivitskyS . Results' analysis of estradiol and progesterone supplementation in luteal phase vs progesterone alone in an assisted reproduction program. Ginecologia y Obstetricia de Mexico2005;73:173‐82. ">Kably Ambe 2005</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0052" title="LamPM , CheungMC , CheungLP , LokHI , HainesCJ . Effects of early luteal‐phase vaginal progesterone supplementation on the outcome of in vitro fertilization and embryo transfer. Gynecological Endocrinology2008;24(12):674‐80. ">Lam 2008</a>; <a href="./references#CD009154-bbs2-0054" title="LicciardiF , KwiatkowskiA , NoyesN , BerkeleyAS , KreyLL , GrifoJA . Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertility and Sterility1999;71:614‐8. ">Licciardi 1999</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0061" title="MartinezF , CoroleuB , PareraN , AlvarezM , TraverJM , BoadaM , et al. Human chorionic gonadotropin and intravaginal natural progesterone are equally effective for luteal phase support in IVF. Gynaecological Endocrinology2000;14:316‐20. ">Martinez 2000</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0065" title="NallapetaS , SharmaV . Intra‐muscular progesterone as a luteal phase support increases live birth rate as compared to vaginal route. Fertility and Sterility2013;100(Supp):S8 (Abs #O‐25). NallapetaS , SharmaV . Relationship of different progesterone preparations on ovarian volumes in women undergoing IVF/ICSI treatment. Fertility and Sterility2013;100(Suppl):S60 (Abs # O‐196). ">Nallapeta 2013</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>; <a href="./references#CD009154-bbs2-0075" title="Rodriguez‐PezinoJ , Saucedo‐de la LlataE , Batiza‐ResendizV , Galache‐VegaP , Santos‐HaliscakR , Hernandez‐AyupS , et al. Vaginal progesterone in assisted reproduction. Human Reproduction. Berlin, Germany, 2004; Vol. 19 Suppl 1:i51. ">Rodriguez‐Pezino 2004</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>; <a href="./references#CD009154-bbs2-0077" title="Saucedo‐de la LlataE , GalacheVP , HernandezAS , SantosHR , ArenasML , PatrizioP . Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility2000;74 Suppl 1:S150 (Abs # P‐175). ">Saucedo 2000</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>; <a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>), OHSS in 10 studies (<a href="./references#CD009154-bbs2-0007" title="AlbertJ , PfeiferS . Luteal phase hormone levels after in vitro fertilization and embryo transfer (IVF‐ET): a prospective randomized trial of human chorionic gonadotropin (hCG) vs. intramuscular (im) progesterone (P) for luteal phase support following stimulation with gonadotropin‐releasing hormone agonist (GnRH‐a) and human menopausal gonadotropins (hMG) [abstract]. Fertility and Sterility. 1991:S18 (Abs # O‐041). ">Albert 1991</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0060" title="MacrolinG , BuvatJ , GuittardC , HerbautJC , LouvetAL , DehaeneJL . [Fécondation in vitro après agoniste de la LHRH: comparison randomisée de soutiens lutéaux par progestérone vaginale seule ou associee a la gonadotrophine chorionique]. Contraception Fertilité Sexualité1993;21(5):434. ">Macrolin 1993</a>; <a href="./references#CD009154-bbs2-0061" title="MartinezF , CoroleuB , PareraN , AlvarezM , TraverJM , BoadaM , et al. Human chorionic gonadotropin and intravaginal natural progesterone are equally effective for luteal phase support in IVF. Gynaecological Endocrinology2000;14:316‐20. ">Martinez 2000</a>; <a href="./references#CD009154-bbs2-0088" title="UgurM , YenicesuO , OzcanS , KelesG , GokmenO . A prospective randomized study comparing hCG, vaginal micronized progesterone and a combination regimen for luteal phase support in an in‐vitro fertilization programme [abstract]. Fertility and Sterility2001;76 Suppl 1:118 (Abs # P‐19). ">Ugur 2001</a>) and multiple pregnancy in 20 studies (<a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>; <a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0043" title="InamdarDB , MajumdarA . Evaluation of the impact of gonadotropin‐releasing hormone agonist as an adjuvant in luteal‐phase support on IVF outcome. Journal of Human Reproductive Sciences2012;5(3):279‐84. ">Inamdar 2012</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0054" title="LicciardiF , KwiatkowskiA , NoyesN , BerkeleyAS , KreyLL , GrifoJA . Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertility and Sterility1999;71:614‐8. ">Licciardi 1999</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>; <a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>; <a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>). </p> </section> </section> <section id="CD009154-sec-0054"> <h4 class="title">Excluded studies</h4> <p>We excluded from the review 129 studies that did not meet our inclusion criteria. In accordance with the guidelines of the MDSG, we excluded all quasi‐randomised trials (<a href="./references#CD009154-bbs2-0102" title="AnseriniP , CostaM , RemorgidaV , SarliR , GuglielminettiE , RagniN . Luteal phase support in assisted reproductive cycles using either vaginal (Crinone 8) or systemic (Prontogest) progesterone: results of a prospective randomized study. Minerva Ginecologica2001;53:297‐301. ">Anserini 2001</a>; <a href="./references#CD009154-bbs2-0103" title="AnthonyFW , SmithEM , GaddSC , MassonGM , ChardT , PerryL . Placental protein 14 secretion during in vitro fertilization cycles with and without human chorionic gonadotropin for luteal support. Fertility and Sterility1993;59:187‐91. ">Anthony 1993</a>; <a href="./references#CD009154-bbs2-0113" title="BuvatJ , MarcolinG , HerbautJC , DehaeneJL , VerbecqP , FourlinnieJC . A randomized trial of human chorionic gonadotropin support following in vitro fertilization and embryo transfer. Fertility and Sterility1988;49:458‐61. MacrolinG , BuvatJ , HerbautJC , LouvetAL , DehaeneJL , RenouardO . Luteal phase support with HCG ‐ can it be of any benefit following in vitro fecundation (IVF)? A controlled randomized study covering 116 cycles [Le soutien de la phase lutéale par HCG a‐t‐il de l'intérêt après fécondation in vitro?]. Gynecologie1988;39:163‐6. ">Buvat 1988</a>; <a href="./references#CD009154-bbs2-0114" title="BuvatJ , MarcolinG , GuittardC , DehaeneJL , HerbautJC , LouvetAL . Luteal support after administration of an LHRH analog for in vitro fertilization. Superiority of vaginal progesterone in comparison with oral progesterone [Soutien lutéal après analogue de la gonadoréline pour fécondation in vitro. Supériorité de la progestérone vaginale sur la progestérone orale]. La Presse Médicale1990;19:527. BuvatJ , MarcolinG , GuittardC , HerbautJC , LouvetAL , DehaeneJL . Luteal phase support after LHRH‐agonist for in vitro fertilization (IVF): vaginal progesterone is superior to oral progesterone and as much effective as human chorionic gonadotropin (hCG) [Soutien lutéal après LHRH‐agonistes pour fécondation in vitro: la progestérone vaginale est supérieure à la progestérone orale, et aussi efficace que la gonadotrophine chorionique (hCG)]. Contraception Fertilite Sexualite1990;18:616‐7. BuvatJ , MarcolinG , GuittardC , HerbautJC , LouvetAL , DehaeneJL . Luteal support after luteinizing hormone‐releasing hormone agonist for in vitro fertilization: superiority of human chorionic gonadotropin over oral progesterone. Fertility and Sterility1990;53:490‐4. BuvatJ , MercolinG , GuittardC , DehaeneJL , VerbecqP , RenouardO , et al. Chorionic gonadotropin support of the luteal phase following in vitro fertilization and embryo transfer. Randomized comparison wih oral progesteronein protocols using triptoreline [Soutien de la phase lutéal par la gonadotrophine chorionique après fécondation in vitro et transfert d'embryon. Comparaison randomisée à la progestérone per os dans les protocoles utilitsant la triptoréline]. La Presse Médicinale1989;18:539. ">Buvat 1990</a>; <a href="./references#CD009154-bbs2-0143" title="HermanA , Ron‐ElR , GolanA , RazielA , SofferY , CaspiE . Pregnancy rate and ovarian hyperstimulation after luteal human chorionic gonadotropin in in vitro fertilization stimulated with gonadotropin‐releasing hormone analog and menotropins. Fertility and Sterility1990;53:92‐6. ">Herman 1990</a>; <a href="./references#CD009154-bbs2-0144" title="HermanA , RazielA , NachumH , StrassburgerD , SofferY , BukovskyY , et al. The benefits of midluteal addition of human chorionic gonadotrophin in IVF using a down‐regulation protocol and luteal support with progesterone [abstract]. Human Reproduction1995;10(Abstract Book 2):63 (Abs #127). HermanA , RazielA , StrassburgerD , SofferY , BukovskyI , Ron‐ElR . The benefits of mid‐luteal addition of human chorionic gonadotrophin in in‐vitro fertilization using a down‐regulation protocol and luteal support with progesterone. Human Reproduction1996;11:1552‐7. ">Herman 1996</a>; <a href="./references#CD009154-bbs2-0167" title="LeetonJ , TrounsonA , JessupD . Support of the luteal phase in in vitro fertilization programs: results of a controlled trial with intramuscular proluton. Journal of In Vitro Fertilization and Embryo Transfer1985;2:166‐9. ">Leeton 1985</a>; <a href="./references#CD009154-bbs2-0172" title="MahadevanMM , LeaderA , TaylorPJ . Effects of low‐dose human chorionic gonadotropin on corpus luteum function after embryo transfer. Journal of In Vitro Fertilization and Embryo Transfer1985;2:190‐4. ">Mahadevan 1985</a>; <a href="./references#CD009154-bbs2-0175" title="McBainJ C , ClarkeG A , MolloyD , YeatesJ , JohnstonW I H , McKennaM . A randomized trial of progesterone support following ovarian stimulation with clomiphene hMG for IVF and GIFT [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:75 (Abs # PP‐126). ">McBain 1987</a>; <a href="./references#CD009154-bbs2-0192" title="PolsonDW , RogersPAW , KrapezJA , LeetonJF . Vaginal progesterone as luteal phase support in an IVF/GIFT programme. European Journal of Obstetrics Gynecology and Reproductive Biology1992;46(1):35‐8. ">Polson 1992</a>; <a href="./references#CD009154-bbs2-0202" title="SmithEM , AnthonyFW , GaddSC , MassonGM . Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme. BMJ1989;298:1483‐6. ">Smith 1989</a>; <a href="./references#CD009154-bbs2-0205" title="SmitzJ , BourgainC , VanWaesgergheL , CamusM , DevroeyP , VanSteirteghemAC . A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Human Reproduction1993;8:40‐5. ">Smitz 1993</a>; <a href="./references#CD009154-bbs2-0223" title="YovichJL , StangerJD , YovichJM , TuvikAI . Assessment and hormonal treatment of the luteal phase of in vitro fertilization cycles. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology1984;24:125‐30. ">Yovich 1984</a>; <a href="./references#CD009154-bbs2-0224" title="YovichJL , McColmSC , YovichJM , MatsonPL . Early luteal serum progesterone concentrations are higher in pregnancy cycles. Fertility and Sterility1985;44:185‐9. ">Yovich 1985</a>; <a href="./references#CD009154-bbs2-0225" title="YovichJL , Rohini EdirisingheW , CumminsJM . Evaluation of luteal support therapy in a randomized controlled study within a gamete intrafallopian transfer program. Fertility and Sterility1991;55:131‐9. ">Yovich 1991</a>), which had been included in an older version of this review (<a href="./references#CD009154-bbs2-0273" title="DayaS , GunbyJ . Luteal phase support in assisted reproduction cycles. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004830.pub2] ">Daya 2004</a>). We excluded all studies that included GIFT or ZIFT in more than 20% of cycles, or that did not mention the percentage of GIFT or ZIFT cycles used (<a href="./references#CD009154-bbs2-0099" title="AllenC , HarrisonRF . Luteal support progesterone vaginal gel v pessary: clinical/endocrine outcome. Human Reproduction2004;19 Suppl:i125‐6. ">Allen 2004</a>; <a href="./references#CD009154-bbs2-0104" title="AraujoEJr , BernardiniL , FrederickJL , AschRH , BalmacedaJP . Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal‐phase support in assisted reproduction. Journal of Assisted Reproduction and Genetics1994;11(2):74‐8. ">Araujo 1994</a>; <a href="./references#CD009154-bbs2-0105" title="deAraujo FilhoE , AschRH , deAraujoE , LuzOA , BalmacedaJP . Prospective and randomized trial comparing human chorionic gonadotropin and intramuscular progesterone for luteal phase support in assisted fertilization [Estudo prospectivo e randomizado comparando gonadotrofina coriônica humana e progesterona intramuscular para suporte da fase lútea em reproduçao assistida]. Revista Brasileira de Ginecologia e Obstetrica1996;18(2):131‐7. ">Araujo Filho 1996</a>; <a href="./references#CD009154-bbs2-0203" title="SmitzJ , DevroeyP , CamusM , DeschachtJ , KhanI , StaessenC , et al. The luteal phase and early pregnancy after combined GnRH‐agonist/HMG treatment for superovulation in IVF or GIFT. Human Reproduction1988;3(5):585‐90. ">Smitz 1988</a>; <a href="./references#CD009154-bbs2-0204" title="SmitzJ , DevroeyP , FaguerB , BourgainC , CamusM , vanSteirteghemA . A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Human Reproduction1992;7:168‐75. SmitzJ , DevroeyP , FaguerB , BourgainC , CamusM , vanSteirteghemAC . A randomized prospective study comparing supplementation of the luteal phase and early pregnancy by natural progesterone administered by intramuscular or vaginal route [Etude prospective randomisee comparant la supplementation de la phase luteale et de la grossesse debutante par la progesterone naturelle administree par voie intra‐musculaire ou vaginale]. Revue Francaise de Gynecologie et d Obstetrique1992;87(10):507‐16. ">Smitz 1992</a>; <a href="./references#CD009154-bbs2-0216" title="vanSteirteghemAC , SmitzJ , CamusM , VanWaesbergheL , DeschachtJ , KhanI , et al. The luteal phase after in‐vitro fertilization and related procedures. Human Reproduction1988;3:161‐4. ">van Steirteghem 1988</a>). </p> </section> </section> <section id="CD009154-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>See the 'Summary of findings' tables for an overall assessment of the quality of evidence for each comparison. We prepared a table for each comparison (<a href="./full#CD009154-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009154-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009154-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD009154-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD009154-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD009154-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD009154-tbl-0007">summary of findings Table 7</a>). See also the risk of bias graph (see <a href="#CD009154-fig-0002">Figure 2</a>) and the risk of bias summary (see <a href="#CD009154-fig-0003">Figure 3</a>) for an overview. </p> <div class="figure" id="CD009154-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009154-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009154-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009154-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009154-sec-0056"> <h4 class="title">Allocation</h4> <p>Forty eight studies did not report the method of randomisation used. Most of those that did report the randomisation method used computerised randomisation (<a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>; <a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>; <a href="./references#CD009154-bbs2-0004" title="Aboulghar , MohamedA , Marie , Heba , Amin , YahiaM , Aboulghar , MonaM , Nasr , Ahmed , Serour , GamalI , Mansour , RagaaT . GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.. Reproductive Biomedicine Online2015;30:52‐56. ">Aboulghar 2015</a>; <a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0018" title="CaligaraC , CarranzaF , RamosJ , RodriguezI , GonzalezA , Fernandez‐SanchezM . Luteal phase support in IVF patients at low risk for OHSS: progesterone vs. progesterone plus HCG. A prospective randomized study. Fertility and Sterility2007;88:S163 (Abs#P‐166). ">Caligara 2007</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>; <a href="./references#CD009154-bbs2-0031" title="FeichtingerM , HejekJ , KemterP , FeichtingerW . Effect of luteal phase support comparing early (day 1) and late (day 4) initiation with pregnancy rates. Journal of Reproductive Medicine and Endocrinology2011;8(4):288‐90. ">Feichtinger 2011</a>; <a href="./references#CD009154-bbs2-0039" title="GorkemliH , AkD , AkyurekC , AktanM , DumanS . Comparison of pregnancy outcomes of progesterone or progesterone plus estradiol for luteal phase support in ICSI‐ET cycles. Gynecologic and Obstetric Investigation2004;58(3):140‐4. ">Gorkemli 2004</a>; <a href="./references#CD009154-bbs2-0041" title="HumaidanP , BungumL , BungumM , AndersenCY . Rescue of corpus luteum function with peri‐ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online2006;13(2):173‐8. ">Humaidan 2006</a>; <a href="./references#CD009154-bbs2-0043" title="InamdarDB , MajumdarA . Evaluation of the impact of gonadotropin‐releasing hormone agonist as an adjuvant in luteal‐phase support on IVF outcome. Journal of Human Reproductive Sciences2012;5(3):279‐84. ">Inamdar 2012</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0052" title="LamPM , CheungMC , CheungLP , LokHI , HainesCJ . Effects of early luteal‐phase vaginal progesterone supplementation on the outcome of in vitro fertilization and embryo transfer. Gynecological Endocrinology2008;24(12):674‐80. ">Lam 2008</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0061" title="MartinezF , CoroleuB , PareraN , AlvarezM , TraverJM , BoadaM , et al. Human chorionic gonadotropin and intravaginal natural progesterone are equally effective for luteal phase support in IVF. Gynaecological Endocrinology2000;14:316‐20. ">Martinez 2000</a>; <a href="./references#CD009154-bbs2-0066" title="NgEHY , MiaoB , CheungW , HoPC . A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. European Journal of Obstetrics Gynecology and Reproductive Biology2003;111:50‐4. ">Ng 2003</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>; <a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>; <a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>). Randomisation lists or tables were often used (<a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>), as was a third party or study investigator (<a href="./references#CD009154-bbs2-0003" title="AboulgharMA , AminYM , Al‐InanyHG , AboulgharMM , MouradLM , SerourGI , et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Human Reproduction2008;23(4):857‐62. ">Aboulghar 2008</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>). <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a> used a telephone‐based electronic interactive voice response system, and <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a> and <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a> used permuted block randomisation. </p> <p>Fifty studies did not report the method of allocation concealment used. Numbered, sealed envelopes were used most of the time (<a href="./references#CD009154-bbs2-0003" title="AboulgharMA , AminYM , Al‐InanyHG , AboulgharMM , MouradLM , SerourGI , et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Human Reproduction2008;23(4):857‐62. ">Aboulghar 2008</a>; <a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0035" title="GeberS , MaiaL , LauarI , ValleMP , SampaioAC . Does recombinant LH combined to progesterone for luteal phase interfere in the outcome of assisted reproduction technique cycles? [abstract]. Fertility and Sterility2007;88 Suppl 1:25 (Abs #66). ">Geber 2007</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0041" title="HumaidanP , BungumL , BungumM , AndersenCY . Rescue of corpus luteum function with peri‐ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online2006;13(2):173‐8. ">Humaidan 2006</a>; <a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0052" title="LamPM , CheungMC , CheungLP , LokHI , HainesCJ . Effects of early luteal‐phase vaginal progesterone supplementation on the outcome of in vitro fertilization and embryo transfer. Gynecological Endocrinology2008;24(12):674‐80. ">Lam 2008</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a>; <a href="./references#CD009154-bbs2-0066" title="NgEHY , MiaoB , CheungW , HoPC . A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. European Journal of Obstetrics Gynecology and Reproductive Biology2003;111:50‐4. ">Ng 2003</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0080" title="SerourAG . Luteal phase support in fresh IVF/ICSI cycles. International Journal of Gynecology and Obstetrics2012;119:S533 (Abs# M007). ">Serour 2012</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>; <a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>; <a href="./references#CD009154-bbs2-0090" title="WilliamsSC , OehningerS , GibbonsWE , VanCleaveWC , MuasherSJ . Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertility and Sterility2001;76:1140‐3. ">Williams 2001</a>). <a href="./references#CD009154-bbs2-0018" title="CaligaraC , CarranzaF , RamosJ , RodriguezI , GonzalezA , Fernandez‐SanchezM . Luteal phase support in IVF patients at low risk for OHSS: progesterone vs. progesterone plus HCG. A prospective randomized study. Fertility and Sterility2007;88:S163 (Abs#P‐166). ">Caligara 2007</a> used a phone call to an unrelated department, <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a> central consultation, <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a> a telephone‐based electronic interactive voice response system and <a href="./references#CD009154-bbs2-0031" title="FeichtingerM , HejekJ , KemterP , FeichtingerW . Effect of luteal phase support comparing early (day 1) and late (day 4) initiation with pregnancy rates. Journal of Reproductive Medicine and Endocrinology2011;8(4):288‐90. ">Feichtinger 2011</a>; <a href="./references#CD009154-bbs2-0043" title="InamdarDB , MajumdarA . Evaluation of the impact of gonadotropin‐releasing hormone agonist as an adjuvant in luteal‐phase support on IVF outcome. Journal of Human Reproductive Sciences2012;5(3):279‐84. ">Inamdar 2012</a> and <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a> a third party nurse. <a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>, <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>, <a href="./references#CD009154-bbs2-0052" title="LamPM , CheungMC , CheungLP , LokHI , HainesCJ . Effects of early luteal‐phase vaginal progesterone supplementation on the outcome of in vitro fertilization and embryo transfer. Gynecological Endocrinology2008;24(12):674‐80. ">Lam 2008</a> and <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a> concealed allocation via an onsite computer system by utilising locked files. </p> <p><a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a> and <a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a> were the only studies that reported using a non‐concealed randomisation list. </p> </section> <section id="CD009154-sec-0057"> <h4 class="title">Blinding</h4> <p>Fourteen studies mentioned that they used blinding (<a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>; <a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0035" title="GeberS , MaiaL , LauarI , ValleMP , SampaioAC . Does recombinant LH combined to progesterone for luteal phase interfere in the outcome of assisted reproduction technique cycles? [abstract]. Fertility and Sterility2007;88 Suppl 1:25 (Abs #66). ">Geber 2007</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0043" title="InamdarDB , MajumdarA . Evaluation of the impact of gonadotropin‐releasing hormone agonist as an adjuvant in luteal‐phase support on IVF outcome. Journal of Human Reproductive Sciences2012;5(3):279‐84. ">Inamdar 2012</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>; <a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>). The other studies did not blind personnel, researchers or participants (<a href="./references#CD009154-bbs2-0003" title="AboulgharMA , AminYM , Al‐InanyHG , AboulgharMM , MouradLM , SerourGI , et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Human Reproduction2008;23(4):857‐62. ">Aboulghar 2008</a>; <a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>; <a href="./references#CD009154-bbs2-0018" title="CaligaraC , CarranzaF , RamosJ , RodriguezI , GonzalezA , Fernandez‐SanchezM . Luteal phase support in IVF patients at low risk for OHSS: progesterone vs. progesterone plus HCG. A prospective randomized study. Fertility and Sterility2007;88:S163 (Abs#P‐166). ">Caligara 2007</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0052" title="LamPM , CheungMC , CheungLP , LokHI , HainesCJ . Effects of early luteal‐phase vaginal progesterone supplementation on the outcome of in vitro fertilization and embryo transfer. Gynecological Endocrinology2008;24(12):674‐80. ">Lam 2008</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0066" title="NgEHY , MiaoB , CheungW , HoPC . A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. European Journal of Obstetrics Gynecology and Reproductive Biology2003;111:50‐4. ">Ng 2003</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>) or did not mention blinding. The studies of <a href="./references#CD009154-bbs2-0064" title="MoiniA , Zadeh ModarressS , AmirchaghmaghiE , MirghavamN , KhafriS , Reza AkhoondM , Salman YazdiR . The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles ‐ a randomized controlled study. Archives of Medical Science2011;7:112‐6. ">Moini 2011</a>, <a href="./references#CD009154-bbs2-0069" title="PatkiA , PawarVC . Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecological Endocrinology2007;23 Suppl 1:68‐72. ">Patki 2007</a> and <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a> were placebo controlled but did not specify the use of blinding. The main reason reported (in the paper or after contact with the original authors) for not blinding was that the study authors believed blinding would be difficult because of the different routes of administration used. We believe it is possible to use proper blinding with a double‐dummy design. </p> </section> <section id="CD009154-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>Fifty‐two studies reported the numbers of and reasons for withdrawal, or reported no drop‐outs. <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a> reported that more participants were recruited than analysed but did not report the reasons, and <a href="./references#CD009154-bbs2-0017" title="BriganteCMM , Mignini RenziniM , Dal CantoM , CoticchioG , ComiR , FadiniR . Efficacy of luteal phase support with GnRH agonists: a preliminary comparative study. Fertility and Sterility2013;100(Suppl):S299 (Abs # P‐521). ">Brigante 2013</a> reported more outcomes than included patients. </p> </section> <section id="CD009154-sec-0059"> <h4 class="title">Selective reporting</h4> <p>As stated before, only an abstract was available for 14 studies, which suggested high risk of selective reporting. Most studies reported planned outcomes, except for 18 (<a href="./references#CD009154-bbs2-0001" title="AbateA , BrigandiA , AbateFG , MantiF , UnferV , PerinoM . Luteal phase support with 17alpha‐hydroxyprogesterone versus unsupported cycles in in vitro fertilization: a comparative randomized study. Gynaecologic and Obstetric Investigation1999;48(2):78‐80. AbateA , BrigandiA , CostabileL , AbateFG , BalzanoE , PerinoM . 17‐alpha‐Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics &amp; Gynecology1997;24(4):190‐2. ">Abate 1999</a>; <a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0025" title="DrakakisP , LoutradisD , VomvolakiE , StefanidisK , KiapekouE , AnagnostouE , et al. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection‐embryo transfer. Gynecological Endocrinology2007;23(11):645‐52. ">Drakakis 2007</a>; <a href="./references#CD009154-bbs2-0031" title="FeichtingerM , HejekJ , KemterP , FeichtingerW . Effect of luteal phase support comparing early (day 1) and late (day 4) initiation with pregnancy rates. Journal of Reproductive Medicine and Endocrinology2011;8(4):288‐90. ">Feichtinger 2011</a>; <a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0038" title="GolanA , HermanA , SofferY , BukovskyI , CaspiE , Ron‐ElR . Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin‐releasing hormone agonist/menotrophin in‐vitro fertilization cycles. Human Reproduction1993;8:1372‐5. ">Golan 1993</a>; <a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>; <a href="./references#CD009154-bbs2-0054" title="LicciardiF , KwiatkowskiA , NoyesN , BerkeleyAS , KreyLL , GrifoJA . Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertility and Sterility1999;71:614‐8. ">Licciardi 1999</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0084" title="TayPYS , LentonEA . The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia2005;60(2):151‐7. ">Tay 2005</a>; <a href="./references#CD009154-bbs2-0087" title="TorodeHW , PorterRN , VaughanJI , SaundersDM . Luteal phase support after in vitro fertilisation: a trial and rationale for selective use. Clinical Reproduction and Fertility1987;5:255‐61. ">Torode 1987</a>; <a href="./references#CD009154-bbs2-0089" title="VimpeliT , TinkanenH , HuhtalaH , RonnbergL , KujansuuE . Salivary and serum progesterone concentrations during two luteal support regimens used in in vitro fertilization treatment. Fertility and Sterility2001;76:847‐8. ">Vimpeli 2001</a>). <a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>, <a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>, <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a> and <a href="./references#CD009154-bbs2-0091" title="WongYF , LoongEPL , MaoKR , TamPPL , PanesarNS , NealeE , et al. Salivary oestradiol and progesterone after in vitro fertilization and embryo transfer using different luteal support regimens. Reproduction Fertility and Development1990;2:351‐8. ">Wong 1990</a> reported outcomes in the Results section that were different from those reported in the Methods section. </p> </section> <section id="CD009154-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>Eight studies were supported by the pharmaceutical companies that had supplied the investigated interventions (<a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0015" title="BeltsosA , SanchezM , DoodyK , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin®) compared to intramuscular progesterone in oil for luteal support in PCOS patients. Fertility and Sterility2011;96(Suppl):S130 (Abs # P‐71). ">Beltsos 2011</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>). Two were supported by a grant from a pharmaceutical company (<a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0089" title="VimpeliT , TinkanenH , HuhtalaH , RonnbergL , KujansuuE . Salivary and serum progesterone concentrations during two luteal support regimens used in in vitro fertilization treatment. Fertility and Sterility2001;76:847‐8. ">Vimpeli 2001</a>), and <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a> was supported by a pharmaceutical company, but this company does not supply the investigated products. One study (<a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>) reported a relatively large number of miscarriages, which were not consistent with reported rates of live birth, clinical pregnancy and ongoing pregnancy. This study was rated as having high risk of bias in this domain. </p> <section id="CD009154-sec-0061"> <h5 class="title">Assessment for publication bias</h5> <p>We looked at the following comparisons: 3.2 Progesterone versus hCG regimens, outcome clinical pregnancy rate (CPR); 4.2 Progesterone versus progesterone + oestrogen (CPR); 6.2.2 Progesterone regimens, outcome CPR: IM progesterone versus vaginal or rectal progesterone; and 6.2.4 Progesterone regimens, outcome CPR: low‐dose vaginal progesterone versus high‐dose vaginal progesterone for publication bias, as these four comparisons involved more than 10 included studies. We did this by making three funnel plots, combining comparisons 6.2.2 Progesterone regimens, outcome CPR: IM progesterone versus vaginal or rectal progesterone; and 6.2.4 Progesterone regimens, outcome CPR: low‐dose vaginal progesterone versus high‐dose vaginal progesterone (see <a href="#CD009154-fig-0004">Figure 4</a>; <a href="#CD009154-fig-0005">Figure 5</a>; <a href="#CD009154-fig-0006">Figure 6</a>). <a href="#CD009154-fig-0004">Figure 4</a> shows most of the studies around the pooled estimate, suggesting that different sizes of studies were included. Although one study (<a href="./references#CD009154-bbs2-0038" title="GolanA , HermanA , SofferY , BukovskyI , CaspiE , Ron‐ElR . Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin‐releasing hormone agonist/menotrophin in‐vitro fertilization cycles. Human Reproduction1993;8:1372‐5. ">Golan 1993</a>) seemed to be out of the expected pattern, we did not see asymmetry; therefore this funnel plot indicated a small risk of publication bias. <a href="#CD009154-fig-0005">Figure 5</a> shows most of the studies around the pooled estimate with the studies reasonably equally divided on both sides. A large space at the lower side of the graph means that small studies may not be published. Overall the funnel plot revealed a small risk of publication bias. <a href="#CD009154-fig-0006">Figure 6</a> shows most of the studies around the pooled estimate with all studies reasonably equally divided on both sides. This funnel plot also showed that small studies may not be published. Overall it indicated a small risk of publication bias. </p> <div class="figure" id="CD009154-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Progesterone vs hCG, outcome: 2.2 Clinical pregnancy rate." data-id="CD009154-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Progesterone vs hCG, outcome: 2.2 Clinical pregnancy rate. </p> </div> </div> </div> <div class="figure" id="CD009154-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 4 [NEW] Progesterone vs progesterone + oestrogen, outcome: 4.2 Clinical pregnancy rate." data-id="CD009154-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 4 [NEW] Progesterone vs progesterone + oestrogen, outcome: 4.2 Clinical pregnancy rate. </p> </div> </div> </div> <div class="figure" id="CD009154-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 [NEW] Progesterone regimens, outcome: 6.2 Clinical pregnancy rate." data-id="CD009154-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 [NEW] Progesterone regimens, outcome: 6.2 Clinical pregnancy rate. </p> </div> </div> </div> </section> </section> </section> <section id="CD009154-sec-0062"> <h3 class="title" id="CD009154-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD009154-tbl-0001"><b>Summary of findings for the main comparison</b> hCG compared with placebo/no treatment for assisted reproduction cycles</a>; <a href="./full#CD009154-tbl-0002"><b>Summary of findings 2</b> Progesterone compared with placebo/no treatment for assisted reproduction cycles</a>; <a href="./full#CD009154-tbl-0003"><b>Summary of findings 3</b> Progesterone compared with hCG regimens for assisted reproduction cycles</a>; <a href="./full#CD009154-tbl-0004"><b>Summary of findings 4</b> Progesterone compared with progesterone + oestrogen for assisted reproduction cycles</a>; <a href="./full#CD009154-tbl-0005"><b>Summary of findings 5</b> Progesterone compared with progesterone + GnRH agonist for assisted reproduction cycles</a>; <a href="./full#CD009154-tbl-0006"><b>Summary of findings 6</b> Progesterone regimens for assisted reproduction cycles</a>; <a href="./full#CD009154-tbl-0007"><b>Summary of findings 7</b> Progesterone + oestrogen regimens for assisted reproduction cycles</a> </p> <section id="CD009154-sec-0063"> <h4 class="title">1. hCG versus placebo or no treatment</h4> <section id="CD009154-sec-0064"> <h5 class="title">Primary outcome</h5> <section id="CD009154-sec-0065"> <h6 class="title">1.1 Live birth/ongoing pregnancy rate</h6> <p>Three studies reported live birth (<a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>). See <a href="#CD009154-fig-0007">Figure 7</a> for details of this comparison. </p> <div class="figure" id="CD009154-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, outcome: 1.1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, outcome: 1.1 Live birth/ongoing pregnancy rate. </p> </div> </div> </div> <p>Live birth and pregnancy rates were higher in the hCG group (OR 1.76, 95% CI 1.08 to 2.86, three RCTs, 527 women, I<sup>2</sup> = 24%, very low‐quality evidence). </p> <p>However this findings was sensitive to choice of statistical model, and when a random‐effects model was used there was no longer evidence of a difference between the groups (OR 1.67, 95% CI 0.90 to 3.12). </p> <p>When the analysis was restricted to live birth, only 38 women were included and again there was no evidence of a difference between the groups (OR 2.20, 95% CI 0.38 to 12.87). </p> </section> </section> <section id="CD009154-sec-0066"> <h5 class="title">Secondary outcomes</h5> <section id="CD009154-sec-0067"> <h6 class="title">1.2 Clinical pregnancy rate (CPR)</h6> <p>Five studies (<a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0087" title="TorodeHW , PorterRN , VaughanJI , SaundersDM . Luteal phase support after in vitro fertilisation: a trial and rationale for selective use. Clinical Reproduction and Fertility1987;5:255‐61. ">Torode 1987</a>) reported this outcome.<br/> Evidence suggested no differences between groups (OR 1.30, 95% CI 0.90 to 1.88, five RCTs, 746 women, I<sup>2</sup> = 0%, very low quality evidence). See <a href="./references#CD009154-fig-0015" title="">Analysis 1.2</a> for details of this comparison. </p> <section id="CD009154-sec-0068"> <p><b>Subgroup analyses<i>for clinical pregnancy rate</i> </b></p> </section> <section id="CD009154-sec-0069"> <p><b>1.2.1 Ovarian stimulation protocol</b></p> <p>Five studies were included in subgroups. Researchers utilised hCG with clomiphene citrate without GnRH agonists (<a href="./references#CD009154-bbs2-0087" title="TorodeHW , PorterRN , VaughanJI , SaundersDM . Luteal phase support after in vitro fertilisation: a trial and rationale for selective use. Clinical Reproduction and Fertility1987;5:255‐61. ">Torode 1987</a>), hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>) or hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>). Evidence suggested no substantial differences from the main analysis in any of the subgroups. See <a href="./references#CD009154-fig-0016" title="">Analysis 1.3</a> for details. </p> </section> <section id="CD009154-sec-0070"> <p><b>1.2.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> <p><i>1.2.3 Duration of treatment</i> </p> <p>Not applicable.</p> <p>1.2.4<i>Number of embryos transferred</i> </p> <p>No data were available for this subgroup analysis.</p> </section> </section> <section id="CD009154-sec-0071"> <h6 class="title">1.3 Miscarriage rate</h6> <p>Two studies (<a href="./references#CD009154-bbs2-0012" title="BeckersNGM , LavenJSE , EijkemansMJC , FauserBCJM . Follicular and luteal phase characteristics following early cessation of gonadotrophin‐releasing hormone agonist during ovarian stimulation for in‐vitro fertilization. Human Reproduction2000;15(1):43‐9. ">Beckers 2000</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>) reported this outcome.<br/> Evidence suggested no differences between groups (OR 1.51, 95% CI 0.37 to 6.21, two RCTs, 140 women, I<sup>2</sup> = 0%). See <a href="./references#CD009154-fig-0017" title="">Analysis 1.4</a> for details of this comparison. </p> </section> <section id="CD009154-sec-0072"> <h6 class="title">1.4 Ovarian hyperstimulation syndrome (OHSS)</h6> <p>One study (<a href="./references#CD009154-bbs2-0014" title="Belaisch‐AllartJ , DeMouzonJ , LapousterleC , MayerM . The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Human Reproduction1990;5:163‐6. ">Belaisch‐Allart 1990</a>) reported this outcome.<br/> <br/> This result showed benefit for the placebo group (OR 4.28, 95% CI 1.91 to 9.60, one RCT, 387 women, low quality evidence). As this result was based on a single study, it should be interpreted with caution. See <a href="./references#CD009154-fig-0018" title="">Analysis 1.5</a> for details of this comparison. </p> </section> <section id="CD009154-sec-0073"> <h6 class="title">1.5 Multiple pregnancy</h6> <p>No studies reported this outcome.</p> </section> </section> </section> <section id="CD009154-sec-0074"> <h4 class="title">2. Progesterone versus placebo or no treatment</h4> <section id="CD009154-sec-0075"> <h5 class="title">Primary outcome</h5> <section id="CD009154-sec-0076"> <h6 class="title">2.1 Live birth/ongoing pregnancy rate</h6> <p>Five studies reported live birth (<a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>; <a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>). </p> <p>Rates of live birth or ongoing pregnancy were higher in the progesterone group (OR 1.77, 95% CI 1.09 to 2.86, five RCTs, 642 women, I<sup>2</sup> = 19%, very low quality evidence). </p> <p>Findings require cautious interpretation, as when the analysis was restricted to live birth, evidence suggested no differences between groups (OR 4.21, 95% CI 0.93 to 19.18, one RCT, 156 women). Heterogeneity was high in the studies of ongoing pregnancy (I<sup>2</sup> = 68%). </p> <p>See <a href="#CD009154-fig-0008">Figure 8</a> for details of this comparison. </p> <div class="figure" id="CD009154-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Progesterone vs placebo or no treatment, outcome: 2.1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Progesterone vs placebo or no treatment, outcome: 2.1 Live birth/ongoing pregnancy rate. </p> </div> </div> </div> <p><i>Sensitivity analyses</i> </p> <p>Pooled findings for live birth/ongoing pregnancy were no longer statistically significant when a random‐effects model was used (OR 1.77, 95% CI 0.96 to 3.26); this underlines the need for caution in interpreting these findings. Other sensitivity analyses did not materially affect the findings. </p> </section> </section> <section id="CD009154-sec-0077"> <h5 class="title">Secondary outcomes</h5> <section id="CD009154-sec-0078"> <h6 class="title">2.2 Clinical pregnancy rate</h6> <p>Seven studies (<a href="./references#CD009154-bbs2-0001" title="AbateA , BrigandiA , AbateFG , MantiF , UnferV , PerinoM . Luteal phase support with 17alpha‐hydroxyprogesterone versus unsupported cycles in in vitro fertilization: a comparative randomized study. Gynaecologic and Obstetric Investigation1999;48(2):78‐80. AbateA , BrigandiA , CostabileL , AbateFG , BalzanoE , PerinoM . 17‐alpha‐Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics &amp; Gynecology1997;24(4):190‐2. ">Abate 1999</a>; <a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0091" title="WongYF , LoongEPL , MaoKR , TamPPL , PanesarNS , NealeE , et al. Salivary oestradiol and progesterone after in vitro fertilization and embryo transfer using different luteal support regimens. Reproduction Fertility and Development1990;2:351‐8. ">Wong 1990</a>) reported this outcome.<br/> Pregnancy rates were higher in the progesterone group (OR 1.89, 95% CI 1.30 to 2.75, seven RCTs, 841 women, I<sup>2</sup> = 0%, low quality evidence). See <a href="./references#CD009154-fig-0020" title="">Analysis 2.2</a> for details of this comparison. </p> <section id="CD009154-sec-0079"> <p><b>Subgroup analyses<i>for clinical pregnancy rate</i> </b></p> </section> <section id="CD009154-sec-0080"> <p><b><i>2.2.1 O</i>varian stimulation protocol</b></p> <p>Findings of the subgroup of four studies (<a href="./references#CD009154-bbs2-0001" title="AbateA , BrigandiA , AbateFG , MantiF , UnferV , PerinoM . Luteal phase support with 17alpha‐hydroxyprogesterone versus unsupported cycles in in vitro fertilization: a comparative randomized study. Gynaecologic and Obstetric Investigation1999;48(2):78‐80. AbateA , BrigandiA , CostabileL , AbateFG , BalzanoE , PerinoM . 17‐alpha‐Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics &amp; Gynecology1997;24(4):190‐2. ">Abate 1999</a>; <a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>) that administered human gonadotropins with or without GnRH agonists were consistent with the main findings, showing benefit for the progesterone group. Benefit was stronger when the study without GnRH agonists was excluded. Studies that administered clomiphene citrate alone without GnRH agonists (<a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>) or human gonadotropins with clomiphene citrate without GnRH agonists (<a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0091" title="WongYF , LoongEPL , MaoKR , TamPPL , PanesarNS , NealeE , et al. Salivary oestradiol and progesterone after in vitro fertilization and embryo transfer using different luteal support regimens. Reproduction Fertility and Development1990;2:351‐8. ">Wong 1990</a>) did not clearly show benefit for the progesterone group. However results of the test for subgroup differences were not statistically significant. </p> <p>See <a href="./references#CD009154-fig-0021" title="">Analysis 2.3</a> for details. </p> </section> <section id="CD009154-sec-0081"> <p><b>2.2.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0082"> <p><b>2.2.3 Duration of progesterone</b></p> <p>Findings of the subgroup of four studies (<a href="./references#CD009154-bbs2-0001" title="AbateA , BrigandiA , AbateFG , MantiF , UnferV , PerinoM . Luteal phase support with 17alpha‐hydroxyprogesterone versus unsupported cycles in in vitro fertilization: a comparative randomized study. Gynaecologic and Obstetric Investigation1999;48(2):78‐80. AbateA , BrigandiA , CostabileL , AbateFG , BalzanoE , PerinoM . 17‐alpha‐Hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics &amp; Gynecology1997;24(4):190‐2. ">Abate 1999</a>; <a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0042" title="HurdWW , RandolphJFJr , ChristmanGM , AnsbacherR , MengeAC , GellJS . Luteal support with both estrogen and progesterone after clomiphene citrate stimulation for in vitro fertilization. Fertility and Sterility1996;66:587‐92. ">Hurd 1996</a>) that administered progesterone for up to 12 weeks were consistent with the main findings, showing benefit for the progesterone group. The subgroup of three studies (<a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0091" title="WongYF , LoongEPL , MaoKR , TamPPL , PanesarNS , NealeE , et al. Salivary oestradiol and progesterone after in vitro fertilization and embryo transfer using different luteal support regimens. Reproduction Fertility and Development1990;2:351‐8. ">Wong 1990</a>) that stopped progesterone at the time of the pregnancy test did not clearly show benefit for the progesterone group. However results of the test for subgroup differences were not statistically significant. </p> <p>See <a href="./references#CD009154-fig-0022" title="">Analysis 2.4</a> for details. </p> </section> <section id="CD009154-sec-0083"> <p><b>2.2.4 Number of embryos transferred</b></p> <p>No data were available for this subgroup analysis.</p> </section> </section> <section id="CD009154-sec-0084"> <h6 class="title">2.3 Miscarriage rate</h6> <p>Three studies (<a href="./references#CD009154-bbs2-0013" title="Belaisch‐AllartJ , TestartJ , FriesN , FormanR G , FrydmanR . The effect of dydrogesterone supplementation in an IVF programme. Human Reproduction1987;2:183‐5. Belaisch‐AllartJ , TestartJ , FriesN , FormanR , HazoutA , Declercl , et al. The effect of dydrogesterone and hCG supplementation in an IVF program [abstract]. 5th World Congress on In Vitro Fertilization and Embryo Transfer Abstract Book. 1987:41 (Abs #PP‐35). ">Belaisch‐Allart 1987</a>; <a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>) reported this outcome.<br/> No evidence suggested differences between groups (OR 1.22, 95% CI 0.49 to 3.03, three RCTs, 425 women, I<sup>2</sup> = 0%). See <a href="./references#CD009154-fig-0023" title="">Analysis 2.5</a> for details of this comparison. </p> </section> <section id="CD009154-sec-0085"> <h6 class="title">2.4 Ovarian hyperstimulation syndrome (OHSS)</h6> <p>No studies reported this outcome.</p> </section> <section id="CD009154-sec-0086"> <h6 class="title">2.5 Multiple pregnancy</h6> <p>One study (<a href="./references#CD009154-bbs2-0022" title="ColwellKA , TummonIS . Elevation of serum progesterone with oral micronized progesterone after in vitro fertilization. Journal of Reproductive Medicine1991;36:170‐2. ">Colwell 1991</a>) reported this outcome.<br/> <br/> Evidence suggested no differences between groups (OR 5.87, 95% CI 0.22 to 155.76, one RCT, 34 women). See <a href="./references#CD009154-fig-0024" title="">Analysis 2.6</a> for details of this comparison. </p> </section> </section> </section> <section id="CD009154-sec-0087"> <h4 class="title">3. Progesterone versus hCG regimens</h4> <section id="CD009154-sec-0088"> <h5 class="title">Primary outcome</h5> <section id="CD009154-sec-0089"> <h6 class="title">3.1 Live birth/ongoing pregnancy rate</h6> <p>Five studies reported live birth (<a href="./references#CD009154-bbs2-0038" title="GolanA , HermanA , SofferY , BukovskyI , CaspiE , Ron‐ElR . Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin‐releasing hormone agonist/menotrophin in‐vitro fertilization cycles. Human Reproduction1993;8:1372‐5. ">Golan 1993</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0060" title="MacrolinG , BuvatJ , GuittardC , HerbautJC , LouvetAL , DehaeneJL . [Fécondation in vitro après agoniste de la LHRH: comparison randomisée de soutiens lutéaux par progestérone vaginale seule ou associee a la gonadotrophine chorionique]. Contraception Fertilité Sexualité1993;21(5):434. ">Macrolin 1993</a>; <a href="./references#CD009154-bbs2-0084" title="TayPYS , LentonEA . The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia2005;60(2):151‐7. ">Tay 2005</a>). Researchers compared progesterone versus hCG (four RCTs, 434 women) or versus progesterone plus hCG (two RCTs, 399 women). </p> <p>Evidence suggested no differences between groups in rates of live birth or ongoing pregnancy (OR 0.95, 95% CI 0.65 to 1.38, five RCTs, 833 women, I<sup>2</sup> = 0%, low quality evidence). </p> <p>Findings were similar, regardless of whether the comparison group received hCG only or hCG plus progesterone. See <a href="#CD009154-fig-0009">Figure 9</a> for details of this comparison. </p> <div class="figure" id="CD009154-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Progesterone vs hCG regimens, outcome: 3.1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Progesterone vs hCG regimens, outcome: 3.1 Live birth or ongoing pregnancy rate. </p> </div> </div> </div> <p>Restriction of the analysis to studies reporting live birth also showed no evidence of differences between groups. </p> </section> </section> <section id="CD009154-sec-0090"> <h5 class="title">Secondary outcomes</h5> <section id="CD009154-sec-0091"> <h6 class="title">3.2 Clinical pregnancy rate</h6> <p>Eighteen studies reported this outcome. Researchers compared progesterone versus hCG (11 RCTs, 1378 women) or versus progesterone plus hCG (seven RCTs, 977 women). </p> <p>Evidence suggested no differences between groups in rates of clinical pregnancy (OR 1.08, 95% CI 0.90 to 1.30, 16 RCTs, 2355 women, I<sup>2</sup> = 0%, moderate quality evidence). </p> <p>Findings did not differ substantially, regardless of whether the comparison group received hCG only or hCG plus progesterone. See <a href="./references#CD009154-fig-0026" title="">Analysis 3.2</a> for details. </p> <p>Because this comparison included more than 10 studies, we prepared a funnel plot to determine the risk of publication bias (see <a href="#CD009154-fig-0004">Figure 4</a>), which is assessed in the section <a href="#CD009154-sec-0059">Selective reporting (reporting bias)</a>. We concluded that this study showed a small risk of publication bias. </p> <section id="CD009154-sec-0092"> <p><b>Subgroup analyses for clinical pregnancy rate</b></p> </section> <section id="CD009154-sec-0093"> <p><b>3.2.1 Ovarian stimulation method</b></p> <p>Four studies of progesterone versus progesterone plus hCG were subgrouped by method of ovarian stimulation. One (<a href="./references#CD009154-bbs2-0091" title="WongYF , LoongEPL , MaoKR , TamPPL , PanesarNS , NealeE , et al. Salivary oestradiol and progesterone after in vitro fertilization and embryo transfer using different luteal support regimens. Reproduction Fertility and Development1990;2:351‐8. ">Wong 1990</a>) utilised hCG with clomiphene citrate without GnRH agonists, and three utilised hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0033" title="FujimotoA , OsugaY , FujiwaraT , YanoT , TsutsumiO , MomoedaM , et al. Human chorionic gonadotropin combined with progesterone for luteal support improves pregnancy rate in patients with low late‐midluteal estradiol levels in IVF cycles. Journal of Assisted Reproduction and Genetics2002;19(12):550‐4. FujimotoA , OsugaY , OoiN , FujiwaraT , YanoT , TaketaniY . Addition of hCG to progesterone as a luteal support improves pregnancy rates for patients with low mid‐luteal oestradiol levels in IVF and ICSI [abstract]. Human Reproduction. 2001; Vol. 16, issue Suppl 1:143 (Abs #P‐143). ">Fujimoto 2002</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0060" title="MacrolinG , BuvatJ , GuittardC , HerbautJC , LouvetAL , DehaeneJL . [Fécondation in vitro après agoniste de la LHRH: comparison randomisée de soutiens lutéaux par progestérone vaginale seule ou associee a la gonadotrophine chorionique]. Contraception Fertilité Sexualité1993;21(5):434. ">Macrolin 1993</a>). Findings did not differ substantially from those of the main analysis in either subgroup (see <a href="./references#CD009154-fig-0027" title="">Analysis 3.3</a>). No studies of progesterone versus hCG alone were available for this subgroup analysis. </p> </section> <section id="CD009154-sec-0094"> <p><b>3.2.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0095"> <p><b>3.2.3 Duration of progesterone</b></p> <p>Seven studies of progesterone versus progesterone plus hCG were subgrouped by duration of progesterone treatment. Six stopped treatment at the pregnancy test (<a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0038" title="GolanA , HermanA , SofferY , BukovskyI , CaspiE , Ron‐ElR . Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin‐releasing hormone agonist/menotrophin in‐vitro fertilization cycles. Human Reproduction1993;8:1372‐5. ">Golan 1993</a>; <a href="./references#CD009154-bbs2-0041" title="HumaidanP , BungumL , BungumM , AndersenCY . Rescue of corpus luteum function with peri‐ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reproductive BioMedicine Online2006;13(2):173‐8. ">Humaidan 2006</a>; <a href="./references#CD009154-bbs2-0050" title="KupfermincMJ , LessingJB , AmitA , YovelI , DavidMP , PeyserMR . A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in‐vitro fertilization and embryo transfer. Human Reproduction1990;5(3):271‐3. ">Kupferminc 1990</a>; <a href="./references#CD009154-bbs2-0058" title="LudwigM , FinasA , Bals‐PratschM , FelberbaumRE , SchopperB , Al‐HasaniS , et al. Prospective, randomized study to evaluate the pregnancy rate using HCG, vaginal progesterone (Utrogest), or a combination of both for luteal‐phase support: preliminary results [abstract]. Human Reproduction. 1999; Vol. 14 Suppl 1:2‐3 (Abs # O‐004). LudwigM , FinasA , KatalinicA , StrikD , KowalcekI , SchwartzP , et al. Prospective, randomized study to evaluate the success rates using hCG, vaginal progesterone or a combination of both for luteal phase support. Acta Obstetricia et Gynecologica Scandinavica2001;80:574‐82. ">Ludwig 2001</a>; <a href="./references#CD009154-bbs2-0061" title="MartinezF , CoroleuB , PareraN , AlvarezM , TraverJM , BoadaM , et al. Human chorionic gonadotropin and intravaginal natural progesterone are equally effective for luteal phase support in IVF. Gynaecological Endocrinology2000;14:316‐20. ">Martinez 2000</a>), and one administered progesterone for up to 12 weeks when pregnant (<a href="./references#CD009154-bbs2-0089" title="VimpeliT , TinkanenH , HuhtalaH , RonnbergL , KujansuuE . Salivary and serum progesterone concentrations during two luteal support regimens used in in vitro fertilization treatment. Fertility and Sterility2001;76:847‐8. ">Vimpeli 2001</a>). Findings did not differ substantially from those of the main analysis in either subgroup. No studies of progesterone versus hCG alone were available for this subgroup analysis. See <a href="./references#CD009154-fig-0028" title="">Analysis 3.4</a> for details of this comparison. </p> </section> <section id="CD009154-sec-0096"> <p><b>3.2.4 Number of embryos transferred</b></p> <p>No data were available for this subgroup analysis.</p> </section> </section> <section id="CD009154-sec-0097"> <h6 class="title">3.3 Miscarriage rate</h6> <p>Five studies reported this outcome. Researchers compared progesterone versus hCG (five RCTs, 735 women) or versus progesterone plus hCG (one RCT, 97 women). </p> <p>Evidence suggested no differences between groups in rates of miscarriage (OR 1.24, 95% CI 0.66 to 12.31, five RCTs, 832 women, I<sup>2</sup> = 0%). Findings did not differ substantially, regardless of whether the hCG group received progesterone as well. See <a href="./references#CD009154-fig-0030" title="">Analysis 3.6</a> for details. </p> </section> <section id="CD009154-sec-0098"> <h6 class="title">3.4 Ovarian hyperstimulation syndrome (OHSS)</h6> <p>Five studies reported this outcome. They compared progesterone versus hCG (four RCTs, 671 women) or versus progesterone plus hCG (three RCTs, 678 women). <a href="#CD009154-fig-0010">Figure 10</a> </p> <div class="figure" id="CD009154-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Progesterone vs hCG regimens, outcome: 3.5 OHSS." data-id="CD009154-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Progesterone vs hCG regimens, outcome: 3.5 OHSS.</p> </div> </div> </div> <p>Progesterone was associated with lower rates of OHSS rates than hCG with or without progesterone (OR 0.46, 95% CI 0.30 to 0.71, 5 RCTs, 1293 women , I<sup>2</sup>=48%) . </p> <p>Findings differed according to whether the hCG group received progesterone as well, though the statistical test for subgroup differences suggested no significant difference between the groups (p=0.30). When progesterone was compared with hCG alone, there was no clear evidence of a difference between the groups (OR 0.57, 95% CI 0.32 to 1.00, 4 studies I<sup>2</sup>=41%). When progesterone alone was compared with hCG plus progesterone, rates were lower in the progesterone alone group, though with substantial statistical heterogeneity (OR 0.36, 95% CI 0.18 to 0.69, 3 RCTs, 678 women ,l<sup>2</sup>=61%). </p> </section> <section id="CD009154-sec-0099"> <h6 class="title">3.5 Multiple pregnancy</h6> <p>One study reported this outcome. Researchers compared progesterone versus hCG (112 women) or versus progesterone plus hCG (97 women). </p> <p>Evidence suggested no differences between groups for this outcome (OR 0.44, 95% CI 0.07 to 2.65, one RCT, 209 women). See <a href="./references#CD009154-fig-0031" title="">Analysis 3.7</a> for details of this comparison. </p> </section> </section> </section> <section id="CD009154-sec-0100"> <h4 class="title">4. Progesterone versus progesterone + oestrogen</h4> <p>After data extraction, we found that different routes of oestrogen administration were used as well as different dosages of oestrogen. Therefore we decided to stratify the analysis on the basis of route of administration. </p> <section id="CD009154-sec-0101"> <h5 class="title">Primary outcome</h5> <section id="CD009154-sec-0102"> <h6 class="title">4.1 Live birth/ongoing pregnancy rate</h6> <p>Nine studies reported live birth (<a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>). Routes of oestrogen administration were oral (six RCTs, 1266 women), transdermal (two RCTs, 219 women) and vaginal (one RCT, 166 women). See <a href="#CD009154-fig-0011">Figure 11</a> for details of this comparison. </p> <div class="figure" id="CD009154-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Progesterone vs progesterone + oestrogen, outcome: 4.1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Progesterone vs progesterone + oestrogen, outcome: 4.1 Live birth/ongoing pregnancy rate. </p> </div> </div> </div> <p>Evidence suggested no differences between groups in rates of live birth or ongoing pregnancy (OR 1.12, 95% CI 0.91 to 1.38, nine RCTs, 1651 women, I<sup>2</sup> = 0%, low quality evidence). </p> <p>Findings were similar when the analysis was restricted to studies reporting live birth (OR 1.32, 95% CI 0.93 to 1.86, three RCTs, 562 women, I<sup>2</sup> = 0%). </p> <p>When data were considered by route of oestrogen administration, findings did not differ substantially from those of the main analysis. </p> </section> </section> <section id="CD009154-sec-0103"> <h5 class="title">Secondary outcomes</h5> <section id="CD009154-sec-0104"> <h6 class="title">4.2 Clinical pregnancy rate</h6> <p>Fourteen studies reported this outcome (<a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0010" title="AtaB , KucukM , SeyhanA , UrmanB . Effect of high‐dose estrogen in luteal phase support on live birth rates after assisted reproduction treatment cycles. Journal of Reproductive Medicine for the Obstetrician and Gynecologist2010;55:485‐90. ">Ata 2010</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0021" title="ColakogluM , ToyH , IcenMS , VuralM , MahmoudAS , YaziciF . The impact of estrogen supplementation on IVF outcome in patients with polycystic ovary syndrome. Human Reproduction2011;26(Suppl 1):i296 (Abs # P‐450). ">Colakoglu 2011</a>; <a href="./references#CD009154-bbs2-0025" title="DrakakisP , LoutradisD , VomvolakiE , StefanidisK , KiapekouE , AnagnostouE , et al. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection‐embryo transfer. Gynecological Endocrinology2007;23(11):645‐52. ">Drakakis 2007</a>; <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0029" title="ErdemM , KutlusoyF , ErdemA , GulerI , MesutO , BiberogluK . Luteal phase support with estrogen in addition to progesterone in patients with poor response to gonadotropins undergoing IVF. Fertility and Sterility2013;100(Suppl 1):S300‐1 (Abs # P‐526). ">Erdem 2013</a>; <a href="./references#CD009154-bbs2-0039" title="GorkemliH , AkD , AkyurekC , AktanM , DumanS . Comparison of pregnancy outcomes of progesterone or progesterone plus estradiol for luteal phase support in ICSI‐ET cycles. Gynecologic and Obstetric Investigation2004;58(3):140‐4. ">Gorkemli 2004</a>; <a href="./references#CD009154-bbs2-0047" title="Kably AmbeA , Ruiz AnguasJ , Walters ArballoF , García BenitezCQ , Karchmer KrivitskyS . Results' analysis of estradiol and progesterone supplementation in luteal phase vs progesterone alone in an assisted reproduction program. Ginecologia y Obstetricia de Mexico2005;73:173‐82. ">Kably Ambe 2005</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0064" title="MoiniA , Zadeh ModarressS , AmirchaghmaghiE , MirghavamN , KhafriS , Reza AkhoondM , Salman YazdiR . The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles ‐ a randomized controlled study. Archives of Medical Science2011;7:112‐6. ">Moini 2011</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>).<br/> <br/> Routes of oestrogen administration were oral (nine RCTs, 1427 women), transdermal (three RCTs, 364 women), vaginal (two RCTs, 301 women) and oral/transdermal (one RCT, 77 women). <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a> was a three‐arm study comparing progesterone, progesterone + oral oestrogen and progesterone + vaginal oestrogen. To make sure we did not duplicate data, we divided data from the progesterone‐only arm by two, so half of the progesterone‐only events and participants were reported under the subgroup 'oral', and the other half of the progesterone‐only events and participants were reported under the subgroup 'vaginal'. </p> <p>When studies were pooled, no evidence suggested differences between groups (OR 0.86, 95% CI 0.72 to 1.04, 14 RCTs, 4169 women, I<sup>2</sup> = 56%, low quality evidence). However substantial heterogeneity was noted for this analysis (56%), and results of the test for subgroup differences were statistically significant (P value = 0.004). </p> <p>When the data were considered by route of oestrogen administration, heterogeneity in the comparison using oral oestrogen was relatively low (I<sup>2</sup> = 16%), and evidence suggested no differences between groups. However heterogeneity in comparisons using other routes of administration was high (I<sup>2</sup> = 56% to 82%), and in studies using transdermal oestrogen, a higher pregnancy rate was reported in the progesterone + oestrogen groups. These findings should be regarded with caution because of the inconsistency observed between studies and the small quantity of data provided. </p> <p>Because this comparison included more than 10 studies, we prepared a funnel plot to determine the risk of publication bias (see <a href="#CD009154-fig-0005">Figure 5</a>), which is discussed in the section <a href="#CD009154-sec-0059">Selective reporting (reporting bias)</a>. We concluded that the study showed a small risk of publication bias. </p> <section id="CD009154-sec-0105"> <p><b>Subgroup analyses<i>for clinical pregnancy rate</i> </b></p> <p><i>4.2.1 Ovarian stimulation protocol</i> </p> <p>Eight studies were subgrouped by method of ovarian stimulation. Seven utilised hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0025" title="DrakakisP , LoutradisD , VomvolakiE , StefanidisK , KiapekouE , AnagnostouE , et al. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection‐embryo transfer. Gynecological Endocrinology2007;23(11):645‐52. ">Drakakis 2007</a>; <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>; <a href="./references#CD009154-bbs2-0064" title="MoiniA , Zadeh ModarressS , AmirchaghmaghiE , MirghavamN , KhafriS , Reza AkhoondM , Salman YazdiR . The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles ‐ a randomized controlled study. Archives of Medical Science2011;7:112‐6. ">Moini 2011</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>), and two utilised hCG with or without GnRH antagonists (<a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>). Findings did not differ substantially from those of the main analysis in either subgroup. See <a href="./references#CD009154-fig-0034" title="">Analysis 4.3</a>. </p> </section> <section id="CD009154-sec-0106"> <p><b>4.2.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0107"> <p><b>4.2.3 Duration of progesterone</b></p> <p>Ten studies were subgrouped by duration of progesterone. Two stopped treatment at the pregnancy test (<a href="./references#CD009154-bbs2-0025" title="DrakakisP , LoutradisD , VomvolakiE , StefanidisK , KiapekouE , AnagnostouE , et al. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection‐embryo transfer. Gynecological Endocrinology2007;23(11):645‐52. ">Drakakis 2007</a>; <a href="./references#CD009154-bbs2-0053" title="LewinA , BenshushanA , MezkerE , YanaiN , SchenkerJG , GoshenR . The role of estrogen support during the luteal phase of in vitro fertilization‐embryo transplant cycles: a comparative study between progesterone alone and estrogen and progesterone support. Fertility and Sterility1994;62:121‐5. LewinA , PisovG , TurgemanR , FatumM , ShufaroY , SimonA , et al. Simplified artificial endometrial preparation, using oral estradiol and novel vaginal progesterone tablets: a prospective randomized study. Gynecological Endocrinology2002;16(2):131‐6. ">Lewin 1994</a>), and eight administered progesterone for up to 12 weeks when pregnant (<a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008</a>; <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0039" title="GorkemliH , AkD , AkyurekC , AktanM , DumanS . Comparison of pregnancy outcomes of progesterone or progesterone plus estradiol for luteal phase support in ICSI‐ET cycles. Gynecologic and Obstetric Investigation2004;58(3):140‐4. ">Gorkemli 2004</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0064" title="MoiniA , Zadeh ModarressS , AmirchaghmaghiE , MirghavamN , KhafriS , Reza AkhoondM , Salman YazdiR . The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles ‐ a randomized controlled study. Archives of Medical Science2011;7:112‐6. ">Moini 2011</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>). Studies in the subgroups were not pooled because of marked heterogeneity (I<sup>2</sup> = 63% to 67%), possibly related to the differing methods of oestrogen administration described within each subgroup. See <a href="./references#CD009154-fig-0035" title="">Analysis 4.4</a>. </p> </section> <section id="CD009154-sec-0108"> <p><b>4.2.4 Number of embryos transferred</b></p> <p>No data were available for this subgroup analysis.</p> </section> </section> <section id="CD009154-sec-0109"> <h6 class="title">4.3 Miscarriage rate</h6> <p>Ten studies reported this outcome (<a href="./references#CD009154-bbs2-0005" title="AghahosseiniM , AleyassinA , KhodaverdiS , EsfahaniF , MohammadbeigiR , MovahediS , et al. Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial. Journal of Assisted Reproduction and Genetics2011;28:785‐90. ">Aghahosseini 2011</a>; <a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0025" title="DrakakisP , LoutradisD , VomvolakiE , StefanidisK , KiapekouE , AnagnostouE , et al. Luteal estrogen supplementation in stimulated cycles may improve the pregnancy rate in patients undergoing in vitro fertilization/intracytoplasmic sperm injection‐embryo transfer. Gynecological Endocrinology2007;23(11):645‐52. ">Drakakis 2007</a>; <a href="./references#CD009154-bbs2-0027" title="ElgindyEA , El‐HaiegDO . Does luteal estradiol supplementation have a role in long agonist cycles? Does luteal estradiol supplementation have a role in long agonist cycles? [abstract]. Fertility and Sterility. 2010; Vol. 88, issue Suppl 1:164 (Abs #168). ElgindyEA , El‐HaiegDO , MostafaMI , ShafiekM . Does luteal estradiol supplementation have a role in long agonist cycles?. Fertility and Sterility2010;93(7):2182‐8. ">Elgindy 2010</a>; <a href="./references#CD009154-bbs2-0028" title="EngmannL , DiLuigiA , SchmidtD , BenadivaC , MaierD , NulsenJ . The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertility and Sterility2008;89(3):554‐61. ">Engmann 2008</a>; <a href="./references#CD009154-bbs2-0030" title="FatemiHM , KolibianakisEM , CamusM , TournayeH , DonosoP , PapanikolaouE , et al. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Human Reproduction2006;21(10):2628‐32. FatemiHM , KolibianakisEM , CamusM , TournayeH , vanSteirteghemA , DevroeyP . Progesterone versus progesterone combined with estradiol as luteal support in cycles stimulated with GnRH antagonist/rec‐FSH for IVF: a randomized clinical trial [abstract]. Fertility and Sterility. 2005; Vol. 84, issue Suppl 1:s322 (Abs #P‐475). ">Fatemi 2006</a>; <a href="./references#CD009154-bbs2-0047" title="Kably AmbeA , Ruiz AnguasJ , Walters ArballoF , García BenitezCQ , Karchmer KrivitskyS . Results' analysis of estradiol and progesterone supplementation in luteal phase vs progesterone alone in an assisted reproduction program. Ginecologia y Obstetricia de Mexico2005;73:173‐82. ">Kably Ambe 2005</a>; <a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>; <a href="./references#CD009154-bbs2-0079" title="SernaJ , CholquevilqueJL , CelaV , Martinez‐SalazarJ , RequenaA , Garcia‐VelascoJA . Estradiol supplementation during the luteal phase of IVF‐ICSI patients: a randomized, controlled trial. Fertility and Sterility2008;90(6):2190‐5. ">Serna 2008</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>). Routes of oestrogen administration were oral (seven RCTs, 1370 women), transdermal (one RCT, 160 women), vaginal (two RCTs, 301 women) and oral/transdermal (one RCT, 77 women). </p> <p>When studies were pooled, no evidence suggested differences between groups (OR 0.98, 95% CI 0.72 to 1.35, 10 RCTs, 1908 women, I<sup>2</sup> = 15%). </p> <p>When data were considered by route of oestrogen administration, findings did not differ substantially from those of the main analysis. However heterogeneity was high in the comparison using vaginal oestrogen (I<sup>2</sup> = 59%). </p> </section> <section id="CD009154-sec-0110"> <h6 class="title">4.4 Ovarian hyperstimulation syndrome (OHSS)</h6> <p>Two studies reported this outcome (<a href="./references#CD009154-bbs2-0019" title="CeyhanST , BasaranM , Kemal DuruN , YilmazA , GoktolgaU , BaserI . Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertility and Sterility2008;89(6):1827‐30. ">Ceyhan 2008;</a><a href="./references#CD009154-bbs2-0055" title="LinH , LiY , LiL , WangW , ZhangQ , ChenX , YangD . Oral oestradiol supplementation as luteal support in IVF/ICSI cycles: a prospective, randomized controlled study. European Journal of Obstetrics Gynecology and Reproductive Biology2013;167:171‐5. ">Lin 2013</a>). Routes of oestrogen administration were oral (one RCT, 461 women) and transdermal (one RCT, 59 women). </p> <p>When these studies were pooled, evidence suggested no differences between groups (OR 0.58, 95% CI 0.20 to 1.68, two RCTs, 461 women, I<sup>2</sup> = 0%, low quality evidence). </p> <p>When the data were considered by route of oestrogen administration, findings did not differ substantially. See <a href="./references#CD009154-fig-0037" title="">Analysis 4.6</a> for details of this comparison. </p> </section> <section id="CD009154-sec-0111"> <h6 class="title">4.5 Multiple pregnancy</h6> <p>No studies reported this outcome.</p> </section> </section> </section> <section id="CD009154-sec-0112"> <h4 class="title">5. Progesterone versus progesterone + GnRH agonist</h4> <section id="CD009154-sec-0113"> <h5 class="title">Primary outcome</h5> <section id="CD009154-sec-0114"> <h6 class="title">5.1 Live birth/ongoing pregnancy rate</h6> <p>Nine studies reported live birth (<a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0004" title="Aboulghar , MohamedA , Marie , Heba , Amin , YahiaM , Aboulghar , MonaM , Nasr , Ahmed , Serour , GamalI , Mansour , RagaaT . GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.. Reproductive Biomedicine Online2015;30:52‐56. ">Aboulghar 2015</a>; <a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0017" title="BriganteCMM , Mignini RenziniM , Dal CantoM , CoticchioG , ComiR , FadiniR . Efficacy of luteal phase support with GnRH agonists: a preliminary comparative study. Fertility and Sterility2013;100(Suppl):S299 (Abs # P‐521). ">Brigante 2013</a>; <a href="./references#CD009154-bbs2-0043" title="InamdarDB , MajumdarA . Evaluation of the impact of gonadotropin‐releasing hormone agonist as an adjuvant in luteal‐phase support on IVF outcome. Journal of Human Reproductive Sciences2012;5(3):279‐84. ">Inamdar 2012</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>; <a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>). Researchers administered the GnRH agonist as a single dose (five RCTs, 1536 women) or in multiple doses (five RCTs, 1325 women). See <a href="#CD009154-fig-0012">Figure 12</a> for details of this comparison. </p> <div class="figure" id="CD009154-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 5 Progesterone vs progesterone + GnRH agonist, outcome: 5.1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 5 Progesterone vs progesterone + GnRH agonist, outcome: 5.1 Live birth or ongoing pregnancy rate. </p> </div> </div> </div> <p>The live birth/ongoing pregnancy rate was lower in the progesterone‐only group than the progesterone + GnRHa group (OR 0.62, 95% CI 0.48 to 0.81, nine RCTs, 2861 women, I<sup>2</sup> = 55%, random effects, low quality evidence). The high statistical heterogeneity in this analysis was due to wide variation between studies in size of the effect, although the direction of the effect was consistent. </p> <p>Findings were similar when the analysis was restricted to studies reporting live birth only (OR 0.34, 95% CI 0.15 to 0.59, three RCTs, 455 women, I<sup>2</sup> = 66%). </p> <p>When the data were considered by number of doses of GnRH agonist, findings did not differ substantially. See <a href="./references#CD009154-fig-0038" title="">Analysis 5.1</a> for details of this comparison. </p> </section> </section> <section id="CD009154-sec-0115"> <h5 class="title">Secondary outcomes</h5> <section id="CD009154-sec-0116"> <h6 class="title">5.2 Clinical pregnancy rate</h6> <p>Eight studies reported this outcome (<a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0004" title="Aboulghar , MohamedA , Marie , Heba , Amin , YahiaM , Aboulghar , MonaM , Nasr , Ahmed , Serour , GamalI , Mansour , RagaaT . GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.. Reproductive Biomedicine Online2015;30:52‐56. ">Aboulghar 2015</a>; <a href="./references#CD009154-bbs2-0017" title="BriganteCMM , Mignini RenziniM , Dal CantoM , CoticchioG , ComiR , FadiniR . Efficacy of luteal phase support with GnRH agonists: a preliminary comparative study. Fertility and Sterility2013;100(Suppl):S299 (Abs # P‐521). ">Brigante 2013</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>; <a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>). Researchers administered the GnRH agonist as a single dose (five RCTs, 1536 women) or in multiple doses (four RCTs, 899 women); One trial had two intervention arms of single and multiple doses (<a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>). </p> <p>Pregnancy rates were lower in the progesterone‐only group (OR 0.66, 95% CI 0.51 to 0.85, eight RCTs, 2435 women, I<sup>2</sup> = 47%, random effects, low quality evidence). High statistical heterogeneity in this analysis appeared to be largely due to wide variation between studies in the size of the effect. See <a href="./references#CD009154-fig-0039" title="">Analysis 5.2</a> for details. </p> <p>When data were considered by number of doses of GnRH agonist, findings were consistent with those of the analysis of live birth/ongoing pregnancy in the single‐dose progesterone group but were not statistically significant in the multiple‐dose group. Results of the statistical test for subgroup differences were not significant. See <a href="./references#CD009154-fig-0038" title="">Analysis 5.1</a> for details. </p> <section id="CD009154-sec-0117"> <p><b>Subgroup analyses for clinical pregnancy rate</b></p> </section> <section id="CD009154-sec-0118"> <p><b>5.2.1 Ovarian stimulation protocol</b></p> <p>In subgroup analyses, findings were consistent with those of the main analysis in the subgroup that received hCG with or without GnRH antagonists (<a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0071" title="PorcuE . Intramuscular versus vaginal progesterone in assisted reproduction [abstract]. Fertility and Sterility. 2003; Vol. 80:S131 (Abs # P‐32). ">Porcu 2003</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>;<a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>) and the subgroup that received hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0004" title="Aboulghar , MohamedA , Marie , Heba , Amin , YahiaM , Aboulghar , MonaM , Nasr , Ahmed , Serour , GamalI , Mansour , RagaaT . GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.. Reproductive Biomedicine Online2015;30:52‐56. ">Aboulghar 2015</a><a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>). Results of the statistical test for subgroup differences were not significant. See <a href="./references#CD009154-fig-0040" title="">Analysis 5.3</a> for details. </p> </section> <section id="CD009154-sec-0119"> <p><b>5.2.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0120"> <p><b>5.2.3 Duration of progesterone (clinical pregnancy rate)</b></p> <p>In subgroup analyses, findings were consistent with those of the main analysis in the subgroup that stopped treatment at the time of the pregnancy test (<a href="./references#CD009154-bbs2-0004" title="Aboulghar , MohamedA , Marie , Heba , Amin , YahiaM , Aboulghar , MonaM , Nasr , Ahmed , Serour , GamalI , Mansour , RagaaT . GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.. Reproductive Biomedicine Online2015;30:52‐56. ">Aboulghar 2015</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>; <a href="./references#CD009154-bbs2-0045" title="IsikogluM , OzgurK , OehningerS . Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection. Journal of Reproductive Medicine2007;52(7):639‐44. ">Isikoglu 2007</a>; <a href="./references#CD009154-bbs2-0085" title="TesarikJ , HazoutA , Mendoza‐TesarikR , MendozaN , MendozaC . Beneficial effect of luteal‐phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist‐ and antagonist‐treated ovarian stimulation cycles. Human Reproduction2006;21(10):2572‐9. ">Tesarik 2006</a>; <a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>). Random effects model. Evidence suggested no differences between groups in the subgroup of women who were treated for up to 12 weeks when pregnant (<a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>). However results of the statistical test for subgroup differences were not significant. See <a href="./references#CD009154-fig-0041" title="">Analysis 5.4</a> for details of this comparison. </p> </section> <section id="CD009154-sec-0121"> <p><b>5.2.4 Number of embryos transferred (clinical pregnancy rate)</b></p> <p>No data were available for this subgroup analysis.</p> </section> </section> <section id="CD009154-sec-0122"> <h6 class="title">5.3 Miscarriage rate</h6> <p>Two studies reported this outcome (<a href="./references#CD009154-bbs2-0074" title="QublanH , AmarinZ , Al‐QudaM , DiabF , NawasrehM , MalkawiS , et al. Luteal phase support with GnRH‐a improves implantation and pregnancy rates in IVF cycles with endometrium of [less‐than or equal to]7 mm on day of egg retrieval. Human Fertility2008;11(1):43‐7. ">Qublan 2008</a>;<a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>). The GnRH agonist was mostly administered in multiple doses. Evidence suggested no differences between groups (OR 1.37, 95% CI 0.53 to 3.52, 2 RCTs, 420 women). See <a href="./references#CD009154-fig-0042" title="">Analysis 5.5</a> for details. </p> </section> <section id="CD009154-sec-0123"> <h6 class="title">5.4 Multiple pregnancy</h6> <p>Four studies reported this outcome (<a href="./references#CD009154-bbs2-0009" title="AtaB , YakinK , BalabanB , UrmanB . GnRH agonist protocol administration in the luteal phase in ICSI‐ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study. Human Reproduction2008;23(3):668‐73. UrmanB . Single dose gonadotropin‐releasing hormone (GnRH) agonist administration in the luteal phase of GnRH antagonist stimulated ICSI‐ET cycles. Directly obtained from author, 17 March 2011. [Clinicaltrials.gov: NCT01007851] ">Ata 2008</a>; <a href="./references#CD009154-bbs2-0043" title="InamdarDB , MajumdarA . Evaluation of the impact of gonadotropin‐releasing hormone agonist as an adjuvant in luteal‐phase support on IVF outcome. Journal of Human Reproductive Sciences2012;5(3):279‐84. ">Inamdar 2012</a>; <a href="./references#CD009154-bbs2-0044" title="IsikAZ , CaglarGS , SozenE , AkarsuC , TuncayG , OzbicerT , et al. Single‐dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reproductive BioMedicine Online2009;19(4):472‐7. ">Isik 2009</a>;<a href="./references#CD009154-bbs2-0093" title="Yildiz , GulsahAynaoglu , Sukur , YavuzEmre , Ates , Can , Aytac , Rusen . The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology2014;182:66‐70. ">Yildiz 2014</a>). Researchers administered the GnRH agonist as a single dose (two RCTs, 724 women) or in multiple doses (one RCT, 426 women) and one study both single and multiple doses.<br/> <br/> Evidence suggested no differences between groups. When the data were considered by number of doses of GnRH agonist, findings did not differ substantially. See <a href="./references#CD009154-fig-0043" title="">Analysis 5.6</a> for details. </p> </section> <section id="CD009154-sec-0124"> <h6 class="title">5.5 Ovarian hyperstimulation syndrome (OHSS)</h6> <p>One study reported OHSS and showed no evidence of a difference between the groups (OR 1.00, 95% CI 0.33 to 3.01, 1 RCT, 300 women, very low quality evidence). See <a href="./references#CD009154-fig-0044" title="">Analysis 5.7</a> for details. </p> </section> </section> </section> <section id="CD009154-sec-0125"> <h4 class="title">6. Progesterone regimens</h4> <section id="CD009154-sec-0126"> <h5 class="title">Primary outcome</h5> <section id="CD009154-sec-0127"> <h6 class="title">6.1 Live birth/ongoing pregnancy rate</h6> <p>Twenty‐five studies compared progesterone regimens and reported live birth (<a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>; <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>; <a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>; <a href="./references#CD009154-bbs2-0015" title="BeltsosA , SanchezM , DoodyK , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin®) compared to intramuscular progesterone in oil for luteal support in PCOS patients. Fertility and Sterility2011;96(Suppl):S130 (Abs # P‐71). ">Beltsos 2011</a>; <a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>; <a href="./references#CD009154-bbs2-0084" title="TayPYS , LentonEA . The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia2005;60(2):151‐7. ">Tay 2005</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>). </p> <p>See <a href="#CD009154-fig-0013">Figure 13</a> for details of this comparison. </p> <div class="figure" id="CD009154-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 6 Progesterone regimens, outcome: 6.1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 6 Progesterone regimens, outcome: 6.1 Live birth or ongoing pregnancy rate. </p> </div> </div> </div> <section id="CD009154-sec-0128"> <p><b>6.1.1 Intramuscular (IM) vs oral</b></p> <p>One study made this comparison and reported live birth (<a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>). No evidence suggested differences between groups (OR 0.71, 95% CI 0.14 to 3.66, one RCT, 40 women, very low quality evidence). </p> </section> <section id="CD009154-sec-0129"> <p><b>6.1.2 IM vs vaginal or rectal</b></p> <p>Seven studies made this comparison and reported live birth (<a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0015" title="BeltsosA , SanchezM , DoodyK , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin®) compared to intramuscular progesterone in oil for luteal support in PCOS patients. Fertility and Sterility2011;96(Suppl):S130 (Abs # P‐71). ">Beltsos 2011</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>;). <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a> was a three‐arm study investigating IM progesterone versus vaginal gel 90 mg daily versus vaginal gel 90 mg twice daily. We combined both vaginal arms and compared them with the IM arm. </p> <p>Live birth and ongoing pregnancy rates were higher in the vaginal/rectal group (OR 1.24, 95% CI 1.03 to 1.50, seven RCTs, 2039 women, I<sup>2</sup> = 71%, very low quality evidence). However, statistical heterogeneity was high, and when a random‐effects model was used, no evidence suggested differences between groups (OR 1.37, 95% CI 0.94 to 1.99). </p> <p>When analysis was restricted to studies reporting live birth, no evidence suggested differences between groups (OR 1.31, 95% CI 0.84 to 2.05, four RCTs, 1222 women, I<sup>2</sup> = 59%, random‐effects model). </p> </section> <section id="CD009154-sec-0130"> <p><b>6.1.3 Vaginal or rectal vs oral</b></p> <p>Four studies made this comparison and reported live birth (<a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>).<br/> Evidence suggested no differences between groups (OR 1.19, 95% CI 0.83 to 1.69, four RCTs, 857 women, I<sup>2</sup> = 32%, low quality evidence). </p> <p>Findings did not differ substantially when analysis was restricted to studies reporting live birth. </p> </section> <section id="CD009154-sec-0131"> <p><b>6.1.4 Low dose vaginal (≤ 100 mg) vs high dose vaginal (&gt; 100 mg)</b></p> <p>Five studies made this comparison and reported live birth (<a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0084" title="TayPYS , LentonEA . The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles. Medical Journal of Malaysia2005;60(2):151‐7. ">Tay 2005</a>). <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a> was a three‐arm study comparing micronised progesterone vaginal gel 90 mg versus vaginal progesterone 100 mg twice daily versus vaginal progesterone 100 mg three times daily. We combined the two high‐dose arms in this comparison. </p> <p>Evidence suggested no differences between groups (OR 0.97, 95% CI 0.84 to 1.11, five RCTs, 3720 women, I<sup>2</sup> = 0%, moderate quality evidence). </p> <p>Findings did not differ substantially when analysis was restricted to studies reporting live birth. </p> </section> <section id="CD009154-sec-0132"> <p><b>6.1.5 Short protocol vs long protocol</b></p> <p>FIve studies made this comparison and reported live birth (<a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>) or ongoing pregnancy (<a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>). <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a> was a three‐arm study comparing micronised vaginal progesterone 200 mg twice daily starting at the evening of hCG administration for final oocyte maturation versus starting at the evening after oocyte retrieval versus starting at the evening after ET. We combined the first two arms. </p> <p>No evidence suggested differences between groups (OR 1.04, 95% CI 0.79 to 1.36, five RCTs, 1205 women, I<sup>2</sup> = 0%, low quality evidence). </p> <p>Findings did not differ substantially when analysis was restricted to studies reporting live birth. </p> </section> <section id="CD009154-sec-0133"> <p><b>6.1.6 Micronised progesterone vs synthetic progesterone</b></p> <p>Two studies made this comparison (<a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>). Both reported live birth.<br/> Evidence suggested no differences between groups (OR 0.90, 95% CI 0.53 to 1.55, two RCTs, 470 women, I<sup>2</sup> = 0%, low quality evidence). </p> </section> <section id="CD009154-sec-0134"> <p><b>6.1.7 Vaginal ring vs vaginal gel</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>) and reported live birth. </p> <p>Evidence suggested no differences between groups (OR 1.09, 95% CI 0.88 to 1.36, one RCT, 1271 women, low quality evidence). </p> </section> <section id="CD009154-sec-0135"> <p><b>6.1.8 Subcutaneous vs vaginal gel</b></p> <p>Two studies made this comparison (<a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>). Both reported live births. </p> <p>Evidence suggested no differences between groups (OR 0.92, 95% CI 0.74 to 1.14, two RCTs, 1465 women, I<sup>2</sup> = 0%, low quality evidence). </p> </section> <section id="CD009154-sec-0136"> <p><b>6.1.9 Vaginal vs rectal</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>) and reported ongoing pregnancy. </p> <p>Evidence suggested no differences between groups (OR 1.28, 95% CI 0.64 to 2.54, one RCT, 147 women, very low quality evidence). </p> </section> </section> </section> <section id="CD009154-sec-0137"> <h5 class="title">Secondary outcomes</h5> <section id="CD009154-sec-0138"> <h6 class="title">6.2 Clinical pregnancy rate</h6> <p>Forty‐one studies compared progesterone regimens and reported clinical pregnancy. See <a href="./references#CD009154-fig-0046" title="">Analysis 6.2</a> for details of this comparison. </p> <section id="CD009154-sec-0139"> <p><b>6.2.1 IM vs oral</b></p> <p>Three studies made this comparison (<a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0054" title="LicciardiF , KwiatkowskiA , NoyesN , BerkeleyAS , KreyLL , GrifoJA . Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertility and Sterility1999;71:614‐8. ">Licciardi 1999</a>; <a href="./references#CD009154-bbs2-0077" title="Saucedo‐de la LlataE , GalacheVP , HernandezAS , SantosHR , ArenasML , PatrizioP . Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility2000;74 Suppl 1:S150 (Abs # P‐175). ">Saucedo 2000</a>).<br/> Evidence suggested no differences between groups (OR 1.96, 95% CI 0.89 to 4.32, three RCTs, 123 women, I<sup>2</sup> = 0%). </p> </section> <section id="CD009154-sec-0140"> <p><b>Subgroup analyses for clinical pregnancy rate</b></p> <p>No data were available for subgroup analyses.</p> </section> <section id="CD009154-sec-0141"> <p><b>6.2.2 IM vs vaginal<i>or</i> rectal</b></p> <p>Thirteen studies made this comparison (<a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0037" title="GeusaS , CausioF , MarinaccioM , StanzianoA , SarcinaE . Luteal phase support with progesterone in IVF/ET cycles: a prospective, randomized study comparing vaginal and intramuscular administration [abstract]. Human Reproduction2001;16 Suppl 1:145 (Abs # P‐111). ">Geusa 2001</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0071" title="PorcuE . Intramuscular versus vaginal progesterone in assisted reproduction [abstract]. Fertility and Sterility. 2003; Vol. 80:S131 (Abs # P‐32). ">Porcu 2003</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0077" title="Saucedo‐de la LlataE , GalacheVP , HernandezAS , SantosHR , ArenasML , PatrizioP . Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility2000;74 Suppl 1:S150 (Abs # P‐175). ">Saucedo 2000</a>; <a href="./references#CD009154-bbs2-0078" title="Saucedo‐de la LlataE , BatizaV , ArenasL , SantosR , GalacheP , Hernandez‐AyupS , et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration [abstract]. Fertility and Sterility2003;18 Suppl 1:130 (Abs # P‐382). ">Saucedo 2003</a>; <a href="./references#CD009154-bbs2-0083" title="SumitaS , SofatSSr . Intramuscular versus intra vaginal progesterone as luteal phase and early pregnancy support in patients undergoing IVF‐ET [abstract]. Fertility and Sterility2003;80 Suppl 3:134‐5 (Abs # P‐44). ">Sumita 2003</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>; <a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>). <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a> was a three‐arm study investigating IM progesterone versus vaginal gel 90 mg daily versus vaginal gel 90 mg twice daily. We combined both vaginal arms and compared them with the IM arm.<br/> Evidence suggested no differences between groups (OR 1.14, 95% CI 0.97 to 1.33, 13 RCTs, 2932 women, I<sup>2</sup> = 43%). </p> <p>Because this comparison included more than 10 studies, we prepared a funnel plot to determine the risk of publication bias (see <a href="#CD009154-fig-0005">Figure 5</a>). This was discussed in the section <a href="#CD009154-sec-0059">Selective reporting (reporting bias)</a>. We concluded that the study showed a small risk of publication bias. </p> </section> <section id="CD009154-sec-0142"> <p><b>Subgroup analyses for clinical pregnancy rate</b></p> </section> <section id="CD009154-sec-0143"> <p><b>6.2.2.1 Ovarian stimulation protocol</b></p> <p>Eleven studies were subgrouped by method of ovarian stimulation. Ten utilised hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0037" title="GeusaS , CausioF , MarinaccioM , StanzianoA , SarcinaE . Luteal phase support with progesterone in IVF/ET cycles: a prospective, randomized study comparing vaginal and intramuscular administration [abstract]. Human Reproduction2001;16 Suppl 1:145 (Abs # P‐111). ">Geusa 2001</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0071" title="PorcuE . Intramuscular versus vaginal progesterone in assisted reproduction [abstract]. Fertility and Sterility. 2003; Vol. 80:S131 (Abs # P‐32). ">Porcu 2003</a>; <a href="./references#CD009154-bbs2-0078" title="Saucedo‐de la LlataE , BatizaV , ArenasL , SantosR , GalacheP , Hernandez‐AyupS , et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration [abstract]. Fertility and Sterility2003;18 Suppl 1:130 (Abs # P‐382). ">Saucedo 2003</a>; <a href="./references#CD009154-bbs2-0083" title="SumitaS , SofatSSr . Intramuscular versus intra vaginal progesterone as luteal phase and early pregnancy support in patients undergoing IVF‐ET [abstract]. Fertility and Sterility2003;80 Suppl 3:134‐5 (Abs # P‐44). ">Sumita 2003</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>; <a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>). Studies in this subgroup were not pooled because of marked heterogeneity (I<sup>2</sup> = 65%). A single study utilised hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>) and reported findings similar to those of the main analysis. See <a href="./references#CD009154-fig-0050" title="">Analysis 6.6</a> for details. </p> </section> <section id="CD009154-sec-0144"> <p><b>6.2.2.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0145"> <p><b>6.2.2.3 Duration of progesterone</b></p> <p>Seven studies were subgrouped by duration of progesterone. Two stopped treatment at the pregnancy test (<a href="./references#CD009154-bbs2-0008" title="ArtiniPG , VolpeA , AngioniS , GalassiMC , BattagliaC , GenazzaniAR . A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program. Journal of Endocrinological Investigation1995;18:51‐6. ">Artini 1995;</a><a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>), and five administered progesterone for up to 12 weeks when pregnant (<a href="./references#CD009154-bbs2-0002" title="AbateA , PerinoM , AbateFG , BrigandiA , CostabileL , MantiF . Intramuscular versus vaginal administration of progesterone for luteal phase support after in vitro fertilization and embryo transfer. A comparative randomized study. Clinical and Experimental Obstetrics and Gynecology1999;26:203‐6. ">Abate 1999a</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0073" title="PropstAM , HillJA , GinsburgES , HurwitzS , PolitchJ , YanushpolskyEH . A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2001;76:1144‐9. PropstAM , HillJA , PolitchJ , YanushpolskyEH . A prospective, randomized study comparing Crinone and intramuscular progesterone supplementation in IVF/ET cycles [abstract]. Fertility and Sterility. 2000; Vol. 74:s30‐1 (Abs #O‐084). ">Propst 2001</a>; <a href="./references#CD009154-bbs2-0083" title="SumitaS , SofatSSr . Intramuscular versus intra vaginal progesterone as luteal phase and early pregnancy support in patients undergoing IVF‐ET [abstract]. Fertility and Sterility2003;80 Suppl 3:134‐5 (Abs # P‐44). ">Sumita 2003</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>). Studies in these subgroups were not pooled because of statistical heterogeneity (I<sup>2</sup> = 68%), and inconsistency was noted in the directions of effect. See <a href="./references#CD009154-fig-0051" title="">Analysis 6.7</a> for details of this comparison. </p> </section> <section id="CD009154-sec-0146"> <p><b>6.2.2.4 Number of embryos transferred</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0147"> <p><b>6.2.3 Vaginal or rectal vs oral</b></p> <p>Seven studies made this comparison (<a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0069" title="PatkiA , PawarVC . Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecological Endocrinology2007;23 Suppl 1:68‐72. ">Patki 2007</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>; <a href="./references#CD009154-bbs2-0077" title="Saucedo‐de la LlataE , GalacheVP , HernandezAS , SantosHR , ArenasML , PatrizioP . Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility2000;74 Suppl 1:S150 (Abs # P‐175). ">Saucedo 2000</a>). </p> <p>Evidence suggested no differences between groups (OR 0.89, 95% CI 0.75 to 1.05, seven RCTs, 2815 women, I<sup>2</sup> = 52%). </p> <p>Heterogeneity was substantial, in part because of the findings of <a href="./references#CD009154-bbs2-0069" title="PatkiA , PawarVC . Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecological Endocrinology2007;23 Suppl 1:68‐72. ">Patki 2007</a>. This study compared vaginal progesterone versus vaginal progesterone + oral progesterone, and the two different routes may have played a role in creating heterogeneity. When this study was omitted from the analysis, the I<sup>2</sup> value was reduced to 25%. </p> </section> <section id="CD009154-sec-0148"> <p><b>Subgroup analyses for clinical pregnancy rate</b></p> </section> <section id="CD009154-sec-0149"> <p><b>6.2.3.1 Ovarian stimulation protocol</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0150"> <p><b>6.2.3.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0151"> <p><b>6.2.3.3 Duration of progesterone</b></p> <p>Five studies were subgrouped by duration of progesterone treatment. Two studies stopped treatment at the pregnancy test (<a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0069" title="PatkiA , PawarVC . Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecological Endocrinology2007;23 Suppl 1:68‐72. ">Patki 2007</a>), and four administered progesterone for up to 12 weeks when pregnant (<a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>). Findings in the subgroup that stopped at the pregnancy test suggested benefit for the oral group, but inconsistency and very high heterogeneity were noted for the subgroup (I<sup>2</sup> = 82%), which indicates that this finding should be regarded very cautiously. Findings in the group that administered progesterone for up to 12 weeks did not differ substantially from those of the main analysis. Results of the test for subgroup differences were not statistically significant. See <a href="./references#CD009154-fig-0052" title="">Analysis 6.8</a> for details of this comparison. </p> </section> <section id="CD009154-sec-0152"> <p><b>6.2.3.4 Number of embryos transferred</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0153"> <p><b>6.2.4 Low dose vaginal (≤ 100 mg) vs high dose vaginal (&gt; 100 mg)</b></p> <p>Twelve studies made this comparison (<a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0026" title="DunstoneT , ZosmerA , HussainS , TozerA , PaneyN , WilsonC , et al. A comparison between Cyclogest pessaries and Crinone gel as luteal support in IVF‐ET cycles [abstract]. British Fertility Society Annual Meeting Abstract Book. 1999:62 (Abs # FC21). ">Dunstone 1999</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0066" title="NgEHY , MiaoB , CheungW , HoPC . A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. European Journal of Obstetrics Gynecology and Reproductive Biology2003;111:50‐4. ">Ng 2003</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0075" title="Rodriguez‐PezinoJ , Saucedo‐de la LlataE , Batiza‐ResendizV , Galache‐VegaP , Santos‐HaliscakR , Hernandez‐AyupS , et al. Vaginal progesterone in assisted reproduction. Human Reproduction. Berlin, Germany, 2004; Vol. 19 Suppl 1:i51. ">Rodriguez‐Pezino 2004</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>). <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a> was a three‐arm study comparing micronised progesterone vaginal gel 90 mg versus vaginal progesterone 100 mg twice daily versus vaginal progesterone 100 mg three times daily. We combined the two high‐dose arms in this comparison. </p> <p>Evidence suggested no differences between groups (OR 0.98, 95% CI 0.87 to 1.09, 12 RCTs, 5659 women, I<sup>2</sup> = 30%). </p> <p>Because this comparison included more than 10 studies, we prepared a funnel plot to determine the risk of publication bias (see <a href="#CD009154-fig-0005">Figure 5</a>). This was discussed in the section <a href="#CD009154-sec-0059">Selective reporting (reporting bias)</a>; we concluded that the study showed a small risk of publication bias. </p> </section> <section id="CD009154-sec-0154"> <p><b>Subgroup analyses for clinical pregnancy rate</b></p> </section> <section id="CD009154-sec-0155"> <p><b>6.2.4.1 Ovarian stimulation protocol</b></p> <p>Nine studies were subgrouped by method of ovarian stimulation. Eight utilised hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0066" title="NgEHY , MiaoB , CheungW , HoPC . A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. European Journal of Obstetrics Gynecology and Reproductive Biology2003;111:50‐4. ">Ng 2003</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>), and one utilised hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0075" title="Rodriguez‐PezinoJ , Saucedo‐de la LlataE , Batiza‐ResendizV , Galache‐VegaP , Santos‐HaliscakR , Hernandez‐AyupS , et al. Vaginal progesterone in assisted reproduction. Human Reproduction. Berlin, Germany, 2004; Vol. 19 Suppl 1:i51. ">Rodriguez‐Pezino 2004</a>). For both subgroups, findings were similar to those of the main analysis. See <a href="./references#CD009154-fig-0053" title="">Analysis 6.9</a> for details. </p> </section> <section id="CD009154-sec-0156"> <p><b>6.2.4.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0157"> <p><b>6.2.4.3 Duration of progesterone</b></p> <p>Nine studies were subgrouped by duration of progesterone. Three stopped treatment at the pregnancy test (<a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0066" title="NgEHY , MiaoB , CheungW , HoPC . A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. European Journal of Obstetrics Gynecology and Reproductive Biology2003;111:50‐4. ">Ng 2003</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>), and six administered progesterone for up to 12 weeks when pregnant ((<a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>). In both subgroups, findings were similar to those of the main analysis. See <a href="./references#CD009154-fig-0054" title="">Analysis 6.10</a> for details. </p> </section> <section id="CD009154-sec-0158"> <p><b>6.2.4.4 Number of embryos transferred</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0159"> <p><b>6.2.5 Short protocol vs long protocol</b></p> <p>Six studies made this comparison (<a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a>; <a href="./references#CD009154-bbs2-0080" title="SerourAG . Luteal phase support in fresh IVF/ICSI cycles. International Journal of Gynecology and Obstetrics2012;119:S533 (Abs# M007). ">Serour 2012</a>; <a href="./references#CD009154-bbs2-0090" title="WilliamsSC , OehningerS , GibbonsWE , VanCleaveWC , MuasherSJ . Delaying the initiation of progesterone supplementation results in decreased pregnancy rates after in vitro fertilization: a randomized, prospective study. Fertility and Sterility2001;76:1140‐3. ">Williams 2001</a>). <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a> was a three‐arm study comparing micronised vaginal progesterone 200 mg twice daily starting at the evening of hCG administration for final oocyte maturation versus starting at the evening after oocyte retrieval versus starting at the evening after embryo transfer (ET). We combined the first two arms.<br/> Evidence suggested no differences between groups (OR 1.14, 95% CI 0.87 to 1.50, six RCTs, 1128 women, I<sup>2</sup> = 5%). </p> </section> <section id="CD009154-sec-0160"> <p><b>Subgroup analyses for clinical pregnancy rate</b></p> </section> <section id="CD009154-sec-0161"> <p><b>6.2.5.1 Ovarian stimulation protocol</b></p> <p>Four studies were subgrouped by method of ovarian stimulation. Two utilised hCG with or without GnRH agonists (<a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0063" title="MochtarMH , VanWelyM , Van derVeenF . Timing luteal phase support in GnRH agonist down‐regulated IVF/embryo transfer cycles. Human Reproduction2006;21(4):905‐8. ">Mochtar 2006</a>), and two utilised hCG with or without GnRH antagonists (<a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>). In both subgroups, findings were similar to those of the main analysis. See <a href="./references#CD009154-fig-0055" title="">Analysis 6.11</a> for details. </p> </section> <section id="CD009154-sec-0162"> <p><b>6.2.5.2 Women with previously failed cycles</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0163"> <p><b>6.2.5.3 Duration of progesterone</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0164"> <p><b>6.2.5.4 Number of embryos transferred</b></p> <p>No data were available for this subgroup analysis.</p> </section> <section id="CD009154-sec-0165"> <p><b>6.2.6 Micronised progesterone vs synthetic progesterone</b></p> <p>Four studies made this comparison (<a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0069" title="PatkiA , PawarVC . Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecological Endocrinology2007;23 Suppl 1:68‐72. ">Patki 2007</a>). </p> <p>Clinical pregnancy rates were lower in the micronised progesterone group (OR 0.79, 95% CI 0.66 to 0.96, four RCTs, 2388 women, I<sup>2</sup> = 19%), suggesting benefit for the synthetic progesterone group. </p> <p><i>Subgroup analyses for clinical pregnancy rate</i> </p> <p>No data were available for subgroup analyses.</p> </section> <section id="CD009154-sec-0166"> <p><b>6.2.7 Vaginal ring vs vaginal gel</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0081" title="HowardB , WeissH , DoodyK . Efficacy of a progesterone vaginal ring compared to a vaginal gel for luteal phase supplementation in patients with and without risk factors for poor ovarian response. Human Reproduction2012;27:Abs# P‐338. PerloeM , WeissH , HowardB . Impact of luteal supplementation with a weekly progesterone vaginal ring during in vitro fertilization (IVF) by day of embryo transfer (ET). Fertility and Sterility2012;98(S1):S4‐5 (Abs # O‐14). SchnellV , HowardB , WeissH . Number of embryos transferred and multiple pregnancy rates in a randomized study of progesterone vaginal ring versus gel for luteal support following in vitro fertilization. Fertility and Sterility2013;99(3):S36‐S37. SilverbergKM , ReapeKZ , HowardBK . Efficacy of a progesterone vaginal ring versus progesterone gel for luteal phases supplementation by body mass index (BMI). Fertility and Sterility2011;96 Suppl:S279 (Abs# P‐538). StadtmauerL , SilverbergKM , GinsburgES , WeissH , HowardB . Progesterone vaginal ring versus vaginal gel for luteal support with in vitro fertilization: a randomized comparative study. Fertility and Sterility2013;99:1543‐9. StadtmauerLA , ReapeKZ , ShuH . Luteal supplementation with a weekly progesterone vaginal ring in infertile women undergoing in vitro fertilization (IVF). Fertility and Sterility. Denver, CO United States, 2010; Vol. 94 Suppl 1:244. ">Stadtmauer 2013</a>). </p> <p>Evidence suggested no differences between groups (OR 1.05, 95% CI 0.84 to 1.31, one RCT, 1271 women). </p> </section> <section id="CD009154-sec-0167"> <p><b>6.2.8 Subcutaneous vs vaginal gel</b></p> <p>Two studies made this comparison (<a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>).<br/> Evidence suggested no differences between groups (OR 0.88, 95% CI 0.71 to 1.08, two RCTs, 1465 women, I<sup>2</sup> = 0%). </p> <p><i>Subgroup analyses for clinical pregnancy rate</i> </p> <p>No data were available for subgroup analyses.</p> </section> <section id="CD009154-sec-0168"> <p><b>6.2.9 Vaginal vs rectal</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>).<br/> <br/> Evidence suggested no differences between groups (OR 1.32, 95% CI 0.68 to 2.56, one RCT, 147 women). </p> </section> </section> <section id="CD009154-sec-0169"> <h6 class="title">6.3 Miscarriage rate</h6> <p>Twenty‐six studies compared progesterone regimens and reported miscarriage. See <a href="./references#CD009154-fig-0047" title="">Analysis 6.3</a> for details of this comparison. </p> <section id="CD009154-sec-0170"> <p><b>6.3.1 IM vs oral</b></p> <p>Three studies made this comparison (<a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0054" title="LicciardiF , KwiatkowskiA , NoyesN , BerkeleyAS , KreyLL , GrifoJA . Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertility and Sterility1999;71:614‐8. ">Licciardi 1999</a>; <a href="./references#CD009154-bbs2-0077" title="Saucedo‐de la LlataE , GalacheVP , HernandezAS , SantosHR , ArenasML , PatrizioP . Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility2000;74 Suppl 1:S150 (Abs # P‐175). ">Saucedo 2000</a>).<br/> Evidence suggested no differences between groups (OR 1.43, 95% CI 0.34 to 6.11, three RCTs, 123 women, I<sup>2</sup> = 13%). </p> </section> <section id="CD009154-sec-0171"> <p><b>6.3.2 IM vs vaginal or rectal</b></p> <p>Six studies made this comparison (<a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0062" title="MillerCE , DoodyKJ , ZbellaE , WebsterB , BushM , ScobeyJ . Efficacy of vaginal progesterone inserts (Endometrin) compared to intramuscular progesterone in oil for luteal support in IVF patients. Fertility and Sterility2010;94 Suppl 1(4):20‐1 Abstract no. O‐68. ">Miller 2010</a>; <a href="./references#CD009154-bbs2-0065" title="NallapetaS , SharmaV . Intra‐muscular progesterone as a luteal phase support increases live birth rate as compared to vaginal route. Fertility and Sterility2013;100(Supp):S8 (Abs #O‐25). NallapetaS , SharmaV . Relationship of different progesterone preparations on ovarian volumes in women undergoing IVF/ICSI treatment. Fertility and Sterility2013;100(Suppl):S60 (Abs # O‐196). ">Nallapeta 2013</a>; <a href="./references#CD009154-bbs2-0070" title="PerinoM , BrigandiA , AbateFG , CostabileL , BalzanoE , AbateA . Intramuscular versus vaginal progesterone in assisted reproduction: a comparative study. Clinical and Experimental Obstetrics and Gynecology1997;24:228‐31. ">Perino 1997</a>; <a href="./references#CD009154-bbs2-0077" title="Saucedo‐de la LlataE , GalacheVP , HernandezAS , SantosHR , ArenasML , PatrizioP . Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility2000;74 Suppl 1:S150 (Abs # P‐175). ">Saucedo 2000</a>; <a href="./references#CD009154-bbs2-0092" title="YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Compared to Crinone, intramuscular progesterone (IMP) delays menstrual bleeding but does not improve pregnancy rates or outcomes in IVF/ET cycles. Fertility and Sterility. 2009; Vol. 92 Suppl 1:243. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization‐embryo transfer cycles: a prospective randomized study. Fertility and Sterility2010;94(7):2596‐9. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinM . Patterns of luteal phase bleeding in in vitro fertilization cycles supplemented with Crinone vaginal gel and with intramuscular progesterone ‐ Impact of luteal estrogen: prospective, randomized study and post hoc analysis. Fertility and Sterility2011;95(2):617‐20. YanushpolskyE , HurwitzS , GreenbergL , RacowskyC , HornsteinMD . Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertility and Sterility2008;89(2):485‐7. ">Yanushpolsky 2010</a>).<br/> Evidence suggested no differences between groups (OR 0.79, 95% CI 0.56 to 1.13, six RCTs, 1468 women, I<sup>2</sup> = 0%). </p> </section> <section id="CD009154-sec-0172"> <p><b>6.3.3 Vaginal<i>or</i> rectal vs oral</b></p> <p>Five studies made this comparison (<a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0032" title="FriedlerS , RazielA , SchachterM , CohenO , YaronM , TartakovskyL , et al. Characteristics of conceptional and non‐conceptional cycles after IVF using micronized progesterone for luteal support: a comparative study of vaginal or oral administration [abstract]. Abstract Book 1. 1998; Vol. 13, issue Abstract Book 1:161 (Abs # P‐063). FriedlerS , RazielA , SchachterM , StrassburgerD , BukovskyI , Ron‐ElR . Luteal support with micronized progesterone following in‐vitro fertilization using a down‐regulation protocol with gonadotrophin‐releasing hormone agonist: a comparative study between vaginal and oral administration. Human Reproduction1999;14(8):1944‐8. ">Friedler 1999</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>; <a href="./references#CD009154-bbs2-0076" title="SalehpourS , TamimiM , SaharkhizN . Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal‐phase support in in vitro fertilization (IVF): a randomized clinical trial. Iranian Journal of Reproductive Medicine2013;11(11):913‐8. ">Salehpour 2013</a>). <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a> was a three‐arm study investigating IM progesterone versus vaginal gel 90 mg daily versus vaginal gel 90 mg twice daily. We combined both vaginal arms and compared them with the IM arm.<br/> Evidence suggested no differences between groups (OR 1.18, 95% CI 0.76 to 1.82, five RCTs, 2220 women, I<sup>2</sup> = 0%). </p> </section> <section id="CD009154-sec-0173"> <p><b>6.3.4 Low dose vaginal (≤ 100 mg) vs high dose vaginal (&gt; 100 mg)</b></p> <p>Nine studies made this comparison (<a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0023" title="Dal PratoL , BianchiL , CattoliM , TarozziN , FlamigniC , BoriniA . Vaginal gel versus intramuscular progesterone for luteal phase supplementation: a prospective randomized trial. Reproductive BioMedicine Online2008;16(3):361‐7. Dal PratoL , BoriniA , BonuMA , MaccoliniA , CattoliM , FlamigniC . Luteal support in IVF: i.m. versus intravaginal progesterone. Human Reproduction. 2004 Suppl 1; Vol. 19:i69‐70 (Abs #O‐198). ">Dal Prato 2008</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0059" title="LudwigM , SchwartzP , BabahanB , KatalinicA , Bals‐PratschM , DiedrichK . Progesterone gel (Crinone 8%) is more comfortable than progesterone suppositories (Utrogest) for luteal phase support and results in comparable pregnancy rates: results of a prospective, randomized study [abstract]. Fertility and Sterility. 2000; Vol. 74:S210 (Abs #P‐S210). LudwigM , SchwartzP , BabahanB , KatalinicA , WeissJM , FelberbaumR , et al. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. European Journal of Obstetrics and Gynaecology2002;103:48‐52. SchwartzP , LudwigM , BabahanB , KatalinicA , Bals‐PratschM , FelberbaumR , et al. Luteal phase support using either progesterone gel (Crinone 8%) or progesterone suppositories (Utrogest): results of a prospective, randomized study [abstract]. Human Reproduction2000;15(Abstract Book 1):43‐4 (Abs #O‐111). ">Ludwig 2002</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0075" title="Rodriguez‐PezinoJ , Saucedo‐de la LlataE , Batiza‐ResendizV , Galache‐VegaP , Santos‐HaliscakR , Hernandez‐AyupS , et al. Vaginal progesterone in assisted reproduction. Human Reproduction. Berlin, Germany, 2004; Vol. 19 Suppl 1:i51. ">Rodriguez‐Pezino 2004</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>). </p> <p>Miscarriage rates were lower in the low‐dose group (OR 0.73, 95% CI 0.55 to 0.98, nine RCTs, 4333 women, I<sup>2</sup> = 0%), suggesting benefit for this group. </p> </section> <section id="CD009154-sec-0174"> <p><b>6.3.5 Short protocol vs long protocol</b></p> <p>Three studies made this comparison (<a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>).<br/> Evidence suggested no differences between groups (OR 0.96, 95% CI 0.61 to 1.50, three RCTs, 662 women, I<sup>2</sup> = 0%). </p> </section> <section id="CD009154-sec-0175"> <p><b>6.3.6 Micronised progesterone vs synthetic progesterone</b></p> <p>Two studies made this comparison (<a href="./references#CD009154-bbs2-0020" title="ChakravartyBN , ShirazeeHH , DamP , ChattopadhyayR , GhoshS , DamM , GoswamiSK . A randomized prospective study comparing dydrogesterone and intravaginal micronised progesterone as luteal phase support in ART cycle [abstract]. Human Reproduction. 2004; Vol. 19:i126 (Abs #P‐364). ChakravartyBN , ShirazeeHH , DamP , GoswamiSK , ChatterjeeR , GhoshS . Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. Journal of Steroid Biochemistry and Molecular Biology2005;97(5):416‐20. ">Chakravarty 2005</a>; <a href="./references#CD009154-bbs2-0034" title="GaneshA , ChakravortyN , MukherjeeR , GoswamiS , ChaudhuryK , ChakravartyB . Comparison of oral dydrogesterone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertility and Sterility2011;95(6):1961‐5. [DOI: 10.1016/j.fertnstert.2011.01.148] ">Ganesh 2011</a>).<br/> Evidence suggested no differences between groups (OR 1.16, 95% CI 0.69 to 1.95, two RCTs, 1793 women, I<sup>2</sup> = 0%). </p> </section> <section id="CD009154-sec-0176"> <p><b>6.3.7 Vaginal ring vs vaginal gel</b></p> <p>No studies reported this outcome.</p> </section> <section id="CD009154-sec-0177"> <p><b>6.3.8 Subcutaneous vs vaginal gel</b></p> <p>Two studies made this comparison (<a href="./references#CD009154-bbs2-0011" title="BakerVL , JonesCA , DoodyK , FoulkR , YeeB , AdamsonGD , et al. A randomized, controlled trial comparing the efficacy and safety of aqueous subcutaneous progesterone with vaginal progesterone for luteal phase support of in vitro fertilization. Human Reproduction2014;29(10):12‐20. [DOI: 10.1093/humrep/deu194] ">Baker 2014</a>; <a href="./references#CD009154-bbs2-0056" title="LockwoodG , GriesingerG , ComettiB . Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in in vitro fertilization: a noninferiority randomized controlled study. Fertility and Sterility2014;101:112‐9. ">Lockwood 2014</a>).<br/> Evidence suggested no differences between groups (OR 0.82, 95% CI 0.44 to 1.54, two RCTs, 1465 women, I<sup>2</sup> = 0%). </p> </section> <section id="CD009154-sec-0178"> <p><b>6.3.9 Vaginal vs rectal</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>).<br/> <br/> Evidence suggested no differences between groups (OR 1.21, 95% CI 0.31 to 4.71, one RCT, 147 women). </p> </section> </section> <section id="CD009154-sec-0179"> <h6 class="title">6.4 Ovarian hyperstimulation syndrome (OHSS)</h6> <p>Two studies compared progesterone regimens and reported OHSS. See <a href="./references#CD009154-fig-0048" title="">Analysis 6.4</a> for details of this comparison. </p> <section id="CD009154-sec-0180"> <p><b>6.4.1 IM vs oral</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>). </p> <p>Evidence suggested no differences between groups (OR 1.00, 95% CI 0.06 to 17.18, one RCT, 40 women, very low quality evidence). </p> </section> <section id="CD009154-sec-0181"> <p><b>6.4.2 IM vs vaginal or rectal</b></p> <p>No studies made this comparison.</p> </section> <section id="CD009154-sec-0182"> <p><b>6.4.3 Vaginal or rectal vs oral</b></p> <p>No studies made this comparison.</p> </section> <section id="CD009154-sec-0183"> <p><b>6.4.4 Low dose vaginal (≤ 100 mg) vs high dose vaginal (&gt; 100 mg)</b></p> <p>Two studies made this comparison (<a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a>; <a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>). <a href="./references#CD009154-bbs2-0024" title="DoodyKJ , SchnellVL , FoulkRA , MillerCE , KolbBA , BlakeEJ , et al. Endometrin for luteal phase support in a randomized, controlled, open‐label, prospective in‐vitro fertilization trial using a combination of Menopur and Bravelle for controlled ovarian hyperstimulation. Fertility and Sterility2009;91(4):1012‐7. ">Doody 2009</a> was a three‐arm study comparing micronised progesterone vaginal gel 90 mg versus vaginal progesterone 100 mg twice daily versus vaginal progesterone 100 mg three times daily. We combined the two high‐dose arms in this comparison.<br/> Evidence suggested no differences between groups (OR 0.91, 95% CI 0.57 to 1.46, two RCTs, 1251 women, I<sup>2</sup> = 0%, low quality evidence). </p> </section> <section id="CD009154-sec-0184"> <p><b>6.4.5 Short protocol vs long protocol</b></p> <p>No studies made this comparison.</p> </section> <section id="CD009154-sec-0185"> <p><b>6.4.6 Micronised progesterone vs synthetic progesterone</b></p> <p>No studies made this comparison.</p> </section> <section id="CD009154-sec-0186"> <p><b>6.4.7 Vaginal ring vs vaginal gel</b></p> <p>No studies made this comparison.</p> </section> <section id="CD009154-sec-0187"> <p><b>6.4.8 Subcutaneous vs vaginal gel</b></p> <p>No studies made this comparison.</p> </section> <section id="CD009154-sec-0188"> <p><b>6.4.9 Vaginal vs rectal</b></p> <p>No studies made this comparison.</p> </section> </section> <section id="CD009154-sec-0189"> <h6 class="title">6.5 Multiple pregnancy</h6> <p>Fourteen studies compared progesterone regimens and reported multiple pregnancy. See <a href="./references#CD009154-fig-0049" title="">Analysis 6.5</a> for details of this comparison. </p> <section id="CD009154-sec-0190"> <p><b>6.5.1 IM vs oral</b></p> <p>Two studies made this comparison (<a href="./references#CD009154-bbs2-0046" title="IwaseA , AndoH , TodaS , IshimatsuS , HarataT , KurotsuchiS , et al. Oral progestogen versus intramuscular progesterone for luteal support after assisted reproductive technology treatment: a prospective randomized study. Archives of Gynecology and Obstetrics2008;277(4):319‐24. ">Iwase 2008</a>; <a href="./references#CD009154-bbs2-0054" title="LicciardiF , KwiatkowskiA , NoyesN , BerkeleyAS , KreyLL , GrifoJA . Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertility and Sterility1999;71:614‐8. ">Licciardi 1999</a>). </p> <p>More multiple pregnancies were reported in the IM arm (OR 4.23, 95% CI 1.16 to 15.40, two RCTs, 83 women, I<sup>2</sup> = 0%), suggesting benefit for the oral arm. This analysis included only 14 events and 80 women, so this finding should be interpreted with caution. </p> </section> <section id="CD009154-sec-0191"> <p><b>6.5.2 IM vs vaginal<i>or</i> rectal</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0094" title="Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernandezE , et al. Efficacy and acceptability of a vaginal ring releasing progesterone for in‐vitro fertilization and oocyte donation [abstract]. Human Reproduction1998;13(Abstract Book 1):118‐9 (Abs #O‐231). Zegers‐HochschildF , BalmacedaJP , FabresC , AlamV , MackennaA , FernándezE , et al. Prospective randomized trial to evaluate the efficacy of a vaginal ring releasing progesterone for IVF and oocyte donation. Human Reproduction2000;15(10):2093‐7. ">Zegers‐Hochschild 2000</a>).<br/> <br/> Evidence suggested no differences between groups (OR 0.97, 95% CI 0.60 to 1.59, one RCT, 505 women). </p> </section> <section id="CD009154-sec-0192"> <p><b>6.5.3 Vaginal<i>or</i> rectal vs oral</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0072" title="PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal phase support after vaginal progesterone: comparative study with micronized oral progesterone. Contraception, Fertilité, Sexualité1997;25:596‐601. PoulyJL , BassilS , FrydmanR , HedonB , NicolletB , PradaY , et al. Luteal support after in‐vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Human Reproduction1996;11:2085‐9. ">Pouly 1996</a>).<br/> <br/> Evidence suggested no differences between groups (OR 1.13, 95% CI 0.50 to 2.58, one RCT, 283 women). </p> </section> <section id="CD009154-sec-0193"> <p><b>6.5.4 Low <i>d</i>ose vaginal (≤ 100 mg) vs high dose vaginal (&gt; 100 mg)</b></p> <p>Five studies made this comparison (<a href="./references#CD009154-bbs2-0016" title="BerghC , LindenbergS . A prospective randomized multicentre study comparing vaginal progesterone gel and vaginal micronized progesterone tablets for luteal support after in vitro fertilization/intracytoplasmic sperm injection. Human Reproduction2012;27(12):3467‐73. ">Bergh 2012</a>; <a href="./references#CD009154-bbs2-0036" title="GeberS , MoreiraACF , DePaulaSOC , SampaioM . Comparison of two different vaginal progesterone for luteal phase support in cycles of assisted reproduction. Jornal Brasileiro de Reproducao Assistida2006;10(1):17‐21. GeberS , MoreiraACF , dePaulaSOC , SampaioM . Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reproductive BioMedicine Online2007;14(2):155‐8. ">Geber 2007a</a>; <a href="./references#CD009154-bbs2-0048" title="KleinsteinJ . Efficacy and tolerability of vaginal progesterone capsules (Utrogest 200) compared with progesterone gel (Crinone 8%) for luteal phase support during assisted reproduction. Fertility and Sterility2005;83(6):1641‐9. Kleinstein , J . Efficacy of Utrogest 200 and Crinone 8% for luteal phase support during ART: a comparative, multicenter study [Abstract]. Human Reproduction. 2004; Vol. 19:i123 (Abs #P‐357). ">Kleinstein 2005</a>; <a href="./references#CD009154-bbs2-0067" title="NgEHY , ChanCCW , TangOS , HoPC . A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. European Journal of Obstetrics Gynecology and Reproductive Biology2007;131(2):182‐8. ">Ng 2007</a>; <a href="./references#CD009154-bbs2-0082" title="StrehlerE , AbtM , El‐DanasouriI , SterzikK . Transvaginal administration of micronized progesterone does not differ to progesterone gel application in the efficacy of luteal phase support in IVF cycles [abstract]. 11th World Congress of In Vitro Fertilization and Human Reproductive Genetics Abstract Book. 1999:287 (Abs # P‐243). ">Strehler 1999</a>).<br/> Evidence suggested no differences between groups (OR 1.24, 95% CI 0.85 to 1.80, five RCTs, 2888 women, I<sup>2</sup> = 0%). </p> </section> <section id="CD009154-sec-0194"> <p><b>6.5.5 Short protocol vs long protocol</b></p> <p>Four studies made this comparison (<a href="./references#CD009154-bbs2-0040" title="GoudgeCS , NagelTC , DamarioMA . Duration of progesterone‐in‐oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial. Fertility and Sterility2010;94(3):946‐51. ">Goudge 2010</a>; <a href="./references#CD009154-bbs2-0049" title="KohlsG , RuizF , MartinezM , HauzmanE , De LaFuenteG , PellicerA , Garcia‐VelascoJA . Early progesterone cessation after in vitro fertilization/intracytoplasmic sperm injection: a randomized, controlled trial. Fertility and Sterility2012;98:858‐62. KohlsG , RuizFJ , De LaFuenteG , ToribioM , MartinezM , PellicerA , et al. Early progesterone cessation after in vitro fertilization. Human Reproduction2010;25 Suppl 1(6):i249 Abstract no. P‐344. ">Kohls 2012</a>; <a href="./references#CD009154-bbs2-0051" title="KyrouD , FatemiHM , ZepiridisL , RivaA , PapanikolaouEG , TarlatzisBC , DevroeyP . Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction2011;26(5):1020‐4. ">Kyrou 2011</a>; <a href="./references#CD009154-bbs2-0068" title="Nyboe AndersenA , Popovic‐TodorovicB , SchmidtKT , LoftA , LindhardA , HojgaardA , et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction2002;17:357‐61. ">Nyboe Andersen 2002</a>).<br/> Evidence suggested no differences between groups (OR 1.13, 95% CI 0.80 to 1.60, four RCTs, 820 women, I<sup>2</sup> = 15%). </p> </section> <section id="CD009154-sec-0195"> <p><b>6.5.6 Micronised progesterone vs synthetic progesterone</b></p> <p>No studies reported this outcome.</p> <p><i>6.5.7 Vaginal ring vs vaginal gel</i> </p> <p>No studies reported this outcome.</p> <p><i>6.5.8 Subcutaneous vs vaginal gel</i> </p> <p>No studies reported this outcome.</p> <p><i>6.5.9 Vaginal vs rectal</i> </p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0006" title="AghsaMM , RahmanpourH , BagheriM , Davari‐TanhaF , NasrR . A randomized comparison of the efficacy, side effects and patient convenience between vaginal and rectal administration of Cyclogest when used for luteal phase support in ICSI treatment. Archives of Gynecology and Obstetrics2012;286:1049‐54. ">Aghsa 2012</a>). </p> <p>Evidence suggested no differences between groups (OR 0.96, 95% CI 0.19 to 4.91, one RCT, 147 women). </p> </section> </section> </section> </section> <section id="CD009154-sec-0196"> <h4 class="title">7. Progesterone + oestrogen regimens</h4> <section id="CD009154-sec-0197"> <h5 class="title">Primary outcome</h5> <section id="CD009154-sec-0198"> <h6 class="title">7.1 Live birth/ongoing pregnancy rate</h6> <p>Two studies comparing progesterone and oestrogen regimens reported ongoing pregnancy. One compared short versus long protocol (<a href="./references#CD009154-bbs2-0031" title="FeichtingerM , HejekJ , KemterP , FeichtingerW . Effect of luteal phase support comparing early (day 1) and late (day 4) initiation with pregnancy rates. Journal of Reproductive Medicine and Endocrinology2011;8(4):288‐90. ">Feichtinger 2011</a>), and one compared low versus high dosage (<a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>). </p> <p><a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a> was a three‐arm study comparing 2 mg oestradiol versus 4 mg oestradiol versus 6 mg oestradiol. We combined the arms with 4 mg and 6 mg oestradiol supplementation. </p> <section id="CD009154-sec-0199"> <p><b>7.1.1 Short protocol vs long protocol</b></p> <p>No studies making this comparison reported live birth.</p> <p>Evidence suggested no differences between groups (OR 1.08, 95 CI 0.81 to 1.43, one RCT, 910 women, low quality evidence). </p> </section> <section id="CD009154-sec-0200"> <p><b>7.1.2 Low dosage vs high dosage</b></p> <p>Evidence suggested no differences between groups (OR 0.65, 95% CI 0.37 to 1.13, one RCT, 285 women, very low quality evidence). </p> </section> </section> </section> <section id="CD009154-sec-0201"> <h5 class="title">Secondary outcomes</h5> <section id="CD009154-sec-0202"> <h6 class="title">7.2 Clinical pregnancy rate</h6> <section id="CD009154-sec-0203"> <p><b>7.2.1 Short protocol vs long protocol</b></p> <p>No reported studies made this comparison.</p> </section> <section id="CD009154-sec-0204"> <p><b>7.2.2 Low dosage vs high dosage</b></p> <p>One study (<a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>) made this comparison. </p> <p>Evidence suggested no differences between groups (OR 0.81, 95% CI 0.48 to 1.37, one RCT, 285 women). See <a href="./references#CD009154-fig-0057" title="">Analysis 7.2</a> for details. </p> </section> </section> <section id="CD009154-sec-0205"> <h6 class="title">7.3 Miscarriage rate</h6> <section id="CD009154-sec-0206"> <p><b>7.3.1 Short protocol vs long protocol</b></p> <p>No studies reported this outcome.</p> </section> <section id="CD009154-sec-0207"> <p><b>7.3.2 Low dosage vs high dosage</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>) . </p> <p>Evidence suggested no differences between groups (OR 3.13, 95% CI 0.86 to 11.39, one RCT, 285 women). </p> <p>See <a href="./references#CD009154-fig-0058" title="">Analysis 7.3</a> for details of this comparison. </p> </section> </section> <section id="CD009154-sec-0208"> <h6 class="title">7.4 OHSS</h6> <p>No studies reported this outcome.</p> </section> <section id="CD009154-sec-0209"> <h6 class="title">7.5 Multiple pregnancy rates</h6> <section id="CD009154-sec-0210"> <p><b>7.5.1 Short protocol vs long protocol</b></p> <p>No studies reported this outcome.</p> </section> <section id="CD009154-sec-0211"> <p><b>7.5.2 Low dosage vs high dosage</b></p> <p>One study made this comparison (<a href="./references#CD009154-bbs2-0086" title="EsraT , VarT , CitilA , DoganM , CicekN . Estradiol supplementation in luteal phase: how much matter?. Human Reproduction. Rome, Italy, 2010; Vol. 25 Suppl 1:i307‐8. TongucE , VarT , OzyerS , CitilA , DoganM . Estradiol supplementation during the luteal phase of in vitro fertilization cycles: a prospective randomised study. European Journal of Obstetrics Gynecology and Reproductive Biology2011;154:172‐6. ">Tonguc 2011</a>). </p> <p>Evidence suggested no differences between groups (OR 0.25, 95% CI 0.06 to 1.12, one RCT, 285 women). See <a href="./references#CD009154-fig-0059" title="">Analysis 7.4</a> for details, </p> </section> </section> </section> </section> <section id="CD009154-sec-0212"> <h4 class="title">8. Funnel plots</h4> <p>For comparisons with more than 10 included studies, we constructed a funnel plot. None of the funnel plots (<a href="#CD009154-fig-0004">Figure 4</a>; <a href="#CD009154-fig-0005">Figure 5</a>; <a href="#CD009154-fig-0006">Figure 6</a>) suggested publication bias. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009154-sec-0213" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009154-sec-0213"></div> <section id="CD009154-sec-0214"> <h3 class="title" id="CD009154-sec-0214">Summary of main results</h3> <p>This systematic review of all randomised controlled trials (RCTs) of luteal phase support from 1987 to 2015 had a broad range of subjects. We had seven comparisons to ensure we included as many studies as possible. Because we did not include quasi‐RCTs, we had to exclude quite a few older studies; therefore we have sparse evidence regarding current standard luteal phase protocols. For an overview of the main findings, see the 'Summary of findings' tables (<a href="./full#CD009154-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009154-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009154-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD009154-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD009154-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD009154-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD009154-tbl-0007">summary of findings Table 7</a>). </p> <p>We can summarise the following results based on our review.</p> <section id="CD009154-sec-0215"> <h4 class="title">Human chorionic gonadotropin (hCG) for luteal phase support</h4> <p>hCG given during the luteal phase may be associated with higher rates of live birth or ongoing pregnancy than placebo or no treatment, but the evidence is not conclusive. hCG increased the risk of ovarian hyperstimulation syndrome (OHSS) (1 RCT only). </p> </section> <section id="CD009154-sec-0216"> <h4 class="title">Progesterone for luteal phase support</h4> <p>Progesterone given during the luteal phase may be associated with higher rates of live birth or ongoing pregnancy than placebo or no treatment, but the evidence is not conclusive. Progesterone was associated with lower rates of OHSS rates than hCG with or without progesterone. </p> </section> <section id="CD009154-sec-0217"> <h4 class="title">Progesterone and oestrogen for luteal phase support</h4> <p>We found no conclusive evidence of differences between groups for any outcome. Supplementation of progesterone with oral oestrogen did not appear to influence live birth and ongoing pregnancy rates, but benefit from transdermal or oral + transdermal oestrogen supplementation is suggested. Findings for supplementation of progesterone with vaginal oestrogen were inconsistent. </p> </section> <section id="CD009154-sec-0218"> <h4 class="title">Progesterone and GnRH agonists for luteal phase support</h4> <p>A relatively new method of luteal phase support involves use of GnRH agonists, which appeared to increase rates of live birth/ongoing pregnancy and clinical pregnancy compared with progesterone alone. There was no evidence of a difference between the groups for other outcomes, though OHSS was reported in only one study. </p> </section> <section id="CD009154-sec-0219"> <h4 class="title">Different progesterone regimens</h4> <p>When we compared routes of progesterone administration, we gathered no conclusive findings. Vaginal progesterone is the most commonly used formulation in Europe according to a survey of 21 European centres (<a href="./references#CD009154-bbs2-0003" title="AboulgharMA , AminYM , Al‐InanyHG , AboulgharMM , MouradLM , SerourGI , et al. Prospective randomized study comparing luteal phase support for ICSI patients up to the first ultrasound compared with an additional three weeks. Human Reproduction2008;23(4):857‐62. ">Aboulghar 2008</a>). Sixteen centres used vaginal progesterone, three used IM progesterone, one used oral progesterone and one hCG. </p> <p>We found several studies investigating Crinone 8% vaginal micronised progesterone gel. Therefore we conducted a comparison to investigate low‐dose (≤ 100 mg) versus high‐dose (&gt; 100 mg) vaginal progesterone. The analysis for the miscarriage rate suggested benefit derived from low‐dose vaginal progesterone. No evidence revealed differences between low‐dose and high‐dose groups for the other outcomes. A new method consists of a weekly progesterone ring, for which we also conducted a comparison. No evidence favoured the vaginal ring or gel. </p> <p>Comparisons of long versus short duration of progesterone administration showed no evidence of differences between groups in live birth and ongoing pregnancy rates. Findings for clinical pregnancy were inconsistent. </p> <p>Comparisons of synthetic versus micronised progesterone yielded no evidence of differences between groups in live birth and ongoing pregnancy rates. However, evidence suggested that synthetic progesterone was associated with a higher clinical pregnancy rate than micronised progesterone. The only synthetic progesterone used was oral dydrogesterone. </p> <p>With regard to multiple pregnancy, the only evidence of differences between groups was seen for the comparison of IM progesterone with oral progesterone, which suggested that IM progesterone is associated with multiple pregnancies to a greater extent than oral progesterone. </p> </section> </section> <section id="CD009154-sec-0220"> <h3 class="title" id="CD009154-sec-0220">Overall completeness and applicability of evidence</h3> <p>Most studies provided 'implantation rate' as an outcome. For clinicians, this outcome is not useful, as they would rather know the pregnancy rate or the live birth rate. </p> <p>For women the most important outcome is live birth, which was reported in only 31 studies. For the 2015 update of this review, we pooled live birth and ongoing pregnancy rates to increase the power of the analysis. Sensitivity analyses limited to studies reporting live birth yielded findings very similar to those obtained for the combined outcome, suggesting that ongoing pregnancy was a reasonable surrogate for live birth in this review. The outcome clinical pregnancy was reported in most studies and did provide a few significant results. To investigate the safety of luteal phase support, we also looked at the negative side effects, OHSS and multiple pregnancy. These outcomes were not reported in all studies; therefore this review might not give an accurate representation of these important factors in luteal phase support. </p> <p>Adverse effects were reported poorly in most of the included studies.</p> <p>Some of the studies that we found investigated procedures or interventions influencing the luteal phase but did not investigate an intervention used as luteal phase support. All of these studies are reported in the <a href="./references#CD009154-sec-0252" title="">Characteristics of excluded studies</a>. </p> <p>We included only first cycle data, and four studies reported more cycles than included women (<a href="./references#CD009154-bbs2-0130" title="Erman AkarM , KursunS , TaskinO , SimsekM , KabaM , UnerM . Intravaginal progesterone gel vs 17oe hydroxyprogesterone caproate in ICSI embryo transfer cycles: a prospective randomized study. Fertility and Sterility2005;84 Suppl 1:320. ">Erman Akar 2005</a>; <a href="./references#CD009154-bbs2-0171" title="LukaszukK , LissJ , LukaszukM , MajB . Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2005;83(5):1372‐6. ">Lukaszuk 2005</a>; <a href="./references#CD009154-bbs2-0212" title="UnferV , CasiniM , CostabileL , GerliS , BaldiniD , DiRenzoGC . 17 alpha‐hydroxyprogesterone caproate versus intravaginal progesterone in IVF‐embryo transfer cycles: a prospective randomized study. Reproductive BioMedicine Online2004;9(1):17‐21. ">Unfer 2004</a>; <a href="./references#CD009154-bbs2-0213" title="UnferV , CasiniML , GerliS , CostabileL , MignosaM , DiRenzoGC . Phytoestrogens may improve the pregnancy rate in in vitro fertilization‐embryo transfer cycles: a prospective, controlled, randomized trial. Fertility and Sterility2004;82(6):1509‐13. ">Unfer 2004a</a>). We contacted the authors but have not received a reply. </p> <p>In our protocol, we stated that we would include two other comparisons: urinary hCG versus recombinant hCG and single‐dose GnRH agonist versus placebo. We found no studies that were conducted to investigate these comparisons. It is unlikely that these comparisons will be made in the future, as hCG is an older method of luteal phase support and is known for its high risk of OHSS. We do not expect new trials to investigate the differences between urinary and recombinant hCG. Nowadays, progesterone is an accepted method for luteal phase support, and it is considered unethical to not provide any form of luteal phase support. Therefore we do not expect any new trials to investigate the effects of GnRH agonists for luteal phase support versus placebo. For these reasons, we chose to remove these comparisons. </p> <p>To make sure we were as thorough as possible, we came up with some additional comparisons: low‐dose vaginal progesterone versus high‐dose vaginal progesterone, short protocol progesterone versus long protocol progesterone, vaginal ring versus vaginal gel, subcutaneous versus vaginal gel, vaginal versus rectal progesterone and progesterone versus progesterone + multiple‐dose GnRH agonist. </p> <p>The included studies used differing inclusion and exclusion criteria, but this was not a limitation for inclusion in our review. </p> <p>In conclusion, we included all first cycles of randomised trials of luteal phase support. We changed our comparisons after we completed our search to ensure that we covered as much as possible on this topic. </p> </section> <section id="CD009154-sec-0221"> <h3 class="title" id="CD009154-sec-0221">Quality of the evidence</h3> <p>This review has a huge number of included studies ‐ 94 studies ‐ that investigated many different interventions for luteal phase support. The total number of included participants was 25,471, but because of the variety of included studies per comparison, the total sample size per comparison ranged from 30 to well over 5000 participants. </p> <p>Only 25 studies (27%) reported methods of randomisation and allocation concealment in sufficient detail, and only half (48/93) were rated as having low risk of attrition bias. More than half were rated as having high risk of bias in one or more domains. Although sensitivity analyses limited to studies with clear description of allocation concealment did not substantially affect any of our findings, we rated down the quality of evidence for all comparisons in our 'Summary of findings' tables because of the high proportions of "unclear" and "high" risk of bias ratings in most studies (<a href="./full#CD009154-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009154-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009154-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD009154-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD009154-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD009154-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD009154-tbl-0007">summary of findings Table 7</a>). </p> <p>Heterogeneity was low for most comparisons. For most cases in which substantial heterogeneity was detected, we were not able to find a clear reason, and for these analyses, our findings should be interpreted with caution. </p> <p>The overall quality of the evidence ranged from very low to moderate. The main limitations were poor reporting of study methods and imprecision. </p> </section> <section id="CD009154-sec-0222"> <h3 class="title" id="CD009154-sec-0222">Potential biases in the review process</h3> <p>Two review authors extracted all data. MvdL extracted data from all studies, and MM and KB divided all studies between them; thus each extracted data from half of the studies. MvdL, who wrote the review, compared all results. In cases of disagreement, CF acted as a third review author and determined the final verdict. This usually happened after consultation with MvdL. This means that MvdL had a big influence on these decisions, and this might have introduced bias. </p> <p>As a result of the large number of topics within the review, we might not have discussed all topics in depth. </p> <p>We are quite sure that we found all relevant studies, but some studies might not have been published at the time of our search and are published now, at the time of publication. As discussed above, four studies did meet our inclusion criteria but reported more cycles than included women (<a href="./references#CD009154-bbs2-0130" title="Erman AkarM , KursunS , TaskinO , SimsekM , KabaM , UnerM . Intravaginal progesterone gel vs 17oe hydroxyprogesterone caproate in ICSI embryo transfer cycles: a prospective randomized study. Fertility and Sterility2005;84 Suppl 1:320. ">Erman Akar 2005</a>; <a href="./references#CD009154-bbs2-0171" title="LukaszukK , LissJ , LukaszukM , MajB . Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization‐embryo transfer cycles. Fertility and Sterility2005;83(5):1372‐6. ">Lukaszuk 2005</a>; <a href="./references#CD009154-bbs2-0212" title="UnferV , CasiniM , CostabileL , GerliS , BaldiniD , DiRenzoGC . 17 alpha‐hydroxyprogesterone caproate versus intravaginal progesterone in IVF‐embryo transfer cycles: a prospective randomized study. Reproductive BioMedicine Online2004;9(1):17‐21. ">Unfer 2004</a>; <a href="./references#CD009154-bbs2-0213" title="UnferV , CasiniML , GerliS , CostabileL , MignosaM , DiRenzoGC . Phytoestrogens may improve the pregnancy rate in in vitro fertilization‐embryo transfer cycles: a prospective, controlled, randomized trial. Fertility and Sterility2004;82(6):1509‐13. ">Unfer 2004a</a>). We contacted these study authors but received no reply, so we did not include these studies. </p> <p>In the 2015 update, we have made several changes and additions to the original protocol (see <a href="#CD009154-sec-0249">Differences between protocol and review</a>). We believe that these changes are likely to have reduced rather than increased the potential for bias in the review, by ensuring that we consider all relevant comparisons and use the latest recommended Cochrane standards. </p> </section> <section id="CD009154-sec-0223"> <h3 class="title" id="CD009154-sec-0223">Agreements and disagreements with other studies or reviews</h3> <p>Upon comparing this review with a previous version (<a href="./references#CD009154-bbs2-0273" title="DayaS , GunbyJ . Luteal phase support in assisted reproduction cycles. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004830.pub2] ">Daya 2004</a>), we found a lot of similarities regarding the quality of included studies. Although this previous review included quasi‐randomised trials, the overall quality of the present review is still poor. As stated in the implications for research section of the previous versions of this review (<a href="./references#CD009154-bbs2-0273" title="DayaS , GunbyJ . Luteal phase support in assisted reproduction cycles. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004830.pub2] ">Daya 2004</a>, <a href="./references#CD009154-bbs2-0274" title="van derLindenM , BuckinghamK , FarquharC , KremerJA , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009154.pub2] ">van der Linden 2011</a>), improvement of the quality of studies, especially in terms of blinding, is important for further research. Among the more recent (after 2004) studies that we have included, the quality of studies does indeed seem to be better, although most of these researchers did not use blinding. In <a href="./references#CD009154-bbs2-0273" title="DayaS , GunbyJ . Luteal phase support in assisted reproduction cycles. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004830.pub2] ">Daya 2004</a>, it was discussed that live birth was not often reported as an outcome. This seems to be improved but in most cases, it still is not the main outcome. </p> <p>We have noted some agreements and some disagreements between the findings of <a href="./references#CD009154-bbs2-0273" title="DayaS , GunbyJ . Luteal phase support in assisted reproduction cycles. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004830.pub2] ">Daya 2004</a> and the results of this review. As no new studies have investigated hCG versus placebo, we found no new results. In all comparisons investigating hCG, we found that hCG involves higher risk of OHSS. This was significant for hCG versus placebo and progesterone versus progesterone + hCG. </p> <p>In the previous versions of this review (<a href="./references#CD009154-bbs2-0273" title="DayaS , GunbyJ . Luteal phase support in assisted reproduction cycles. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD004830.pub2] ">Daya 2004</a> and <a href="./references#CD009154-bbs2-0274" title="van derLindenM , BuckinghamK , FarquharC , KremerJA , MetwallyM . Luteal phase support for assisted reproduction cycles. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD009154.pub2] ">van der Linden 2011</a>), no evidence favoured a particular route of administration. Both versions of the review reported no differences in effect between different doses of vaginal progesterone. </p> <p>Both reviews found higher pregnancy rates for progesterone in GnRH agonist‐stimulated cycles. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009154-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009154-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009154-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009154-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Progesterone vs hCG, outcome: 2.2 Clinical pregnancy rate." data-id="CD009154-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Progesterone vs hCG, outcome: 2.2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 4 [NEW] Progesterone vs progesterone + oestrogen, outcome: 4.2 Clinical pregnancy rate." data-id="CD009154-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 4 [NEW] Progesterone vs progesterone + oestrogen, outcome: 4.2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 [NEW] Progesterone regimens, outcome: 6.2 Clinical pregnancy rate." data-id="CD009154-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 [NEW] Progesterone regimens, outcome: 6.2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, outcome: 1.1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, outcome: 1.1 Live birth/ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Progesterone vs placebo or no treatment, outcome: 2.1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Progesterone vs placebo or no treatment, outcome: 2.1 Live birth/ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Progesterone vs hCG regimens, outcome: 3.1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Progesterone vs hCG regimens, outcome: 3.1 Live birth or ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Progesterone vs hCG regimens, outcome: 3.5 OHSS." data-id="CD009154-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Progesterone vs hCG regimens, outcome: 3.5 OHSS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Progesterone vs progesterone + oestrogen, outcome: 4.1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Progesterone vs progesterone + oestrogen, outcome: 4.1 Live birth/ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 5 Progesterone vs progesterone + GnRH agonist, outcome: 5.1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Forest plot of comparison: 5 Progesterone vs progesterone + GnRH agonist, outcome: 5.1 Live birth or ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 6 Progesterone regimens, outcome: 6.1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Forest plot of comparison: 6 Progesterone regimens, outcome: 6.1 Live birth or ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 1 Live birth/ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 2 Clinical pregnancy rate." data-id="CD009154-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 3 Clinical pregnancy rate: subgroup analysis by COH method." data-id="CD009154-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 3 Clinical pregnancy rate: subgroup analysis by COH method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 4 Miscarriage rate." data-id="CD009154-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 4 Miscarriage rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 5 OHSS." data-id="CD009154-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Human chorionic gonadotropin (hCG) vs placebo or no treatment, Outcome 5 OHSS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progesterone vs placebo or no treatment, Outcome 1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Progesterone vs placebo or no treatment, Outcome 1 Live birth/ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progesterone vs placebo or no treatment, Outcome 2 Clinical pregnancy rate." data-id="CD009154-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Progesterone vs placebo or no treatment, Outcome 2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progesterone vs placebo or no treatment, Outcome 3 Clinical pregnancy: subgroup analysis by COH method." data-id="CD009154-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Progesterone vs placebo or no treatment, Outcome 3 Clinical pregnancy: subgroup analysis by COH method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progesterone vs placebo or no treatment, Outcome 4 Clinical pregnancy: subgroup analysis by treatment duration." data-id="CD009154-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Progesterone vs placebo or no treatment, Outcome 4 Clinical pregnancy: subgroup analysis by treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progesterone vs placebo or no treatment, Outcome 5 Miscarriage rate." data-id="CD009154-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Progesterone vs placebo or no treatment, Outcome 5 Miscarriage rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Progesterone vs placebo or no treatment, Outcome 6 Multiple pregnancy." data-id="CD009154-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Progesterone vs placebo or no treatment, Outcome 6 Multiple pregnancy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone vs hCG regimens, Outcome 1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Progesterone vs hCG regimens, Outcome 1 Live birth or ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-003-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone vs hCG regimens, Outcome 2 Clinical pregnancy rate." data-id="CD009154-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Progesterone vs hCG regimens, Outcome 2 Clinical pregnancy rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone vs hCG regimens, Outcome 3 Clinical pregnancy: progesterone vs progesterone + hCG: subgroup analysis by COH method." data-id="CD009154-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Progesterone vs hCG regimens, Outcome 3 Clinical pregnancy: progesterone vs progesterone + hCG: subgroup analysis by COH method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone vs hCG regimens, Outcome 4 Clinical pregnancy: progesterone vs hCG: subgroup analysis by treatment duration." data-id="CD009154-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Progesterone vs hCG regimens, Outcome 4 Clinical pregnancy: progesterone vs hCG: subgroup analysis by treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-003-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone vs hCG regimens, Outcome 5 OHSS." data-id="CD009154-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Progesterone vs hCG regimens, Outcome 5 OHSS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone vs hCG regimens, Outcome 6 Miscarriage rate." data-id="CD009154-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Progesterone vs hCG regimens, Outcome 6 Miscarriage rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Progesterone vs hCG regimens, Outcome 7 Multiple pregnancy." data-id="CD009154-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Progesterone vs hCG regimens, Outcome 7 Multiple pregnancy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-004-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 1 Live birth/ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-004-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 2 Clinical pregnancy rate." data-id="CD009154-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 3 Clinical pregnancy: subgroup analysis by COH method." data-id="CD009154-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 3 Clinical pregnancy: subgroup analysis by COH method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 4 Clinical pregnancy: subgroup analysis by treatment duration." data-id="CD009154-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 4 Clinical pregnancy: subgroup analysis by treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 5 Miscarriage rate." data-id="CD009154-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 5 Miscarriage rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 6 OHSS." data-id="CD009154-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Progesterone vs progesterone + oestrogen, Outcome 6 OHSS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-005-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 1 Live birth or ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 2 Clinical pregnancy rate." data-id="CD009154-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 2 Clinical pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 3 Clinical pregnancy: subgroup analysis by COH method." data-id="CD009154-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 3 Clinical pregnancy: subgroup analysis by COH method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 4 Clinical pregnancy: subgroup analysis by treatment duration." data-id="CD009154-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 4 Clinical pregnancy: subgroup analysis by treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 5 Miscarriage rate." data-id="CD009154-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 5 Miscarriage rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 6 Multiple pregnancy." data-id="CD009154-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 6 Multiple pregnancy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 7 OHSS." data-id="CD009154-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Progesterone vs progesterone + GnRH agonist, Outcome 7 OHSS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 1 Live birth or ongoing pregnancy rate." data-id="CD009154-fig-0045" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 1 Live birth or ongoing pregnancy rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 2 Clinical pregnancy rate." data-id="CD009154-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 2 Clinical pregnancy rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 3 Miscarriage rate." data-id="CD009154-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 3 Miscarriage rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 4 OHSS." data-id="CD009154-fig-0048" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 4 OHSS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 5 Multiple pregnancy." data-id="CD009154-fig-0049" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 5 Multiple pregnancy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 6 Clinical pregnancy: IM vs vaginal/rectal: subgroup analysis by COH method." data-id="CD009154-fig-0050" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 6 Clinical pregnancy: IM vs vaginal/rectal: subgroup analysis by COH method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 7 Clinical pregnancy: IM vs vaginal/rectal: subgroup analysis by treatment duration." data-id="CD009154-fig-0051" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 7 Clinical pregnancy: IM vs vaginal/rectal: subgroup analysis by treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 8 Clinical pregnancy: vaginal/rectal vs oral: subgroup analysis by treatment duration." data-id="CD009154-fig-0052" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 8 Clinical pregnancy: vaginal/rectal vs oral: subgroup analysis by treatment duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 9 Clinical pregnancy: low vs high dose vaginal: subgroup analysis by COH method." data-id="CD009154-fig-0053" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 9 Clinical pregnancy: low vs high dose vaginal: subgroup analysis by COH method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 10 Clinical pregnancy: low vs high dose vaginal: subgroup analysis by duration of treatment." data-id="CD009154-fig-0054" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 10 Clinical pregnancy: low vs high dose vaginal: subgroup analysis by duration of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Progesterone regimens, Outcome 11 Clinical pregnancy: short vs long protocol: subgroup analysis by COH method." data-id="CD009154-fig-0055" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 Progesterone regimens, Outcome 11 Clinical pregnancy: short vs long protocol: subgroup analysis by COH method. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progesterone + oestrogen regimens, Outcome 1 Live birth/ongoing pregnancy rate." data-id="CD009154-fig-0056" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Progesterone + oestrogen regimens, Outcome 1 Live birth/ongoing pregnancy rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progesterone + oestrogen regimens, Outcome 2 Clinical pregnancy rate." data-id="CD009154-fig-0057" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Progesterone + oestrogen regimens, Outcome 2 Clinical pregnancy rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progesterone + oestrogen regimens, Outcome 3 Miscarriage rate." data-id="CD009154-fig-0058" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Progesterone + oestrogen regimens, Outcome 3 Miscarriage rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009154-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/urn:x-wiley:14651858:media:CD009154:CD009154-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_t/tCD009154-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Progesterone + oestrogen regimens, Outcome 4 Multiple pregnancy." data-id="CD009154-fig-0059" src="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Progesterone + oestrogen regimens, Outcome 4 Multiple pregnancy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/media/CDSR/CD009154/image_n/nCD009154-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009154-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">hCG compared with placebo/no treatment for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>hCG compared with placebo/no treatment for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> <b>Intervention:</b> hCG<br/> <b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo/No treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> hCG</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000<br/> (128 to 281) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.76<br/> (1.08 to 2.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>527<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<br/> (141 to 256) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.3<br/> (0.9 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>746<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Very low<sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>155 per 1000<br/> (76 to 292) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 4.28<br/> (1.91 to 9.6) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>387<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most domains of most studies. </p> <p><sup>b</sup>Serious imprecision with low event rate. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Findings compatible with meaningful benefit for hCG group, or with no effect. </p> <p><sup>e</sup>Serious imprecision; single study with low event rate. </p> <p><sup>f</sup>Findings not statistically significant when random‐effects model was used (OR 1.67, 95% CI 0.90 to 3.12), or when analysis was restricted to studies reporting live birth. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">hCG compared with placebo/no treatment for assisted reproduction cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009154-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progesterone compared with placebo/no treatment for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with placebo/no treatment for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> <b>Intervention:</b> progesterone<br/> <b>Comparison:</b> placebo/no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Placebo/no treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/> (42 to 103) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.77<br/> (1.09 to 2.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>642<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>174 per 1000<br/> (126 to 234) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.89<br/> (1.3 to 2.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>841<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported in any included studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most domains of most studies. </p> <p><sup>b</sup>Serious imprecision with low event rate. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup> Findings not statistically significant when random‐effects model was used (OR 1.77, 95% CI 0.96 to 3.26), or when analysis was restricted to studies reporting live birth. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Progesterone compared with placebo/no treatment for assisted reproduction cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009154-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Progesterone compared with hCG regimens for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with hCG regimens for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> <b>Intervention:</b> progesterone<br/> <b>Comparison:</b> hCG (alone or with progesterone) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> hCG (alone or with progesterone)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000<br/> (138 to 254) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.95<br/> (0.65 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>833<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>284 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/> (263 to 340) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.08<br/> (0.9 to 1.3) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2355<br/> (16 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>118 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>58 per 1000</p> <p>(39 to 87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.46</p> <p>(0.30 to 0.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1293</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/> Low<sup>a,c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most domains of most studies. </p> <p><sup>b</sup>Serious imprecision with low event rate. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Findings compatible with meaningful benefit for either group, or with no effect </p> <p>e Some inconsistency: I<sup>2</sup>=48% overall, I<sup>2</sup>=60% in progesterone vs hCG subgroup </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Progesterone compared with hCG regimens for assisted reproduction cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009154-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Progesterone compared with progesterone + oestrogen for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with progesterone + oestrogen for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> <b>Intervention:</b> progesterone<br/> <b>Comparison:</b> progesterone + oestrogen (route of oestrogen: oral, transdermal, vaginal or oral + transdermal) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone + oestrogen</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>393 per 1000<br/> (345 to 444) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.12<br/> (0.91 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1651<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a, b, c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>433 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>397 per 1000<br/> (355 to 443) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.86<br/> (0.72 to 1.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2169<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a, d, f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>51 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000<br/> (11 to 82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.58<br/> (0.2 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>461<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b, c, e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most domains of most studies. </p> <p><sup>b</sup>Serious imprecision with low event rate. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Serious inconsistency with substantial statistical heterogeneity (I<sup>2</sup> = 56%). Limiting analysis to the 9 studies using oral oestrogen yielded OR of 1.01 (95% CI 0.80 to 1.27) and reduced heterogeneity (I<sup>2</sup> = 16%). </p> <p><sup>e</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias both 'high risk' and 'low risk' </p> <p><sup>f</sup>Two studies with an outlying result. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Progesterone compared with progesterone + oestrogen for assisted reproduction cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009154-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Progesterone compared with progesterone + GnRH agonist for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone compared with progesterone + GnRH agonist for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> women who had undergone IVF/ICSI<br/> <b>Setting:</b> clinic<br/> <b>Intervention:</b> progesterone luteal support<br/> <b>Comparison:</b> progesterone + GnRH agonist </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone + GnRH agonist</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone luteal support</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>356 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>255 per 1000<br/> (209 to 309) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.62<br/> (0.48 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2861<br/> (9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>405 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000<br/> (258 to 367) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.66<br/> (0.51 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2435<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000<br/> (17 to 137) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> <p>(0.33 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>300<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p>Very low<sup>e,f,</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Evidence of significant heterogeneity I<sup>2</sup> = 69% </p> <p><sup>b</sup> Only three of the studies reported on live birth as an outcome </p> <p><sup>c</sup> Evidence of heterogeneity I<sup>2</sup>=47% </p> <p><sup>d</sup> Some studies used multiple doses and some used single doses. We have used subgroup analysis to explore this further </p> <p><sup>e</sup> Lack of detail to make a judgement of risk of bias </p> <p><sup>f</sup> Evidence based on a single trial </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Progesterone compared with progesterone + GnRH agonist for assisted reproduction cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009154-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Progesterone regimens for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone regimens for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction<br/> Comparisons of progesterone regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>IM vs oral</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>151 per 1000<br/> (34 to 478) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.71<br/> (0.14 to 3.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>IM vs vaginal/rectal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000<br/> (272 to 353) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.24<br/> (1.03 to 1.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2309<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Vaginal/rectal vs oral</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>205 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>235 per 1000<br/> (176 to 303) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.19<br/> (0.83 to 1.69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>857<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Low dose vaginal vs high dose vaginal</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000<br/> (266 to 324) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.97<br/> (0.84 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3720<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Short protocol vs long protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>664 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>672 per 1000<br/> (609 to 728) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.04<br/> (0.79 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1205<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Low<sup>a,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Micronised vs synthetic</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>220 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000<br/> (130 to 305) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.9<br/> (0.53 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>470<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b,c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Vaginal ring vs vaginal gel</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>441 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>462 per 1000<br/> (409 to 517) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.09<br/> (0.88 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1271<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c,f,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> <p>Subcutaneous vs vaginal gel</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>358 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>339 per 1000<br/> (292 to 388) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.92<br/> (0.74 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1465<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c,g,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Live birth or ongoing pregnancy</p> <p>Vaginal vs rectal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>306 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>360 per 1000</p> <p>(220 to 528)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.28</p> <p>(0.64 to 2.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>147</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS</p> <p>IM vs oral</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>50 per 1000</p> <p>(3 to 475)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.00</p> <p>(0.06 to 17.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OHSS</p> <p>Low dose vaginal vs high dose vaginal</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>60 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>55 per 1000</p> <p>(35 to 86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.91 (0.57 to 1.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1251</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> Low<sup>b,c,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>OHSS rates not reported for other comparisons.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the median control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most study domains. </p> <p><sup>b</sup>Very serious imprecision with low event rate; findings compatible with meaningful benefit in either arm or with no effect. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Very serious inconsistency with varying directions of effect (I<sup>2</sup> = 71%). Findings not statistically significant when random‐effects model was used, or when analysis was restricted to studies reporting live births. </p> <p><sup>e</sup>Serious imprecision with low event rate; findings compatible with meaningful benefit in the oral arm or with no effect. </p> <p><sup>f</sup>Serious imprecision; findings compatible with meaningful benefit in the gel arm or with no effect. </p> <p><sup>g</sup>Serious risk of bias due to inadequate reporting of study methods in 1 or more studies. </p> <p><sup>h</sup>Serious imprecision; findings compatible with meaningful benefit in the subcutaneous arm or with no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Progesterone regimens for assisted reproduction cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009154-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Progesterone + oestrogen regimens for assisted reproduction cycles</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Progesterone + oestrogen regimens for assisted reproduction cycles</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Population:</b> subfertile women<br/> <b>Setting:</b> assisted reproduction <br/> Comparisons of progesterone and oestrogen regimens </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Comparison</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Progesterone regimens</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth/ongoing pregnancy ‐ short vs long protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>309 per 1000<br/> (251 to 372) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.08</p> <p>(0.81 to 1.43)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>910</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth/ongoing pregnancy ‐ low vs high dose protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>342 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>253 per 1000<br/> (161 to 370) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.65</p> <p>(0.37 to 1.13)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> <p>(1 RCT)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS ‐ short vs long protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Not reported in any studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OHSS ‐ low vs high dose protocol</p> </td> <td align="left" class="table-tint table-highlight" colspan="4" rowspan="1" valign="top"> <p>Not reported in any studies</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the risk in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Serious risk of bias due to inadequate reporting of study methods. Risk of bias unclear in most study domains. </p> <p><sup>b</sup>Serious imprecision; findings compatible with meaningful benefit in either arm or with no effect. </p> <p><sup>c</sup>Number of studies was not sufficient for assessment of publication bias. </p> <p><sup>d</sup>Very serious imprecision with low event rate; findings compatible with meaningful benefit in either arm or with no effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Progesterone + oestrogen regimens for assisted reproduction cycles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/full#CD009154-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009154-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Human chorionic gonadotropin (hCG) vs placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth/ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>527</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.08, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.2 [0.38, 12.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ongoing pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.05, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.90, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy rate: subgroup analysis by COH method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>746</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.90, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Human gonadotropins with clomiphene citrate without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.54, 2.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Human gonadotropins with or without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.94, 2.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Human gonadotropins with or without GnRH antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.33, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.37, 6.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.28 [1.91, 9.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Human chorionic gonadotropin (hCG) vs placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009154-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progesterone vs placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth/ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>642</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.09, 2.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Live birth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.21 [0.93, 19.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ongoing pregnancy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.91, 2.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.30, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy: subgroup analysis by COH method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.30, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Clomiphene citrate alone without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.54, 45.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Human gonadotropins with clomiphene citrate without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.86, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Human gonadotropins with or without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.22, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical pregnancy: subgroup analysis by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.30, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Stop at pregnancy test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.74, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.37, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.49, 3.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.87 [0.22, 155.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Progesterone vs placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009154-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Progesterone vs hCG regimens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.65, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Progesterone vs hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>434</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.54, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Progesterone vs progesterone + hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.58, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Progesterone vs hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.94, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Progesterone vs progesterone + hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy: progesterone vs progesterone + hCG: subgroup analysis by COH method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>722</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.65, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Human gonadotropins with clomiphene citrate without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.22, 13.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Human gonadotropins with or without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.63, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical pregnancy: progesterone vs hCG: subgroup analysis by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.85, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Stop at pregnancy test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>783</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.84, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to 12 weeks when pregnant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.46, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.30, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Progesterone vs hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.32, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Progesterone vs progesterone + hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.18, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.66, 2.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Progesterone vs hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.66, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Progesterone vs progesterone + hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.15, 5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.07, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Progesterone vs hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.07, 7.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Progesterone vs progesterone + hCG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.01, 4.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Progesterone vs hCG regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009154-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Progesterone vs progesterone + oestrogen</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth/ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.91, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.87, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Transdermal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.56, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Vaginal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.76, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.72, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oral oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.80, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Transdermal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>364</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.26, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Vaginal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.67, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Oral and transdermal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.10, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy: subgroup analysis by COH method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.73, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Human gonadotropins with or without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.70, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Human gonadotropins with or without GnRH antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.51, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical pregnancy: subgroup analysis by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Stop at pregnancy test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.34, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to 12 weeks when pregnant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.74, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.03, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Oral oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Transdermal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.09, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Vaginal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.08, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Oral and transdermal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.22, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.20, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Oral oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.22, 2.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Transdermal oestrogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.01, 4.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Progesterone vs progesterone + oestrogen</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009154-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Progesterone vs progesterone + GnRH agonist</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.39, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Multiple dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.42, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.51, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.44, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Multiple dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.44, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical pregnancy: subgroup analysis by COH method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.56, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Gonadotropins with or without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1919</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.61, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Gonadotropins with or without GnRH antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.30, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinical pregnancy: subgroup analysis by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.62, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Stop at pregnancy test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.57, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to 12 weeks when pregnant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>570</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.70, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.53, 3.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.18, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Multiple dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.50, 4.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.54, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Single dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.52, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Multiple dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.40, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Progesterone vs progesterone + GnRH agonist</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009154-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Progesterone regimens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth or ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 IM vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.14, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 IM vs vaginal/rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.03, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Vaginal/rectal vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.83, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Low dose vaginal vs high dose vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Short protocol vs long protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.79, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Micronised vs synthetic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>470</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.53, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Vaginal ring vs vaginal gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.88, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Subcutaneous vs vaginal gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.74, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 Vaginal vs rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.64, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 IM vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [0.89, 4.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IM vs vaginal/rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2932</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.97, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Vaginal/rectal vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2815</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.75, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Low dose vaginal vs high dose vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.87, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Short protocol vs long protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.87, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Micronised vs synthetic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.66, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Vaginal ring vs vaginal gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.84, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Subcutaneous vs vaginal gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Vaginal vs rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.68, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 IM vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.34, 6.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 IM vs vaginal/rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.56, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Vaginal/rectal vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.76, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Low dose vaginal vs high dose vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Short protocol vs long protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>662</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.61, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Micronised vs synthetic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.69, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Subcutaneous vs vaginal gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.44, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Vaginal vs rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.31, 4.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 IM vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.06, 17.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Low dose vaginal vs high dose vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.57, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 IM vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.23 [1.16, 15.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 IM vs vaginal/rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.60, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Vaginal/rectal vs oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>283</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.50, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Low dose vaginal vs high dose vaginal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.85, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Short protocol vs long protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.80, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Vaginal vs rectal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.19, 4.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Clinical pregnancy: IM vs vaginal/rectal: subgroup analysis by COH method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Human gonadotropins with or without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Human gonadotropins with or without GnRH antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinical pregnancy: IM vs vaginal/rectal: subgroup analysis by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Stop at pregnancy test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Up to 12 weeks when pregnant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinical pregnancy: vaginal/rectal vs oral: subgroup analysis by treatment duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.73, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Stop at pregnancy test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.50, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Up to 12 weeks when pregnant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.77, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Clinical pregnancy: low vs high dose vaginal: subgroup analysis by COH method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Human gonadotropins with or without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Human gonadotropins with or without GnRH antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.49, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Clinical pregnancy: low vs high dose vaginal: subgroup analysis by duration of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.92, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Stop at pregnancy test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.67, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Up to 12 weeks when pregnant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.91, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Clinical pregnancy: short vs long protocol: subgroup analysis by COH method <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.75, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Human gonadotropins with or without GnRH agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.58, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Human gonadotropins with or without GnRH antagonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.79, 2.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Progesterone regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009154-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Progesterone + oestrogen regimens</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Live birth/ongoing pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short protocol vs long protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>910</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.81, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Low dosage vs high dosage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.37, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical pregnancy rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low dosage vs high dosage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.48, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Miscarriage rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low dosage vs high dosage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.86, 11.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Multiple pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low dosage vs high dosage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.06, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Progesterone + oestrogen regimens</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009154.pub3/references#CD009154-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009154.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009154-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009154-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009154-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="ru#CD009154-note-0002">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009154\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009154\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009154\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009154\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009154\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=cdmLYOAV&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009154.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009154.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009154.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009154.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009154.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724452835"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009154.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724452839"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009154.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6325a8fcf3fd',t:'MTc0MDcyNDQ1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 